var title_f3_43_3760="Venn diagram hyperventilation syndrome";
var content_f3_43_3760=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F83782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F83782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 486px\">",
"   <div class=\"ttl\">",
"    Hyperventilation syndrome and overlapping disorders",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 578px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperventilation and overlapping clinical pictures. In the assessment of the patient presenting with hyperventilation, one needs to consider the potential contributions of behavioral disorders and seemingly inappropriate dyspnea in the presence of known cardiopulmonary disease. The size of the circles is not meant to imply relative prevalence of the conditions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_43_3760=[""].join("\n");
var outline_f3_43_3760=null;
var title_f3_43_3761="Surgically removed polyp";
var content_f3_43_3761=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F53872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F53872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Surgically removed polyp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 229px; height: 467px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHTAOUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDkfF3/ACNmtf8AX7P/AOjGrJrW8Xf8jZrX/X7P/wCjGrJr6+Hwo+DqfG/UKKKKogKKKKACiiigAooooAKKKKACiiigAooqW2ge5njiiUs7nAA70ALbW0tzIEhRnY+gqxPpl1B9+PivWdL8PW2kWEcRiPnFQZZAMlj6fSnX0UARg8OISOmM8+tcs8So9D2aGUTqRvJ2PFyCpwRikr0q68M6fcIzklWIznd0ridZ0iTTpmAO+MHhsVtCrGexyYnL6uH1kroy6KKK0OEKKKKACiiigAooooA3vC3/AC9f8B/rRR4W/wCXr/gP9aK5qnxM66Xwor+Lv+Rs1r/r9n/9GNWTWt4u/wCRs1r/AK/Z/wD0Y1ZNbw+FHPU+N+oUUUVRAUUUUAFFFFABRRRQAUUUUAFFFFABXYfD0QQ3rXUyEtEMqQM4P0rkBya9j+GNkfDNimt6pAVhmRlg3EAu5HHXt15rKvNQg2ztwFF1q8YpGhDex3Cbg5crzk5BHsfeqV1gxBk3swOcbySB/Wq6XkjTSTTTs7uW3bzwee3+NR3kN0UeSxmHmoc7HPyN7V5Eqj3Puo0raGBqGs/2VciOTavmONrOCB9D6VPdSQX9udz7s/e29ASKdrirqFoQYWQ9JIpVHB+vp7157Za3JpF+9lctm3B/d5X7w9M1MavK12FUoqaaZY1G3a3uXQqRg8fSqldDe3VnNGFkZVD8ISc7SelYM0bRSMjDkV7FGqqiPi8xwX1ad1sxlFFFbHmhRRRQAUUUUAb3hb/l6/4D/Wijwt/y9f8AAf60VzVPiZ10vhRX8Xf8jZrX/X7P/wCjGrJrW8Xf8jZrX/X7P/6Masmt4fCjnqfG/UKKKKogKKKKACiiigAooooAKKKKACiinxIZJFUDJJxQBseFNCl1zURErCOCMeZNKeiIOpruPFOuQizQiNxY2cXk2yk5IXH3iB3NQ6tbzaB4Wt9MtLVvtVyi3FxKueh6Kf51xt9cW0XlwXqghh87h8kH0PpXh43Fc0uVbI+7yLLPY0/az+KX5F/4e3dxq7XU7IZYQ2VjdyCR+Fd+IraW2jeKGVXYfvFbhQc8Yrh/AFxBDdyrZv5aF/lkQ4J+h9a9Qkt7l5PPk2J5o3xqJPMOOhyT3rlpTvFHs1YWlqcXr0LrGZ+QqjGFGWH1ryHxpA8/mfMY5l5Ax1r3/XoA1sduD/eUEg/XivIviFay22n7raPEi/MSTnilMiUbo8vttUvLGIwTMzW7YIY9R6deldzYah/aNksrf6xPlJ9awAlvqlr9oAVC3yNGwzitbQ7NLPTwsZyCTnmu7ANqe+h87nUE6DbL9FFFeyfIBRRRQAUUUUAb3hb/AJev+A/1oo8Lf8vX/Af60VzVPiZ10vhRX8Xf8jZrX/X7P/6Masmtbxd/yNmtf9fs/wD6Masmt4fCjnqfG/UKKKKogKKKKACiiigAooooAKKKKACt3wVYnUPEVnCOcuCfoKwq7/4W6c87Xt5GfmjXYB9etZ1ZckHI6cHR9tXjT7s7HxHfy3kWwlBHbltkmcg9Of0rzaWxt7jVGF5LFEZQSWPzKg9SAM10/iycQiOKRG8zfhQhA+v4V53qsJu2YWSvHJuI3AkH/wCuK+XryV7n6th6SjFI3PDBjs5potOKzfvlGFJJAH8Q9q9YW6UxRRRyxySICzjGGDHt79K8++GmlyaNqUwlMVz5iqx3rw4HbrzXo2r2UMk6l7E2LsPlwuNv+6fSii2o3FXUXKzMjUVk+ZoUfft+hYVxfiK0M1py5LtyOuR7V6XcQzRxkSf6QSoIJxnHpxXG3glTzkuRGm/OwnoPbNbdbM5HseJS2DWV+8ax4DNuBU85/wAK24Hc2iCTaDnovrVzUbaX7a0g5cNx3DfSi/txbsEHqWx9a7svj79z53OpWw7RUooor2D44KKKKACiiigDe8Lf8vX/AAH+tFHhb/l6/wCA/wBaK5qnxM66Xwor+Lv+Rs1r/r9n/wDRjVk1reLv+Rs1r/r9n/8ARjVk1vD4Uc9T436hRRRVEBRRRQAUUUUAFFFPjRpHVI1LMTgAUAMqeC0uLggQwu+fQV2mk+BLyB1k1iBoyUEiw55I9TXVWWmxmxEs4aC3zhIkXk/Uj+lc88RCPmerhcqqVlzS0R5Y2iagoy1s4GM11vgQ3dnZajH5MoLBSDkBevrXZnSDdhRIFgVhjgnJ+orYvdLsLHwzCbdS8iKwkkJ4lOeoGePyrmr4pODXc9rBZOqOIhO+zPJtfs7i81yBXfdhNwLcgevHetzSLO1EUqXJnaRYiYngUN83vnoKqvcz3RJFpLJKHwpkOMZ9/Suv+HtmLJL651KyuNQtSmZFiYKLdTwScEbuM14F1fQ+4n7kL9jhLmS6a2aSJlEkTExtvxtx9P5V3vhHVry60y3bVgk8hXCFnI2+4riPiM2h2mvQx+H5nn00rja5JXdz8q9yPrWl4RMk+mXElqsaxWo3lC+GJz0XPWppScZsmrGM6ae1z0G8EO4fvh8oBAxgnnt2zXNeIbOFwWEQbI+UuOc10tjcefaRLFbWuQnzPIhZj69+MVk6sWa3aNljWMtxwcj2znpXda+p5j00PJLuEtdtG24PypaToee1Z2rMTc4b7wABrq72CGS4DsrZWTsewrkNTbdfzk/3jXqYGFk2fKZ7P3VHzKtFFFegfMBRRRQAUUUUAb3hb/l6/wCA/wBaKPC3/L1/wH+tFc1T4mddL4UV/F3/ACNmtf8AX7P/AOjGrJrW8Xf8jZrX/X7P/wCjGrJreHwo56nxv1CiiiqICiiigAooooAAM16z8JPDthb3EWta3PCqpl4Ldj8zkdCR9a5r4baDBqmrRy6hG72qMPkUZMjf3RXpmuTxy32xIVWGI4SOIBdgHQMe/TpXFiq/KuRHuZRl0sRL2j2Q7ULhr+6urprlQzEA4OGAPYCqElwsUEavNOI0Pypvyg+gqKa9t32wIpEg6LGmBWVd3V8o8pbRYm3/ACOzD5q8qdVdD7ajheVanQadcu2rQw/LwpJHoO2K2pIxJZ3IjwoIIBZc8+tcroOn3aTz3lyhE0uAcHIVR2rqzcNb6DL5oGXBAC9/SojO6bkbyp+8uU8/1NZoJUVroog4Y4OCfp2q7aXsqafcRW9xPDC5zIgYgSfX1oS0t5Y57m5M6+QpAVQDlvfPauZ1nX205PKKstzgB9ygr7Vy7as9KykrFS+s7a9vUSFFzF8+9h0Pv9a6jw7HEkUjWzAtEMMSVyCfQd/rXN2Ek7xC4vBjzHByeh9K7bTrtDbNaAQi23mUbYxvVvY9cGlRWtya7bVkbVgcIWWTKPg5J4z9ar6vgQbh16glTmnQRKIzCULAjOG7GofEEkf2EJIGBA6kfqK7Vex5U17xws7yxz3Hl5LHLZ7AfSuFnkMszu3ViTXYyXaW93I7ZAdOrcZH071xjnLsfU16uBd4Hxmf6Tj8xtFFFdx88FFFFABRRRQBveFv+Xr/AID/AFoo8Lf8vX/Af60VzVPiZ10vhRX8Xf8AI2a1/wBfs/8A6Masmtbxd/yNmtf9fs//AKMasmt4fCjnqfG/UKKKKogKKKKACnINzgCm10HhPRm1XVLe36ea4TOM4zSbsrsuEHOSiup6V4EsLzRfBFzqkILS3P7qGNR8wB+8y479fpUcz6g9mywxxxuOdhGTj610+rX9vb6fFo+jTXEMVqnlvKjABwOGGDz1rEaeJbKWaWVUiiUMFPBc9u1fOV6rnJtn6ZlWE9hRjGxW0axO+W5lh2zTdCDkn8O1XbW1F1qCJBB5krdEU7ix9xT4/GMer6THYSafYoyfckVSrIcdQPX3qsbryin2OHZJHkJPB8sjexb0rk9orWuevGE3dtWOgtZNwuIDBIskCnzFx9361h3PiCx02/t11cNLaYIGJMFTjgj3FGreNLb+z/sdrYJZLEcyt5hkkkbvubHP615v4pe41y2naCMkR8odwUn8KiVfSy3Khh3ZuasdfqFp4jvNVitYrIq97EbhJridQJYxzuYg8cdq5DUtIexgjv7q4tZGmY7khbe8QBxhsj+Rrei8V2niLwZZWGqW91HrGnxGJbhGARl7bs8npiuM1rUWMsNrGys8n3gxO0e4qJteppT52ry0NX+0I1iiDyQyqo42N82Pfk1t+HdXgkmIV2ZyMsW+6BXnGr7ZYQFALRkjYg+72wT3FerfDLUri08KtYSWdjcRkkyx3CBgOPYZB/GqpSblZEVk4x01Ok0y532yKgLN/EdvXHeszxPIFj3N8wI78Y+lSafLGZWaEMZVyg2Htnpz2+tZHii+3XKecVQZI2qMLgjrXbzPlscFSNnc425jxcMoDAMR94k8VhXUflXEkY6KxFdDb4uNVTYCcnBwenuKwdQVlvZw4wd5/nXq5f8ACz4riBfCyvRRRXonzQUUUUAFFFFAG94W/wCXr/gP9aKPC3/L1/wH+tFc1T4mddL4UV/F3/I2a1/1+z/+jGrJrW8Xf8jZrX/X7P8A+jGrJreHwo56nxv1CiiiqICiiigByDc4Hqa9g8JadHodgt0XT7U8e7zAf9SpHOO2SPyrzDw7YtqGrW8CDJZwMfjXqmtXEaWk9kXS4kGYysK4UgcdfSuHHVXCFl1PoeH8JGtWdSS0ichd+J3l1tLW0tmkgOTFIAfnb0zXX6NdXsVlKLkJGJV2kyRhjj0Gfu/WuHh066JiS2d/JQ8KHGUPsa6+2uIJtKeK/u0WcqVcSYH6GvmuaTbcj9IjCNkkPxYGZHiSOWcn5hGoLDtn2ps9lFZBHiErRFtzIjEkt7LVDwKdO07UJV0zUbdJXmwk11wu8D7pPQc9M8V6W2tHxN4XudOCQrr6tt8qBAd5B+8CcAe5zUJKSvsy6lR0pJWuuvkcFpujTeI7+7g021Z5LcAyrJhQM98HrSPaR2ssizQGGQYQqi9MevpUkCarp97Mk8H2d26uCyO+OMZB5HHWpVnuY5Lp9QykZxs3ODwO/rShY3bbd7q3Q8v1m4IstT+xbtyv/CxUjn071d+F/hJ/FpvbzV7pLKxslG6QoWaVjyEwDnHBzisPxZf73vorCNMySF2J6dOg+tdh8GZfDen2Ut94jgu11m0fzIIzueOYdsDBCkHvkdaiCUpWIxMnGHu3v5GrrN3YatodpYafZ6dYpFO3mpZ2xQEAYDiUkl8/StXwnp4hsL+K1uUeIAMXkQNKQCM49P61F4+1q7uNMW71WBHv7iMG2SFzGlspOeRj5sjvmsPwNf8Amu6yxBGBCl2fdtz+FdcElI5Lfu+x2UlqH2yRuQ6jJ5wcVw/iq52M5KDzeoDDH5V6BdokaS/ZSkwU4DqOG9/WvPPGkf2hVZtxcHLkHaRW8l2OaTujmtMvwmowySKwBBUMpHGfeodVGL6X6+uay455o74RSbtikBDnPert02+4kbkjPU162XO8WfF8Qv4URUUUV6R8uFFFFABRRRQBveFv+Xr/AID/AFoo8Lf8vX/Af60VzVPiZ10vhRX8Xf8AI2a1/wBfs/8A6Masmtbxd/yNmtf9fs//AKMasmt4fCjnqfG/UKKKKogKKKKAPRvg39hg1eS81EkRRLjIXdyeOgrr7iC1uJnFsu2DcfJDLkgZ7+lcF4CXbESR95uPyrv45UbOFy3CjnH414mYS/eH3vDlFRw/OupUWxQcnKFehXpXM+LNEkmZLmzcNJa/vG3LuGPTn+Vd2sBdg/Acf5HapHgiVW3EeYw2sWFeTUpucbH1dOryvU8hsZLVpJ2uvs8s0q+biKMoVI9eDXZ+GdQjHh7VJ7G53zMVjWEOgI7k7euPcEVk6z4eJ1F/7GdYbiQYkBGASfTNGi6QIIrmPBmkjGXIQ9vbrXJCMou1jsbjJas6WO5nENpNeXQeSVDhIX3JGR2Oen0rjviD4oFoVssRu86HnOenA+lad5vuLaJba6nhMfIJiKF/bJ/nXG+HfDF1rvihzezW8MiAs/2mQcqPTPGa0cpNcq6ifLH3mU9M8JahfJHOBHhmySrZY/Xn9a37fSbnw/I13psC/aYyCplw43DnoTjFehQ2Vlpulw/YrhZ4BwyLxIpHY8cVymtalZTvO1ubhVBYiOMBiOOhNaKjGC8zPmc91ocZqGvaxrxmF27LqTvh4wcD0G1e34Vs+GdI8Q+H/FEmm6tuguDGspQ4zt65yD+lZWgPaP450lpcKsl1Hu39VG4Zz7V7j4pQWvxLv7q+QSWxijymBu244Iz75opq8rtnNVnaSgl0E1CAIzRiIxBo1YBxyQV+9+NeeeLoCu1W+UdMnjcO2BXoer6u9zdb5U8qRlASPG1RH2IHpXIa9Gt2GfYVVOVAYH9K7HZnM00tTy27hYJFMVXa52FicEEGiUYkYVtw2YuWuLKaIfPlkkznB9qyLxDHMVYEMAMg16+X/Cz4riJaxZBRRRXony4UUUUAFFFFAG94W/5ev+A/1oo8Lf8AL1/wH+tFc1T4mddL4UV/F3/I2a1/1+z/APoxqya1vF3/ACNmtf8AX7P/AOjGrJreHwo56nxv1CiiiqICiiprSIz3MUSjJZgKAPSfBEJTRoB5kEDyb2MkrhAFA7miLVIJrkoHZjGcjHOOevtVT4gs1hDp1vpoVI0hEbqwOGYc9R05rF003Bm8uSTlV5xwAO/NfMY6rzVWfqmS4f2WFin2PSrO/liZd7blADEuOlaD3qzQ5jVcPkYJ/lXJRrdyQoGgYKI8Kw4yO3Oen1qRZbeGNUklZ2TGeeQa4XUa0PajRi9S5f2YnVXijUyYI3L95fesmznNokkjje5bY3menqD3rQF5DbvIg3Akb8HI5HpXGHVLq5vttzHLNCZG2lCE+meKhTV/M05bbnR3l9E8aMshlUg4Kkgj1GO1YFksk8MsyaezypKSjLyVU9jk1s6e1tPFNHDMqXL/AOtjLAbvT8fcVwmr6rrFhJcDTTvSJsEhCT19aqUtmw8jrdRvZILVcxSwM65LoS3X1PrXL6NZ3OqasyQyzsm8ne/GfU471t+Dpr7U7eWTUo/OJOcMcBWPUH0Fen+Fr6PSNLuYIrO2FxIytGypwhHXJNVGDnZ30M5zcVors8wTwPcfaPOkmRXL7t7A7j6V65pmn3utaTaSeIXjaCyzCZ4Mm4YH7ucjGOg9ao3CxJp8l1Ld28QBOYxIC3PcDsBVfSdWW+s5EtZ3mi3Z4yBuHfk84raMIxdjmqJzV1uiGXR4EvpruW5nmkwEQSsCFQdAPw7Vm6qkFujSKwbd0zwR9K6N2M4EbYdQeTjqaxNfttqGQ7W4+Y9eBV7K5lO9tTzm6doL6HDfvd24knGaztbdZNSmdAApORg5qbWMvcsCzRMp+UryR7+wqreq5CyPtOR95ehr1stnvE+P4hpN01NdGVKKKK9U+PCiiigAooooA3vC3/L1/wAB/rRR4W/5ev8AgP8AWiuap8TOul8KK/i7/kbNa/6/Z/8A0Y1ZNa3i7/kbNa/6/Z//AEY1ZNbw+FHPU+N+oUUUVRAVv+B7QXfiS1Q4wrbvyrArqfhsf+KqthuC5Dcn6VM/hZtQSlVin3R1fjgwiVWdFcBhhMZxx71z04V7NgHVSp+TkZx3HrW1473XE07q4T7Pty2O3rXG6raLJFHKQ8nlnahYZxnvkGvlsaveufrWXWVNI7nwJrNolnqmh3kcck99EVSZ3KlCBkcc/pWJBqMcLIl1CNgPz3Bxhfzq58D7RW8f2c15LsSMOEOPvtjABrj/AIx2E+leNtZtA7pF5xkQAdm+btx3rgk2ops76c4+2lTXVX/Q7G81Sydy9nd2xdjuLRvu3DGORnisZbmLzWijnaJ2Of3ZBx3P515ppmg30+2UOYB1DEYJHt613trpKzRxm6Tz3C7R0QfUkVjGb5rnTKGh2mhWNhPNb3EUSTOv3pAeQT+lbstja28xt4Y4TFIQX4ByfUiuV0eaXTYNoZWhUbDnnHtkdK6i01YeW0kqbUVQEfAKkepNdtOUWjnlF3ujJ1Y2WlbeluhPBVcLk+pqzoviXQ5bK7l1m4ukaNSEhhgyZW9d2O3HWuO+JHiGG5sPKjYsFZWcqpIPcYI7V5rdeITd3FvHaLLGIyQJFYhmzUyqcr02Jmrqz0Z6bN4ntdc0xbaGExSru864Uklx2BHQfhVXRtcutHuzatfb0I3IWU9fTnpmud8P2eoW3nTOqmFzljuzhvU5rWfwxd6k8csTmSMvuRlb5ffJPI/KiKlK0luZSlFaHp9pq6vbI8yP8y5AIyMj9eKNbeO/0ZpbeAobU4nZWGCh5UkHnr6Vn2dhHY28cUURMowrDqM9yKt6gnl6Re20dqhkl2/vGbGADnaB7118jsckpdTzbVo0ctKXAkcfKEye/pVAbv7NdSh2lshj1NdTa6czGOSa3/ecgueQv61Be2oEslu0ke90JCr6iu3BPlqJs8PM6Tq0JI46inOu1yvpTa90/PQooooAKKKKAN7wt/y9f8B/rRR4W/5ev+A/1ormqfEzrpfCiv4u/wCRs1r/AK/Z/wD0Y1ZNa3i7/kbNa/6/Z/8A0Y1ZNbw+FHPU+N+oUUUVRAVreFrhrbX7ORWK/vACRWTWn4cjEms22eAGySe2KUtjSlfnVu533imOdZ5YZ2YwzJ0fkY9K5OYSvKiQsZEUFWXAxn3/AAr0PxTHG/kEkgzR4yp54+vWuInsHguFlV9oZhuVhkMegOexr5jGxd7n6xl81YvaMZdLmS4jYRMmJEI6Z9uafrVknizWf7Qv2Z7ybBYJwrEDpj0qJEd5WEpLKDhl24I9uKjuk+yTALCTFncsgGP1rzJPS3Q9qCV+ZbmPrNhdXcsMOnXZtY0yz4T8hWxFqcVkLW3vpYHfYEygO5iOpqtc38cM3muNoZT8rDn6g1zpuJbmRft8sSOMgeWgGB65+lYX1udPLdWZ2k2pWkikwSoIdwXIGMmua1/UriSwa3lmaKPBwyyH8BiskRXEsjjTVeSJ24Vn+Q+4Hao9S0m9YATw4JGMh+frS5pMXIlsRaLd2M8T2UhTy2XgE7ufXFYV1psVjKJrN2ZtxOwH+VNn0N4nHlPgg5Ktxj6Gun0uyE9u0V1Mv2jG358HI9a1jK+jOapT6jvCmttPHIDvhmxsdvvsfcJ0OK9DtNQhh022kTUDJap8snlKhc57le34V5ha2r2urCCeCRYt2N0YGW9MH0rvBas9osVtZWkZm43s/wC8P14rspTaRwzjrqd/b3VsbeJmbdGVykiEEj/69U4NQgvY7iMTebGhwcjkY6ZNYXhHTLrTfMia72wPyIWKsFPqDVnV7iO0aR1n2Szjy0dY96g+jV2KbauzknG2xX+0PbakNmxklJUo45/A9M1m68Y1kWc48xOuBhm+hqETSQ3CRXQeUq2VIYADA646g1DrV359hcTXEYDof4MgYx71pTnY4qkeZNM5S6/4+HIOQTkVDUkMsVzp0U0cgaTOGXoV/Co69+nLnipI/OMXRdGtKD6BRRRVnOFFFFAG94W/5ev+A/1oo8Lf8vX/AAH+tFc1T4mddL4UV/F3/I2a1/1+z/8Aoxqya1vF3/I2a1/1+z/+jGrJreHwo56nxv1CiiiqICug8FQmXWIzt3AdQa5+uq8AQmXU8A4zxUzdotnRhY81aK8zv9fjUx2pYfKi7euQD24rnmZFuCNykA/w9jnoa7G8tGl0O5RwN0SbhuAyDXEiVEYySrhj94HBGfSvncTrufp+DdloWBbEs9xCXk83lkQ8gjvVqG0Uw7GiZ1JztDEhTU0EyLEjTgBZD8mFyy+3FLKGdWAyFBwuDgkV5s4pHr05NorppkFxeItzF5kZwCgO3cncAV13xU8IaNYeEtOl0rSreCCKQOHz+8+YdDnqPqeMVgpncmyIKuOGJHJr0fw5q1pr+h3GjarD5axpt3sdqkduexzUximmuplipzg4VVqk9UfPcGpQaQojW3Z167IlwRV+KJryFZHJ8uVeGZRuBPak8X6Jd6RrbW0gb5WwpKYDA9+mfoaqw6mbZGa4R9sQwQzEjNc+ztI9RPmjeJla1pERlWKG5YTgfJ8vXPsKhsNJFtKzTujKOm4lWY1s373V3La3FvaSJFgHLDIUVqPYQT2zF2fYSCgODj9OKcYXegpSstTAjjmGXmEjRA/K2ckHtn1xXT6JdxTxRpJDEt0OVfG0flXOapEdOuY8y7cn5SDwB2JrMvr26Vj5b7fL6nGD+Nbwny6nJOFz00XM8jMY0t2AyMbsEH39asNBC1qTJH8/XAO7B9R2rzvw7qf76Ga+mm3LgEM2FJz3Hc13mpah59iZdOIZmIwwBUDH867IVFJXON0rvlMvxDplrJp0j25eS4tyJFVCFYmuD1JLy/sJCxurZE5/ekbpD9K7iXUFkhdJVZJz1XkE575rkdX1GTzpkd3QDKlW7jH51dziq0+XSxhWcSQKC/D/AHD8uAR7VZkQoxBrmNU1CeKRREg2bfmCnOPfFbWg6guqaSJCS0kTFdx7ivYwNZNezZ8bnmFTft4/Mt0UUV6J8yFFFFAG94W/5ev+A/1oo8Lf8vX/AAH+tFc1T4mddL4UV/F3/I2a1/1+z/8Aoxqya1vF3/I2a1/1+z/+jGrJreHwo56nxv1CiiiqICu0+G1tLLqIkQHap5xXGKNzADvXtfw40ZbTTQzcO4DNz3PSsa8lGDO/LaTqYiNuh0EqY013dAxlJUZU8ev1rgLiJHu5BMm7ngEdcV6Rqw8jSBKm4CIF/cV5/czXF5cQ3M4SJJOUzgY+p714VZn6NhVpcpyWzK5a3dkVOTtOVBq1ZApMhkdNuMjPr3wDzTmKYdlQq2MnJwPwx3qKA8ttwq7eDk4/OvPmtT1absi69wVJcFAAThSRx+FZc91MxDhnVA+eJPyIp8qzt8kEaqpXLEr39KqpHI8exUACna2c4+oJrnludlNqx6f4Zn0zxHYyWevI51K5G1b6UKWOOgHpj9a4Txz4XudB1WK1uFieCTDR3B/j55G3+dRm+FpZ74mZNnTJ4A77iazda1s6j5DSamL+A4Xc8+9o/ZM+9KcoteZNHDzhU5ov3X0/yLhvYLdnEeGt0cJN8+3ycjrtI5/Co9WkW0jil+1RxQfdChP9Ye341QjvNPSKeO4tz5RBead2BTcRj161yXibW44AscJH7tg0RWTKj0HWj2jSN3BXNG9u1lkwE82Ikbz/AHc+5rL1poAhkywkPJK5bP1JrF06e6ldmuJvkJztbO0k9asy2863DI0qNHIexOOPakpNomULEWnX1vK6RzAKzN8oI6mvYNKsp76wght3cs6AfKnAx9O3vXhmv2LQrHNCygK4YAdD711uifFLVbLTUt9HijhvVQp9pPLKuOQB0IP0rejOML8xwVuZS907TUNC1DTL+eHV1ICgyAgEMRngqfSuC8axsbl5BKdxUMgzkEY6E+tdbY2usajZxS6jc3cy7AwEhxtJHQAdBXEeOrO4ttzkYJUldx/nXXtG9jz68uY4vWpxIiNAWB25Y1a8D6gI7k2b5CvnGexrEvZ5Z48PEoJwdyn5R+FR6e7wXSPEw8wHKt1/CujDVeSakeDjaftIODPUGBViD1FJUVlM9xZxSSKFkwARUtfRJ3V0fDVIOnJxfQKKKKZBveFv+Xr/AID/AFoo8Lf8vX/Af60VzVPiZ10vhRX8Xf8AI2a1/wBfs/8A6Masmtbxd/yNmtf9fs//AKMasmt4fCjnqfG/UKKKVVLEKBkniqINjwnZfb9Zt7cLuZmA6Zr6QsdIGmWQhhEc0oTc7rwBx0zXCfCDwtNYI2p3sRSZwBErDkD1r1BVyzks2H7V5WLq80rJ6I+qybDOnD2klqzGv7POgXCzjaWiY7QeenrXC6NoV1qOkW728CwxpFhzNJhUAPUg8/pXo+rXCRRqAqkY79Dz3rM1HVru+jeKeVVVgCVRQobn1615873PqaMpW91HnCWsn2xo43LR8gbejD2NTXWnxhd7cuFCgKduT7g101xpypF+7OZS2TuOCfT6Vz2sGYEcb1bjHf35rjqpR3PVpS5tjCuZFS3ZI5dsjnOcj9RmlsZpfKfz7kxzBfkCjJb6DpWtaeGbvWy4gt3lVFwWGF2/WoL3w5Npt+bS8fZPDjLZDY9MGudpvU6YTipct9TCuoVG0SNJIJDhgSQOR0YVBafCjxNe4uNK0ueOLG5PMdIgeOoDEHmtSe1kS7RLtmmwCwK9Bzx0Nek6/wCILi20GxRtYvF1gwIVhtk8uMKehbIyTj3/ACrONKMruXQutXqw5VR3fe/6Hlfh74da1qenatHFFFbNp7EXEUp+dnxnC4yD615pe2MUWo+Tgs2MuQMkfn0Ne8eFPHp8J3l+1/ZT3cN4wkmk3DzA47nPXjtXjPjbXbfV/EOpana2/wBmSeVisY4wpGOcfnRKMUlYqjOs6klUXu6WZnebaoPLkIIdcBW6g1T1BmihzDI8S54GQcY+lVFa3ZpmmJO9QoLE5H41Da21w5CQuHjGeCeKyTZ0yehLbX6zgiQLGQpyzZOTjrVnwLb28+qulzA08mQUyCAoz1qhPY3UOCqGRCMEkcEH0q34O1T7BrYEv7tycEMMDj1rpp/EkzycRqe93My2lrEAxyMfOx+6Pp3rzH4h3JvLhol2soUnJBX8K2tR1WJbMzJJ5iSk7dpDbvYZ6CuXNlNf288s4KzE8pvzt9OOwr0HLn0PPqvSxxE4Zo1QHK4IU9dvtmstrVIhu8wgc7XYHn8q66WyWJ5wpEYAyzc8n6d/wrMuEUEjymPGD2UinE8yvDojY8K3j3FuYZCWMQ2q3qK265zw+7Q6t5aE7JUDEZzgiukb7xr6DCy5qaufF5rDlr37iUUUV0Hmm94W/wCXr/gP9aKPC3/L1/wH+tFc1T4mddL4UV/F3/I2a1/1+z/+jGrJrW8Xf8jZrX/X7P8A+jGrJreHwo56nxv1Cu4+F+hQanrEc18cW0bDJBA+vWuIUZOB1r1fwPZNp9jEshCs48whuME9PxrLEz5KbO7LMP8AWMQovZanr9kIFjKwZ+zrnbuOcj61cjiCwlnIxzzisnRCkkAHAG7BPQH3FaMsThhh1EAU5GDkntXjSPs7JOyMXUv3jvtI2Dgn0rHJXzhGJeecjGTn3rZvURI2O04bnA61gvcBpnSURgr/AKsevuSK5qk7HqUI3Rb2FQEDEsf+WgHFcxqsObkgDIZhj5uPr1rZUzXBRQxOM5yMYA96hvNMASR5DuAGQAMsR+Vc9R8yO2laOjZd8Eau+l6pHAcNb3XEqleoHAIJNR+OZ9MuNU8rRoIQkQxJLEvEjn3HXHrWHcQq8TI5wmOAQcDHY9xTNOulNwI412xhPv4Has1LSzNFRXtParczbm3utwzmQgbSc4Kr/n0rV8JWK6jqMKeXPduzhRuc+XtHHft9KW91A7miAVO/yjn61ueA737NfLJFHdTAIV2wrnk/QdazjFc9jpqTlGk5RWpznxG8FahpF0LkRJd2U0pAaMBdmeg25rzfxH4T1O3tzqMul3KWm7y/OZNoB+lexfELxlqMED2Mayx7x5UiTLkuPXkDB9xXn9r441W900eHdQkaTT5p1VvkDMqZ5AI560pwhzWFQniPZJzs/wDL/M8lu9ILFpI2L7G5BUirumxxxwgtHls/Kqjt7+teifFfwFfeEkt72O6W40m6O1WA2vkjIBH0ritK8tlMTMdwOV3H5l+vvSUbSsy/awqR5oO6IoICrRGKJ/JLEbTn5fSk8UeHo542aAbrhQWXg/Oe4BrrYYBaphnMqnnzBgEH6GsPVpCkkinBJPLq2ck9O/Fb2sc01dWRk6K4lsBIdxZDsbfj5TjsO1b2nBvL+zi4Ee8jCSRkbhjkVzUdw8UxmT5dxwQF4z3raN8iRpNmTftO1+vTmuilax5ta6G61psEMLeYj78fcVPu155dBRG2JNuCcBskgf4V2uqeIXvIXzIVlHA4zk+3b8K5bUFJWNUVVkYZJAwT7EVro37pw1drMf4WuQ2sW6uSd6kBm757iuvcYYg1w+kq1te2s0uNokAbA9eld1P/AK085r2sDK9No+OzmNppkdFFFdp4pveFv+Xr/gP9aKPC3/L1/wAB/rRXNU+JnXS+FFfxd/yNmtf9fs//AKMasmtbxd/yNmtf9fs//oxqya3h8KOep8b9SexGbyEHu4r2yVXjhjMQVtuMrnOeK8TsZPKvIZCM7WBrv45dY1Nmj0zIaU7VZVyST2HvXHjr8qPfyCynK56n4XnMyI0RDRliQe34V0d45igJwMty1ct4J0eTR9JSHU5mW/hJ3IAWRx/vDvW9fzM1mxjUh+gJ6CvKb0ufTpXmZt86StHGJBxwAePxrn1hMV8IVjHyfMpUfLn39613MjIZHCFl4Pfj2NRXERbfK53EjKqWIx75xXLN3Z6NL3ULbNGARIxB6cetbGmsIbhDEUMzMF2MBjr79Kw1HmRp5kQB4OM5/I1ZldfLJYoQP73PNCZclfQi+KWmnVb1U04C3mtxueWMZDZ7NxgVwAsZ4mREK+anzHaQefxr1eGbTk0h1DnzWTZNHGdpfnIIJ6+4rzvX7+DS5hNcOkZdtmG4BPtWFSC3OjCTaj7O2xzup2svl5hlMLuMlV5JH1PArZ8B+JZvCupGS7hkmtSP3gVgDyOvJ5IqvfGK8smICwSY++c4YGs61tw0CReXC7PhSXfp9PSsbcsro75JVYOEtiv8VPFE/iTWpLuxjeGHYEjV+TgeuPrVT4e3PhOS1nt/GMWoWt31S7t3Ygj+7tAOP1qfX9POnO8F1Ev2iRd3yFXUr2IK1y8NoySEM+1QQygn/PNJu0rvUfsk6ShDReR6XF4qsLDwJrA8T/bLiRne10mG+QghMcHHY4wdx/CvItF8l3XABK8tnIOab47n1TxJqDX+qXLXUsMSxKx2rhB0GAB/jXNpdXVpHDFAm1P4sdTz3olVuzOnR9ne/U9FutYtLrOQsRGBuZTz9K5LULmQXbqtvvtm46jOfWrWn30DMUubfdHKcMycsOOvJxVSQbJnJcvEp4bGBjtkUpSb1Lsii7J5G5mKo0u1c9h7mrdtsljbaWbBwOePpxWO9ylx50Usrc5KccAjtUnh28jghVCRkMc84wK6KE+55GKjaRJfWoiiQA4G8kAjPJqC0YiZfNJVT1LDJb8a6BI47qVm+Vwwwo43Z96yvEFutpICJYmY4wVFdaVtVsedV3Kty1siKIZAWWQfIxPFdY67doBOMDrXBxxyS3ab1xnBwvAr0G7TYy+hUEce1exl70kfK53HSMiCiiivRPnTe8Lf8vX/AAH+tFHhb/l6/wCA/wBaK5qnxM66Xwor+Lv+Rs1r/r9n/wDRjVk1reLv+Rs1r/r9n/8ARjVk1vD4Uc9T436jkOGB969i8AvH/oqgyYCmUkdmxwa8br1D4XzS+arkblVSq8Z59qwxSvA9TJp8te3dHr9vvMADJ7nJzmrrmFbMFUDuTkoQRx6HtVS0fKhXZsnB9CK0IYftSvEz+UhB2uw4Ht+VeJPzPsV3Zz0ZJyFKjA4UDP8AOqTySlmXyW3ZwDnFSlPLup4kfeqk7JSMZ96jkQOjecHAI5bNc8k2ejBrcQRh921CAMAqDwPwpHXuOCRggZI/KoQIIfLjcFY15VBkk/Q960ockAkrycKAf61O5r8JUnmlS077XOSmeuPevL/HAstZiIuD58UTkJ5Z2kMOtem+IbiCy0+aS9YrAAdx9f6149e27W6FlVPLcllVckKCe3euat/KduGV9ShbXN6vlQxs7BBtTGPlHTmtFo7lI3bccIhDnu2fasrUJZrVY4tOb95J8xZ+cfhjOaseFNP1y+luRFb3FxOBuZYlLAr9O1crbvY9KNoq70Kb6ozXq2xgMkW0ENyOKzrPW8XcsM0U6uG+SONcsf8ACt/UYGnljN1CLWRXK4kHOKj8M+Fbuz11rosJ0PI84Z3A9xz2pat2LuralbUtMe5dWEbBioLgjkVzeqWU1tFmBlEinBBx369q9fu7iGN2tpIQbv726M4Ur2yK5DWbKGON5nTep5BBO3nqK1cVYxc7s4zRNPs9U1ZYdX1ePRrQRMxnlQsu8DgAAjk9KyI76NoLhAVkZW2rKV+8PX2qPXJ1e7GxlaJjyvWkt7F5sxeXtJ5Crycf0qE76GFS6bKYQsP3Zbax64P+cU20tN+pYuGXCD5VYkj2rrLWyZbdilvcLBENrysuEUnoD71k20QF6xzvGMI3CkHPf1reitTzsVsbXmRx2oQfIrcupH3j9RWBrqEyoEJ8vgAZyPpmr8e/kqoeQHGcBQPoD1+tZWoTSzDlg+0nv0r0E7qx5FTTYXTLaOaZ1WJwIwrgHuM+tdzqQIMQJB+QYIORXKeCZgutSmVgUEJAY/0FdXqJJKlyrEjjHpXtYBWg2fM5xrApUUUV3nzRveFv+Xr/AID/AFoo8Lf8vX/Af60VzVPiZ10vhRX8Xf8AI2a1/wBfs/8A6Masmtbxd/yNmtf9fs//AKMasmt4fCjnqfG/UfEpeRVHUnFeqeDrCW3u7FzuSJQW2qcFjjv7V5xokZe+jwu4g8CvatChSK1geQEyq2CGU9x1Brlxk2o2PbyOipVHN9DqbSRkdMj5j1C85rTiZUj3bsfNnGAayLSBghJJJPdug+hrWgkiKFCvmDHP/wCuvHsz612MW6TzrhpHG7B+XBI2+vFRgbi6tyo6he9XbyNreJnCbQDnbngiqMjBDuDlUPUYyef6VEkrHTB32K7RJ/aEBlcgRk+WCOcEYP1rRiDn7vB7VWtizSATYaNfuSEDI9qmEm3O6TbgZ6ZA9/asbbm7k3ZFO+t1lim+0KpIQj5gDkdc155qOkves4XbG5IAGOg9K7dpzf2txDavuusEElcbfwFYNrp91pqbNRUmQHgg71b8OtYTSZ20G46HOWXh5bSNml+aQMckHkcZzXc+APG1hoen3FrHbNcTMdyyLhcn0JPauan1O3gd53RHiRDl48tjHbHauC0rVpbvxAxszElqHJKv0/CuVz9lLQ9CVFYmm41NjW8UapqF1rL3d1EEe6lLr5PzAD6dq2orhneBYsq2AoVxgEex7Vl6/qC20iyYaQEYKqmcfhRpUzXkDBoNsgIG7cduPTHY1mpWk9TdpciVtEdRbwX2p3kMVhEZb8fdQYBbHXPt+lY3jW2vLK6lTVrVYbhU/ehQMHjtt4/Kr4m1XTZI77S5Ps0sfAdTuI9Rg+tc1rupavqF7LNqskReTkszfP8AQ47Yrok7LTc4ldz6W/E8+v8ASIrueOSNvLhBJG5cM3PQYrfsbOxFzA+pPJFbk5aW3AD7R6Z7+xq3Z6LrXiea/udJihurbTog0zMwj8sewPU8V1HiHwraWnwq0XXYYwlzOzLct5hbfknbweB0p0qbWpyYivHmUU9TL8VXvhZNHhg8NR6nbznm6N7JlJeOuATz7jFcfo2ntfSSSwgJBHyzuMqe351gyzXGo6xHZ2Tsd5K4A+Yn0r0bwzpBjghGza6giSNm2kgDuM8100oc0tjhqy0smcvq2nCxUBz5uORtbnj+92rBigLgtKF8tSWDYOME11mtGQTSuNuFzkR4BHt71yAvUEs6wuyMDwdpBJ+tdCSTOCoVBEYr0yxDO0/MuevPFd1eNu8skEbkDYz0yK4GJWucZcOzyD5iSWFdzOADtVtwXC5x1wK9bLtmfN53L3ERUUUV6R8yb3hb/l6/4D/Wijwt/wAvX/Af60VzVPiZ10vhRX8Xf8jZrX/X7P8A+jGrJrW8Xf8AI2a1/wBfs/8A6Masmt4fCjnqfG/U3fCEZfVEIGcEcfjXudnAsYBA4I4z6+9eJ+BH2a2gG3cema9utpkmZv3Ww4HIOfxrgxu6Pp8iVqba7mhCWWIqPnjHb09ver9oFkVSCyqOq+lZMQcqNgBwOO+fwq7p7OUAc4OecV573PoLXRcukWKJhnORgYGa5902jbnax4DDnP4V0MgMmAdoVe45Fch4m1COy2Ox2RlwvBznmsqrsrm+HTbsXsRogfzNzZ53D9apT3/mDyrYlCz7W3/KxHtVdtU07EqmdEjUfNlwSPwqPSYTLePdPL5kbYMWRwPoa5W76I7oxsrs6Hw3pEForGOEtJK253z8zGtm60Wzud6aksqALxsHOak0pFUbohtIxj/9VakhlnfdISX6cDitlFcvL0OKdWSndM8wbwtBbTTWzqzW85LbSMbs+uOlcbqXw+s9PaaTT2miZ8sEY5/Kvd7u0V1IJyCORWZPZR7V3jIHQnBrlnhVI9OjmDWrPGdA8yJjBLp19LPLwszLkcepxwK7aPwbqFy1mxMA+0knaCM7u5OBwK6aZYVkKiPJHQbsVseHrywtUk82QxzycKSDj6A04YVRWuosTj5tXgjzTXdCuLOQ20t4E8g/MUAKnj1+lea+MmiW6uLbSrYE7R5hY52/j0r0bxfBdXv2iCxaRVkYkuxJbOe5rJ8JaDaXdjqFlruoRWVzHGWHnYBlGeMdM/zpygr2Q/atRvL5ng8Fnr6SyfZYJJInbLEE/rjtXQix8TXkEdoyJHajLDcxKrnqcV61oWlQpAga3MQQ4VFPGPWrEtgROrxbc5IyRg/Q9qUIW3YprqjwWfw5f6RqAu7V3mljIcjbgNj0Pau8t9US8sRd3ENxFPMCCgIdOB1z1BNdBq1oshklT/WLyAExge56VUgs1NshMQBPHynjNdFJWfunFVVjgr24QzfZt5DSHKgnI9OTWP4o0EQxeVETyB87H7x9q9AuNPZJmSZIwCOVkTPft2rkvEkZjuo4IPMQp8ud2AB+da8t1dnDVZzPh2O6GsQQi2LSQtvCKMhsV1cUpmjMj53M7E5+tWPD8qRW91DJgsAGEi/eHbGfeotqooReg9e9exgqfLC58rnNVO0OolFFFdx4BveFv+Xr/gP9aKPC3/L1/wAB/rRXNU+JnXS+FFfxd/yNmtf9fs//AKMasmtbxd/yNmtf9fs//oxqya3h8KOep8b9TU8NOE1u0LMVUuATXuNs7KQ4eMrgck4OP5V8+wyGKZJB1Ug16/4f1eDUNKG5uCMMoA4rlxcG0mj3sirRjKVNvc7GIgtgbggI+YHGRVoTHzsxj3ORyB9K5TTr24LySEyeRnaqs3b1Nb9nIdgOQpPPsDXmWPqkmak1yShy2CRjIWvH/FmrSeIvEP2KMAR2rfNJG33mH8I/rXQeMriSwlaW1vJUaaIiVQxYMOg47fhXD+Flee7XyIgI42IJGRtGemD1rhrycnynpYWnGK5zsotOeWO38q2t3kI6MuCoxyT7111lp6M0XlAxogHyoe+MZ+lUtKh2FFRSxYcc/nmussLTYwfaeelKNJbjrVeVWLdgGgRY2DYAxu7n3rXBYR72D591xxUVhbyGVdgG4HPqF+tbc0bNC/mvkY6KMCtG+U8upUVzmri4lO/Ee0Doa5bxDPqkVvI6IvlryqqMlvzrsJIsHGe9U7yzE0bx7wN3Bx2pThJrRnVRqxi9jx7TvGupS31yh05pVh4cocFD78c1uadruoXU8gbSLiNQN25iMNx2rbuNKt9Kv4n2SLEwIkdVBDfX1NXrKbzIi0isoPIGPw/yKzpxntJndUqQa5ox3KEd5Jq25tS0828hTarI4AOOhPrWF4kijt0tC0i4J2Bieue2a7Ewlk3bCFzgYPX8KaLDz5VE9uhhT++OQ3YgVry3VjFVFHXocijGzttqM4HTBG7PFSaRZ3GqalFbw485+gJOwDqSa6268P2t1HiWNsDBBRsHPbNQLaHTghs/3LgEBo8KRnqM1LpMl1017u553rskdpeXltJLCywuUZgThsfz5qlp4luLUG2YrESGwoB2j37gU7xn4de9kEcFwUM24uR97d6k9xVGzgvrLTlnlTdFE/lSXKkD5sdCe/5UUU1Jpk1ZJpMfq8cawuSNsi85UZUY7Y9PevNNVHn3eVYCXcQ2OVCn+Rrudb1RLhQzbVIXDDcQa841ENcXiOcRAZVCDtJ59q6JPY4KqRp2i4Erc5wAe1PqvpWFtZRJJulZvlGc4HvVivcwv8JWPiM1T+sO7Ciiiug803vC3/L1/wAB/rRR4W/5ev8AgP8AWiuap8TOul8KK/i7/kbNa/6/Z/8A0Y1ZNa3i7/kbNa/6/Z//AEY1ZNbw+FHPU+N+oVb0+8ktJwyMQueQDVSiqauKE3B80dz0bT9dBjLW6M03HGeM+/tXZadfpLAryHDEbiUPGfQDvXiljcmJuScDt613Ph/U/PhUGQ7WOCoAI/8ArV5Nej7OWmx9vluPWJp6/F1M7xfevquuiKCXiAdQNu456V1OkWkcUGRGQzMC5PBFc7aRpFr0pdQQ0hClxngd/wD61dvEg328KjbvIyy/4V5jj712fRwqWjY6DQrbMayyLyTjce4rrbZASihhtHfFVbKz8hVC4ORgZP8AOtFkWNBt2oBxitFGyOGrU52bkRigt/3brgDOSaoSXLzDLEDHQc1TWRdvAzirM0QhSMsVLOM8dqzUVF6nOo2Yyb7mehzzmqUr/wCyCDz1FWZHBboTioH2u+QMds1dzaCsZ2pKsiFZRuVh26VlRXDBNknBXIXd0I9vWti4YAZPOPQ9vSuf83+0SGhTy40OPmGGzn0rOTsdlKN42N3R9MF2k08zzC3iG4bOCW9BVu3vDHJtmPmO6nBkXAA9j3rOtr+4sbOSESZB9OMevFeef8JpE/ipdJtjJKsOSz527TnpS51FXZKozqSd9j1SeUldp5jPOR61n3Ue7erKcMD07+9JFdK8aZBGfXipZ2Pl5UsAOceldKs0czi4s4/XIkXBMar8pyx5/XtXkWvyyWF24lDGBslAz8Aj2r2PWgJIpElKhieMg8+nNeDfExCY5VEjq8OFB2kck8msp+6ro0ep3/wwt/Dc+l67d+I9RtBbJZkOmQrxBvTd1bjjGeteUaW2iXviOaH+0v7J0gyM0VxdxtOyJ2BA6k4rnrrRo3s0XfuuGXcXYkn8+lLBrWs2vhi48OLLbx2UcxuZMxr5jEDnD4zj2qFJtps5auidjp4bJLUPKlwLgSO2yRVKqy54ODyMjnFPqj4Vna80KVySzRyDkjoMVer6TDtOlGx8PmV/rErhRRRWxwG94W/5ev8AgP8AWijwt/y9f8B/rRXNU+JnXS+FFfxd/wAjZrX/AF+z/wDoxqya1vF3/I2a1/1+z/8Aoxqya3h8KOep8b9QoooqiBRWppbmE+ckuxjxjPO7tisqp7aYRnDAEZzyKyrQ54NHZgMR7CspPY6aK5dJEkuZFTEm9TjkjvXb6bqRvLqwbz4wisDvOeB6GuAa5tZrDyfNCOc7do6ev0qppl62lIZhi4t1bJfrz7+leFVpuLP0ChiE1ufTtldxvbo/OAOfr9auSyjZkOMY6NXKeH9ZhvtGtr2IBlaMZC88gdBWn/aCSwozApxwrgEj61DlZalqnzO6NRJS3ykc9ueac06RSqHZQ7cKD3rJiu1Lb1yXPYHA/GrS3G4ZKfOp5GP5Vjz3NXRsXTIVds8E84JqBpAGwo+VR1IxWfqk6PCZXIVU52gnJrz+61fXNb1CSKGGW3tEYxkqefxH+FZuvZ2NoYbmV27HoMr+fIYk2nPXnOPy71KtosYyMIeAWIHNZ/hfSG0uxbfcPK7NvdpM5rbVcggfxDuMn61tTTerMqslF8sHoZ2owwpG24Z9WrkLDS9Jt/FT30MSNf7QxDEsDXbytOYSZIwsY4LMvU+ornrix+ya7b3EsFt5csP34pNz5z/GD0/ClON7aDpTVmmzo9WaC/vEm+bKqIzs5Qn2HX8ajlaCGKUFpmmAwg28fj6UyzvGtJBNGgYgZGayde1bzpZHkdVdxkkcAfga3jG2xzWbfL0M7V5lXcS5KlegGRn3rw34kytJIlvFkvIwO3BJwPX2r0d/GEWma3b3DwpesjjbbjrI3YKADk/hXLeLbnUvEnjC81PWtOl0y6IWKO2cYaNRyA2e5zUT958qHKXKc1a6fHdWjBkKyhR8q8Yb6H6VgeIdFVbW5v4yItiFZRnIJHHJ9a9Nlsljt/lKKxGd20Ag/X+lcF4zBTw9cW+9FMsw6ng4rZQSWpy1HoY3gq7Uafc20Y3ByHOf4ce9bVc/4JhMC3ccyKGI8xH7t2x7iugr1sG26KufHZr/AB9OwUUUV1HmG94W/wCXr/gP9aKPC3/L1/wH+tFc1T4mddL4UV/F3/I2a1/1+z/+jGrJrW8Xf8jZrX/X7P8A+jGrJreHwo56nxv1CiiiqICiiigBxG9WG9kLd1/qKdZTJDLt34YA7gflyf61HTZo1lXDcMOhrCtQjUV1uengswlQdp6xO98Paj/YyJNHIFt3GQ8mdqt35B6V1n/CRFolWW687zWBUQpg+wBrzHwveTIkljcxM8JBKMo3ADvnNWptKZS01hJIIMZ8rPAPqBXhYrDyg9j7jA46FWKkmet6RqLSyuky7yD8rBxlfy4rbtbxo4MsHklJ7HOa8U0fVb7SS0dvJG64+452gfXNbH/CWX8G6e4PkxAAbEQMp981xJKOrPS9pz6HqE9wLuwZJl2sSQV6fTmsTwRpjaStx5krFp5TIN5zgH3NczZeKLKeOF4TOoRgxRX3ZPuPSum0rXbS5k2JJnbzgcfpWlOMW7k1JtR5Ud5HIgXKBW7Ec8/jT3nyGIwcYAArAs9bgklxvUHpgHv6YxU8l5Gh3Bxuwffiuo4nHua8urJHZfZriyS4TPAZ9uf0rK1XWoobCa2stPt7VZF+Zs7mI9uBVR71WByAQo49a5XxJqMCjCZ3xqT06Hv1pOKQRgr3KeseJp9H0o393GRp5lEImHzjd1xge1eP+L/iJqGrv9m0ESBGGC5HzfgK6XxN4lN/pNvpwhtfssEpcOq/vJCe5PQitDRT4Vn0XSraxtov7ZSSSW/laIhhnO1dxHIxg4FZNub5UzXVK9jkfh5p8qLb6rM9w19HISj7zuiYHg+1exaz4cni0O21jVZVea7f7sjFnPH3ie9Y5tYLSIz20aZc5KgY3e+asXF9earPZWMk0sxkZYYiz8JkgcDtXRTp8qSMJp35mafhDSodQ1QLNpkl1bKjKgBPkvIBnDn09vp614x8QNHn/wCEquba6W0h8h8tb2su+OEtyV+o4+lfQfxX8X2Pw88KRabocsX9sSp9ngHG6MH70p9+PzxXz9aWbXV0qrHJNNI3z4G95SfcfeOaqH7x6bHBVmV9NhWDTZiUTJIVSD0ptW7+JrZvszxGIxk/Ic5X2OeaqV7VGPLBI+QzGfPXdugUUUVqcJveFv8Al6/4D/Wijwt/y9f8B/rRXNU+JnXS+FFfxd/yNmtf9fs//oxqya1vF3/I2a1/1+z/APoxqya3h8KOep8b9QoooqiAooooAKKKKANjwxdi21DDgMjqVwx46V0MdybdkWQqIjkxSqOv41xMTmOQOOoOa7aykg1izRQCrqvzAgEDHoK48ZBySl2PfyXEKLdJkGswW99bSNBKiz443DnjtnvWdpMk6Rk3kZRvuiN+c+4xUsumTWc7Szkrbu2QgOSoHcEdq0oZEmt4PJMhRSSSq5P4jrXjzp3dz6qnV0sammRRyBJR5TnGAuApA/nVjyUDgYIc8B2GMn61Ui03f5b2jgMBv345z+NWY4rxtoYsQTlSi8Z+lChY052WbPzobhnicvls4BOT602TxdaQ3Eyyyn5CFeN2Py/THepbC3nbKzTykgkjHf2+lGpaVb3EfmQWyvMFO7GAT68jrT5X0GpO1ytf+ONLjUSWwWRyclFkAyMf54rD1XVk1eDEUZgaVc7WPDDuM9q5/WdJS3jnaExxsp5Eingexrmryz1ybMFpiWAHPzPtwfr3rKXPs0XGpG+5Z1a8Jn2yqoRECBI0AXA6H3q58P5Wn1oSeWUiIIwoOG/GuWu9K1+5BM2yNVwcNIMD6AZzWjpVvcafJCI5ZYppBgEZGD14xmphGXMtNB1K0LaM9b17UooInhkt2kUjcSDhV9q574b3p1b4g6dZ6fM8Dxv5isfmA2gnv64rk9V1C+86OA3U0z/eZ2yv5Z61m6R4kl8Ja3BqlnBFLd2zFgs8e/LY+9XTe7ucdWreOhueNNL1G/1u81fWLmKO/OoSQtZSgmVgOSw7bBwPxrtPhLrWmeH9eub/AFGXy444GEMpXeEfHcdT6cV5XaeJdT8T67ealqc0lxfTZAXZt2jPbsK2cYwDjAOQo559Se5rtw2H5436M8TG46NH1L3iDUpNX1u91CYgyXEhfKrtHtx24rPo60V6aVlZHy05OcnJ9Qooopkm94W/5ev+A/1oo8Lf8vX/AAH+tFc1T4mddL4UV/F3/I2a1/1+z/8Aoxqya1vF3/I2a1/1+z/+jGrJreHwo56nxv1CiiiqICiiigAooooAKu6dfSWcgKHAzmqVFJpNWZcJypyUo7o9Aj1az1KzIkLF+gjKjKn2PpXPyahNp80sSOFDYPm4yYz9f51gqxXoSPpUiCeT7k4O75XDru4/rXn18K170dT6TCZtGbUamj/A9A0vVY5VjQOGAPzDOc+/HrXVK0KwRKhTJGcnnNea2uhm1gjlsLgmRTvMfZh7itKC/uLdFWZnhXORujwM+57VycrW6PchWT3O3Mispw8cYxzv7YrGn1yyiiMcas8gbAVen1zXP33iJI1IdWO07gy5yc//AF6qaPqC6tK3nCJAvBQ8MPfkc0t2U6umhsiFNTLiW33xlgRv6HHb6Uy6t/s0RjEKuMEBSMhfarbzxW6wRgkh+EKg+meT0HSi71G0hs2N4Y2HXJYHP0rRQSRk59znkhaORDEqhYxny8ZU+9Yt5Bc4P2bKzB9zYycj1X3+taCeKoYrmT7P9m8tT93ftc+2ax9T1q6vUaa1txFOxxuQ5GO/41LimT7RLqZWsXLTSSF53YqAo3NyTUfhO3t5tYs7jWp5YLJJVaRggLFc8kf0p0OlybvtF82F6lWOCfTNTx2yiQSuWOPuoTwPfFb0MPKb10PPxuNjSidD4t1ptd8QXd+pYQuxEKlQpVOwwKxaUnJyetJXpxSikl0PlKk3Uk5MKKKKZAUUUUAb3hb/AJev+A/1oo8Lf8vX/Af60VzVPiZ10vhRX8Xf8jZrX/X7P/6Masmtbxd/yNmtf9fs/wD6Masmt4fCjnqfG/UKKKKogKKKKACiiigAooooAKcrFTkU2igDd0jVjbkI7so7OOSK72O70+60xcSQyOU5BPPHtXktOV2U5BIPqKxnRjLY9TD5nOkuWSujv7mysiJGk+RWGQ0p3Y/AVzt6+mxbVRgzYwfL5wfrWI00jDDO5HoWNR9KzWFXU2qZu/sRJJLu7jZkF6/lbsIuWJx/Ksq4llkmXPnFM/Myxk5/DmtLJ2kHBHoaYsUa/djVc+nFDwse5CzWT+JBaWul7Du2Fj8x8wZIrcj1GyhtjFHB5jfw7FyoP8qxkIjGIwqg9cClLE9Sa1jQgkQ8zl0QS/PN5jkkjoucge59TTetFFapJKyPPqVJVJc0mFFFFBmFFFFABRRRQBveFv8Al6/4D/Wijwt/y9f8B/rRXNU+JnXS+FFfxd/yNmtf9fs//oxqya1vF3/I2a1/1+z/APoxqya3h8KOep8b9QoooqiAooooAKKKKALmm6bfapcNBpllc3k6qXMdvE0jBcgZwoJxyPzrS/4Q7xP/ANC5rP8A4Ay//E10Pwhmltp/Fs9vI8U0fh67dJEYqyMChBBHIIPeue/4THxP/wBDHrP/AIHS/wDxVYOdRzcY20OlU6cYKU7632D/AIQ7xP8A9C5rP/gDL/8AE0f8Id4n/wChc1n/AMAZf/iaP+Ex8T/9DHrP/gdL/wDFUf8ACY+J/wDoY9Z/8Dpf/iqf77y/EX7jz/AP+EO8T/8AQuaz/wCAMv8A8TR/wh3if/oXNZ/8AZf/AImj/hMfE/8A0Mes/wDgdL/8VR/wmPif/oY9Z/8AA6X/AOKo/feX4h+48/wD/hDvE/8A0Lms/wDgDL/8TR/wh3if/oXNZ/8AAGX/AOJo/wCEx8T/APQx6z/4HS//ABVSL4r8VtC0q6/rhiUgM4vJdoJ6AnNH77y/EP3Hn+BH/wAId4n/AOhc1n/wBl/+Jo/4Q7xP/wBC5rP/AIAy/wDxNH/CY+J/+hj1n/wOl/8AiqP+Ex8T/wDQx6z/AOB0v/xVH77y/EP3Hn+Af8Id4n/6FzWf/AGX/wCJo/4Q7xP/ANC5rP8A4Ay//E0f8Jj4n/6GPWf/AAOl/wDiqP8AhMfE/wD0Mes/+B0v/wAVR++8vxD9x5/gH/CHeJ/+hc1n/wAAZf8A4mj/AIQ7xP8A9C5rP/gDL/8AE0f8Jj4n/wChj1n/AMDpf/iqP+Ex8T/9DHrP/gdL/wDFUfvvL8Q/cef4B/wh3if/AKFzWf8AwBl/+Jo/4Q7xP/0Lms/+AMv/AMTR/wAJj4n/AOhj1n/wOl/+Ko/4THxP/wBDHrP/AIHS/wDxVH77y/EP3Hn+Af8ACHeJ/wDoXNZ/8AZf/iazdS02+0u4WDU7K5s52UOI7iJo2K5IzhgDjg/lWl/wmPif/oY9Z/8AA6X/AOKrofi9NLcz+Ep7iR5ZpPD1o7yOxZnYlySSeSSe9JTqKajK2o3CnKDlC+ltzgKKKK3OY3vC3/L1/wAB/rRR4W/5ev8AgP8AWiuap8TOul8KK/i7/kbNa/6/Z/8A0Y1ZNa3i7/kbNa/6/Z//AEY1ZNbw+FHPU+N+oUUUVRAUUUUAFFFFAHd/Cf8A5nH/ALFu8/8AZK4SrVjf3dh9o+xXEsH2iFreXy2xvjb7yn1BwOKq1nGFpOXc1lNShGPa4UUUVoZBRRRQAV6pplrqV78F7+2ke1K/aEuLaMzwo3lLkucZBzkdDye1eV0VnVp89vJ3NqNX2bd1umvvO1+F9lp97famLqC0u9RjtGfT7W7fbFNNkcHJAJx0BPNdRaQWFnZahd61oOhxaqmoWkX2XIaNEYDcQqvjkckZIBPSvIqKidByk3c0p4hQily7f12PVvHVnoA0DxImn2OnW8un6okdrJbsd7xsuWySx3DP4DtivKaKKulT9mrXuZ1qvtZc1rBRRRWhiFFFFABXd/Fj/mTv+xbs/wD2euEq1fX93f8A2f7bcSz/AGeFbeLzGzsjX7qj0AyeKzlC8lLsaxmowlHvYq0UUVoZG94W/wCXr/gP9aKPC3/L1/wH+tFc1T4mddL4UV/F3/I2a1/1+z/+jGrJooreHwo56nxv1CiiiqICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAN7wt/y9f8B/rRRRXNU+JnXS+FH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph shows resected nasal/sinus polyp tissue. The bottom portion of the specimen demonstrates the characteristic white (or sometimes grey), avascular nature of poylp tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel Hamilos, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_43_3761=[""].join("\n");
var outline_f3_43_3761=null;
var title_f3_43_3762="Lactating breast abscess treated with needle aspiration";
var content_f3_43_3762=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F74709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F74709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Lactating breast abscess before and after needle aspiration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    If the overlying skin is normal, aspiration under ultrasound guidance is the preferred method of management.",
"    <br>",
"     (A) This shows appearance at presentation.",
"     <br>",
"      (B) This shows appearance following treatment with aspiration and antibiotics.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Courtesy of Michael J Dixon, MD.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_43_3762=[""].join("\n");
var outline_f3_43_3762=null;
var title_f3_43_3763="Patient information: Meningitis in children (The Basics)";
var content_f3_43_3763=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?16/35/16946\">",
"         Patient information: Aseptic meningitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/1/31762\">",
"         Patient information: Bacterial meningitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?43/38/44642\">",
"         Patient information: Ear infections (otitis media) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/40/40578\">",
"         Patient information: Fever in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/47/33522\">",
"         Patient information: Flu (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/31/3570\">",
"         Patient information: Headache (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/56/28546\">",
"         Patient information: Seizures (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/53/17234\">",
"         Patient information: Sinusitis in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/48/12035\">",
"         Patient information: Vaccines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/34/28194\">",
"         Patient information: Viral meningitis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/12/35013\">",
"         Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/48/1796\">",
"         Patient information: Meningitis in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/18/37156\">",
"         Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/36/42566\">",
"         Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Meningitis in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/meningitis-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H728529755\">",
"      <span class=\"h1\">",
"       What is meningitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Meningitis is a condition that can cause fever, headache, and a stiff neck. Meningitis happens when the tissues that surround the brain and spinal cord (called the &ldquo;meninges&rdquo;) get infected. This can occur after a child has an infection in another part of the body. The germs can travel through the blood to the tissues that surround the brain and spinal cord.",
"     </p>",
"     <p>",
"      There are 2 main types of meningitis, depending on which germs are causing the infection. &ldquo;Bacterial meningitis&rdquo; is caused by bacteria. &ldquo;Viral meningitis&rdquo; is caused by viruses.",
"     </p>",
"     <p>",
"      It is important that doctors figure out if a child has bacterial or viral meningitis. This is because bacterial meningitis is a medical emergency. If bacterial meningitis is not treated quickly, it can lead to brain problems such as deafness or learning problems. Bacterial meningitis can even lead to death. Viral meningitis is usually less serious, and does not usually lead to long-term brain problems or death.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H728529762\">",
"      <span class=\"h1\">",
"       What are the symptoms of meningitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Bacterial and viral meningitis can cause many of the same symptoms. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Headache",
"       </li>",
"       <li>",
"        Stiff neck",
"       </li>",
"       <li>",
"        Nausea or vomiting",
"       </li>",
"       <li>",
"        Acting confused, or being hard to wake up",
"       </li>",
"       <li>",
"        Having light bother a person&rsquo;s eyes",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Newborn babies can also have other symptoms that include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Not feeding well",
"       </li>",
"       <li>",
"        Diarrhea",
"       </li>",
"       <li>",
"        A bulging soft spot on the skull",
"       </li>",
"       <li>",
"        Being more sleepy or acting more upset than usual",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Sometimes, bacterial and viral meningitis have different symptoms. Children with bacterial meningitis may have seizures or red-purple spots on the skin. Children with viral meningitis may have a runny nose, muscle aches, cough, or a red-pink rash.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H728529769\">",
"      <span class=\"h1\">",
"       When should I bring my child to the doctor?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you think that your child might have meningitis, bring him or her to the doctor or hospital right away.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H728529776\">",
"      <span class=\"h1\">",
"       Is there a test for meningitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Doctors can do different tests to figure out if a child has meningitis and what type it is. Tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        &ldquo;Lumbar puncture,&rdquo; also known as a spinal tap &ndash; During this procedure, a doctor puts a thin needle in the lower back and removes a small amount of spinal fluid. Spinal fluid is the fluid that surrounds the brain and spinal cord. He or she will do lab tests on the spinal fluid.",
"       </li>",
"       <li>",
"        CT scan, or other imaging tests &ndash; Imaging tests can create pictures of the inside of the body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H728529783\">",
"      <span class=\"h1\">",
"       How is meningitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on the type of meningitis.",
"     </p>",
"     <p>",
"      Bacterial meningitis is treated in the hospital with:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Antibiotic medicines that go into a child&rsquo;s vein",
"       </li>",
"       <li>",
"        Other treatments, such as medicines to keep the blood pressure normal",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Viral meningitis is not treated with antibiotics. That&rsquo;s because antibiotics do not kill viruses. Treatment for viral meningitis includes:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Rest",
"       </li>",
"       <li>",
"        Drinking fluids",
"       </li>",
"       <li>",
"        Medicine to reduce the fever and headache",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      It can take a few days for test results to show whether a child has bacterial or viral meningitis. But bacterial meningitis needs to be treated quickly, so doctors usually start antibiotics right away. Then, doctors wait for the test results to know if they should continue or stop the antibiotics.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H728529790\">",
"      <span class=\"h1\">",
"       Can meningitis be spread from one person to another?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The bacteria and viruses that cause meningitis can be spread from one person to another.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H728529797\">",
"      <span class=\"h1\">",
"       Can meningitis be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help reduce the chance of getting meningitis, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Make sure that your child gets the vaccines your doctor or nurse recommends &ndash; Certain vaccines can reduce the chance of your child getting meningitis.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If someone in your home has meningitis, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Avoid spreading germs &ndash; For example, wash your hands before eating, and do not share cups or silverware.",
"       </li>",
"       <li>",
"        Ask your doctor or nurse about taking antibiotics &ndash; Sometimes doctors prescribe antibiotics for other people at home to prevent them from getting meningitis.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4261466\">",
"      <span class=\"h2\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=see_link\">",
"       Patient information: Fever in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/31/3570?source=see_link\">",
"       Patient information: Headache (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=see_link\">",
"       Patient information: Vaccines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/38/44642?source=see_link\">",
"       Patient information: Ear infections (otitis media) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/53/17234?source=see_link\">",
"       Patient information: Sinusitis in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=see_link\">",
"       Patient information: Flu (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/56/28546?source=see_link\">",
"       Patient information: Seizures (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/35/16946?source=see_link\">",
"       Patient information: Aseptic meningitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/1/31762?source=see_link\">",
"       Patient information: Bacterial meningitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/34/28194?source=see_link\">",
"       Patient information: Viral meningitis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/48/1796?source=see_link\">",
"       Patient information: Meningitis in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=see_link\">",
"       Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/18/37156?source=see_link\">",
"       Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/12/35013?source=see_link\">",
"       Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?3/43/3763?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15649 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-125.39.66.147-B9BF6B98CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_43_3763=[""].join("\n");
var outline_f3_43_3763=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H728529755\">",
"      What is meningitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H728529762\">",
"      What are the symptoms of meningitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H728529769\">",
"      When should I bring my child to the doctor?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H728529776\">",
"      Is there a test for meningitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H728529783\">",
"      How is meningitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H728529790\">",
"      Can meningitis be spread from one person to another?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H728529797\">",
"      Can meningitis be prevented?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4261466\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/35/16946?source=related_link\">",
"      Patient information: Aseptic meningitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/1/31762?source=related_link\">",
"      Patient information: Bacterial meningitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/38/44642?source=related_link\">",
"      Patient information: Ear infections (otitis media) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=related_link\">",
"      Patient information: Fever in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=related_link\">",
"      Patient information: Flu (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/31/3570?source=related_link\">",
"      Patient information: Headache (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/12/35013?source=related_link\">",
"      Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/48/1796?source=related_link\">",
"      Patient information: Meningitis in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/56/28546?source=related_link\">",
"      Patient information: Seizures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/53/17234?source=related_link\">",
"      Patient information: Sinusitis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=related_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/18/37156?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=related_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/34/28194?source=related_link\">",
"      Patient information: Viral meningitis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_43_3764="Retroperitoneal nodes CT";
var content_f3_43_3764=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F58932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F58932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retroperitoneal lymphadenopathy in follicular non-Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography&nbsp;of the abdomen at the level of the renal pelvis in a patient with extensive follicular non-Hodgkin lymphoma. There is massive enlargement of the retroperitoneal nodes (blue arrow), along with matted mesenteric nodes (red arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Arnold S Freedman, MD, Jonathan W Friedberg, MD, and Pam DePiro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_43_3764=[""].join("\n");
var outline_f3_43_3764=null;
var title_f3_43_3765="Acetaminophen, caffeine, and dihydrocodeine: Patient drug information";
var content_f3_43_3765=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Acetaminophen, caffeine, and dihydrocodeine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/45/5847?source=see_link\">",
"     see \"Acetaminophen, caffeine, and dihydrocodeine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F129440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Trezix&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3491790",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Acetaminophen may cause very bad liver problems. Your risk is higher if you take more than 4 grams of acetaminophen a day, drink beer, wine, or mixed drinks, or have liver disease. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701413",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to acetaminophen, caffeine, dihydrocodeine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, bowel block or liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are addicted to drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701044",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink beer, wine, or mixed drinks or take any drugs that have alcohol.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696680",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid other sources of acetaminophen. An overdose may cause problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3927405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug with other strong pain drugs or if you are using a pain patch without talking to your doctor first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694768",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take more than what your doctor told you to take. Liver problems may happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11258 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-1.234.2.38-C3DAD56939-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_43_3765=[""].join("\n");
var outline_f3_43_3765=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129440\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026459\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026461\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026460\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026465\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026466\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026468\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026463\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026464\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026469\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026470\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/45/5847?source=related_link\">",
"      Acetaminophen, caffeine, and dihydrocodeine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_43_3766="Central hyalinizing sclerosis - high power";
var content_f3_43_3766=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Liver biopsy showing central hyalinizing sclerosis in a patient with alcohol abuse (high power, Gomori trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A central vein is surrounded by scar tissue (blue). Several fat-filled and swollen hepatocytes are evident. This lesion is thought to be one of the earlier findings in patients whose alcohol abuse will eventually cause cirrhosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_43_3766=[""].join("\n");
var outline_f3_43_3766=null;
var title_f3_43_3767="Screening for intracranial aneurysm";
var content_f3_43_3767=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for intracranial aneurysm",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/43/3767/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/43/3767/contributors\">",
"     Robert J Singer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/43/3767/contributors\">",
"     Christopher S Ogilvy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/43/3767/contributors\">",
"     Guy Rordorf, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/43/3767/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/43/3767/contributors\">",
"     Jose Biller, MD, FACP, FAAN, FAHA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/43/3767/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/43/3767/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/43/3767/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subarachnoid hemorrhage (SAH) is often a devastating event. Approximately 10 percent of patients die prior to reaching the hospital and, of those who make it in time, only one-third will have a \"good result\" after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most SAHs are caused by ruptured saccular aneurysms. Recommendations for screening for aneurysms and methods of screening are discussed here. The epidemiology and pathogenesis of intracranial aneurysms and management of unruptured aneurysms, and screening for new aneurysms after treatment for SAH are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25225?source=see_link\">",
"     \"Unruptured intracranial aneurysms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link&amp;anchor=H29#H29\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\", section on 'Early rebleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of intracranial saccular aneurysms by radiographic and autopsy series is approximately 0.4 to 6.0 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/2\">",
"     2",
"    </a>",
"    ], or between 1 to 18 million people in the United States. In adult patients without risk factors, the best estimate is that approximately 2 percent harbor asymptomatic cerebral aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/3\">",
"     3",
"    </a>",
"    ]. Of patients with cerebral aneurysms, 20 to 30 percent have multiple aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/4\">",
"     4",
"    </a>",
"    ]. Aneurysmal SAH occurs at an estimated rate of 6 to 16 per 100,000 population [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/4\">",
"     4",
"    </a>",
"    ]. In North America, this translates into approximately 30,000 affected persons per year. Thus, most aneurysms do not rupture.",
"   </p>",
"   <p>",
"    The probability of rupture is related to the size of the aneurysm. Small aneurysms (less than 6 mm in diameter) are most commonly identified with screening, and these are at low risk for rupture (",
"    <a class=\"graphic graphic_figure graphicRef63534 \" href=\"UTD.htm?42/27/43454\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, patients with smaller aneurysms (&lt;10 mm) that have ruptured have a better prognosis than larger aneurysm rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aneurysm surgery is associated with significant morbidity in mortality. In an international multicenter report of 1449 patients with unruptured intracranial aneurysms, the rate of surgery-related morbidity and mortality in those without a prior history of bleeding from a different aneurysm was 18 percent at 30 days and 16 percent at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/5\">",
"     5",
"    </a>",
"    ]. The one-year rates were affected by age: 6.5 percent under age 45; 14 percent between the ages of 45 and 64; and 32 percent over the age of 64. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These findings suggest that widespread screening for cerebral aneurysm is not warranted. This was also the conclusion in guidelines published by the American Stroke Association [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, screening may be considered in some populations at relatively high risk of cerebral aneurysm formation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First-degree relatives of patients with cerebral aneurysm, when two or more family members have been affected.",
"     </li>",
"     <li>",
"      Patients with a heritable disorder associated with the presence of intracranial aneurysm, such as autosomal dominant polycystic kidney disease (ADPKD), glucocorticoid remediable hyperaldosteronism (GRA), and connective tissue diseases such as Ehlers-Danlos syndrome IV and pseudoxanthoma elasticum [",
"      <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RELATIVES OF PATIENTS WITH CEREBRAL ANEURYSM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family members of patients with intracranial aneurysms are at increased risk of having an aneurysm. In one study, for example, the age-adjusted prevalence of incidental aneurysms in first-degree relatives of patients with an aneurysm was 9 percent, a number significantly higher than the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/11\">",
"     11",
"    </a>",
"    ]. Only a small proportion of these families had an identifiable hereditary syndrome known to be associated with aneurysms. In a second report of patients with mostly sporadic SAH, intracranial aneurysms were found in 4 percent of first-degree relatives (approximately twice that of the general population) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/12\">",
"     12",
"    </a>",
"    ]. The mode of inheritance is variable, with autosomal dominant, recessive, and multifactorial transmission evident in different families [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a large population study from Scotland, the estimated 10-year prospective risk of SAH for relatives free of SAH at the time of the index SAH increased in an ascending manner according to the relationship to the index case as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One second degree relative, 0.3 percent (95% CI 0.0-0.6)",
"     </li>",
"     <li>",
"      One first degree relative, 0.8 percent (95% CI 0.2-1.5)",
"     </li>",
"     <li>",
"      Two first degree relatives, 7.1 percent (95% CI 0.2-14.0)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The wide confidence intervals around these risk estimates reflect the small numbers of SAH events that occur in relatives of index cases, even in large population studies. Nonetheless, the risk for first degree relatives of patients with SAH appear to be much higher than that of the general population, where the 10-year prospective risk of SAH is about 0.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/15\">",
"     15",
"    </a>",
"    ]. The risk of aneurysm among family members of patients with aneurysm is also influenced by those risk factors (cigarette smoking, hypertension) that affect aneurysm formation in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25225?source=see_link&amp;anchor=H3#H3\">",
"     \"Unruptured intracranial aneurysms\", section on 'Pathogenesis and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Familial aneurysms tend to rupture at a smaller size and younger age than sporadic aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/11,17\">",
"     11,17",
"    </a>",
"    ]. Siblings often experience rupture in the same decade of life [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/17\">",
"     17",
"    </a>",
"    ]. Families with intracranial aneurysms do not appear to demonstrate the phenomenon of anticipation, ie subsequent generations are not more likely to develop SAH at younger ages than previous generations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple cerebral aneurysms are also more common in the familial syndrome than among those with sporadic aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most cerebral aneurysms are initially discovered in families after rupture causes SAH. Thus, screening studies have predominantly looked at relatives of patients who have suffered a SAH. Recommendations for screening asymptomatic family members of patients with SAH for the presence of intracranial aneurysms depend upon the number of affected relatives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Two or more affected first-degree relatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening of asymptomatic first-degree relatives is generally recommended in families that have two or more individuals with aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/20\">",
"     20",
"    </a>",
"    ]. One study that employed this approach found aneurysms by magnetic resonance angiography (MRA) in 37 of 400 (9 percent) asymptomatic individuals among 68 families with a history of aneurysmal SAH [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Analytic models have come to different conclusions regarding the efficacy of screening, depending in part on the role of conventional angiography in screening and the choice of aneurysm treatment used in their model. One study suggested that this approach would not be effective in reducing morbidity and mortality unless aneurysm prevalence was substantially greater than 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/22\">",
"     22",
"    </a>",
"    ]. However, another study found that a screening program could reduce morbidity and mortality in this population in a cost-effective manner [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the decision is made to screen, it is uncertain what screening interval is appropriate. In a study that recommended repeat screening at five-year intervals, 74 patients had one repeat screening and 28 patients had a second repeat screening [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/24\">",
"     24",
"    </a>",
"    ]. Ten new aneurysms were detected in nine patients; two patients had a SAH three years after a negative screening procedure.",
"   </p>",
"   <p>",
"    The American Stroke Association guidelines concluded that while people with two or more first degree relatives with intracranial aneurysm have an increased incidence of intracranial aneurysms, the cost effectiveness of screening in these populations has not been evaluated. They suggest that screening in these individual should be considered on an individual basis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our usual practice is to screen relatives with MRA yearly for three years and then expand the screening interval to every five years for those who had no aneurysms detected on the initial three scans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     One affected first-degree relative",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lifetime risk of SAH for individuals with only one affected first-degree relative is relatively small, ranging from 1 to 4.7 percent at age 70 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/12,14\">",
"     12,14",
"    </a>",
"    ], although the risk of aneurysm formation may be higher [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some advocate screening in this population as well, but this approach is not generally recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/20\">",
"     20",
"    </a>",
"    ]. In one study, for example, 626 first-degree relatives of 160 patients with sporadic subarachnoid hemorrhage were screened with magnetic resonance angiography, followed by conventional angiography in those thought to have aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/25\">",
"     25",
"    </a>",
"    ]. Aneurysms were found in 25 first-degree relatives (4 percent), twice the prevalence in the general population, but less than one-half the prevalence of people with two or more first-degree relatives with SAH. Eighteen underwent surgery: 5 with medium sized aneurysms (5 to 11 mm in diameter); 11 with small aneurysm (less than 5 mm); and 2 with both small and medium-sized aneurysms. Outcome was assessed at six months after surgery and was combined with a decision analysis model to estimate the effectiveness of screening:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eleven patients who underwent surgery experienced a",
"      <strong>",
"       decrease in function",
"      </strong>",
"      at six months.",
"     </li>",
"     <li>",
"      Surgery increased life expectancy by 0.9",
"      <span class=\"nowrap\">",
"       month/person",
"      </span>",
"      screened at the expense of 19 years of decreased function per person.",
"     </li>",
"     <li>",
"      The number of relatives who would need to be screened to prevent one SAH during a lifetime was 149; 298 would have to be screened to prevent a fatal SAH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies have also found that the quality of life and functional outcome of many patients who undergo screening followed by angiography and surgery is diminished for at least one year [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/26\">",
"     26",
"    </a>",
"    ]. Furthermore, the gain in life expectancy per person screened is considerably lower than the benefits offered by other screening programs. These observations suggest that screening of patients with only one affected first-degree relative is not warranted. This was also the conclusion of guidelines published by the American Stroke Association [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HEREDITARY SYNDROMES ASSOCIATED WITH ANEURYSM FORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral aneurysm formation is more common in individuals with certain hereditary syndromes as discussed below. Despite this risk, the American Stroke Association guidelines concluded that screening is not efficacious in these populations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Autosomal dominant polycystic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of cerebral aneurysm in ADPKD is approximately 4 percent in young adults, increasing with age to as high as 10 percent in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. Patients with a family history of intracranial aneurysm or SAH appear to be at greatest risk [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/27,31,32\">",
"     27,31,32",
"    </a>",
"    ]. In one study, for example, asymptomatic intracranial aneurysms were found in 6 of 27 patients (22 percent) with, and only 3 of 56 patients (5 percent) without a positive family history [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=see_link\">",
"     \"Extrarenal manifestations of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been estimated that aneurysm rupture occurs in 65 to 75 percent of affected patients with ADPKD, a value higher than that of non-ADPKD patients with an intracerebral aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/30\">",
"     30",
"    </a>",
"    ]. Aneurysm rupture in ADPKD most often occurs before the age of 50 and in patients with poorly controlled hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/30\">",
"     30",
"    </a>",
"    ]. In addition, patients who have already had one aneurysm clipped following a cerebral bleed may be at increased risk of new aneurysm formation for as long as 15 years after the initial surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, the role for radiologic screening of asymptomatic patients with ADPKD is unsettled. As mentioned above, the decision is based upon weighing the risks of aneurysm surgery versus the benefits of possibly preventing aneurysm rupture; the risk-benefit ratio in asymptomatic patients with ADPKD is uncertain. At present, routine screening is recommended only for high-risk patients, such as those with a previous rupture, a positive family history of an intracerebral bleed, warning symptoms, a high-risk occupation in which loss of consciousness would place the patient or others at extreme risk, and prior to surgery that is likely to be associated with hemodynamic instability with hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/27,32\">",
"     27,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=see_link&amp;anchor=H6#H6\">",
"     \"Extrarenal manifestations of autosomal dominant polycystic kidney disease\", section on 'Recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other hereditary disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with glucocorticoid-remediable aldosteronism (GRA) are at increased risk of hemorrhagic stroke, in part due to a relatively high frequency of cerebral aneurysm rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22615?source=see_link\">",
"     \"Familial hyperaldosteronism\"",
"    </a>",
"    .) It has been suggested that all patients with genetically proven GRA should undergo screening for cerebral aneurysm at puberty and every five years thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/34\">",
"     34",
"    </a>",
"    ]. However, the benefit of such an approach has not been proven and, as in all patients, must be weighed against the risk of prophylactic surgery for small aneurysms that might not rupture.",
"   </p>",
"   <p>",
"    Connective tissue diseases such as Ehlers-Danlos syndrome and pseudoxanthoma elasticum are associated with an increased risk of cerebral aneurysm formation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/13,17\">",
"     13,17",
"    </a>",
"    ], but no studies have specifically addressed the issue of screening.",
"   </p>",
"   <p>",
"    Bicuspid aortic valve is a congenital condition with familial clustering in some cases. In one case-control study, the frequency of intracranial aneurysm was higher in this population compared to a control group (9.8 versus 1.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/35\">",
"     35",
"    </a>",
"    ]. However, the benefit of an aneurysm screening program in individuals with bicuspid aortic valve has not been evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CHOICE OF SCREENING TEST",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the decision is made to screen, MR angiography (MRA) or CT angiography (CTA) are reasonable choices [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/29,31,36,37\">",
"     29,31,36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MRA can identify aneurysms 3 to 5 mm or larger [",
"      <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/38\">",
"       38",
"      </a>",
"      ]. In one cohort study of 138 patients with suspected intracranial aneurysm, volume-rendering, 3D-time-of-flight MRA at 3 Tesla had a greater than 95 percent sensitivity and accuracy for detection of aneurysms [",
"      <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CTA also will frequently miss aneurysms smaller than 3 mm, and in patients with a low prior probability of aneurysm may have false positive results for aneurysms reported as large as 7 mm (",
"      <a class=\"graphic graphic_figure graphicRef81565 graphicRef69728 \" href=\"UTD.htm?19/35/20030\">",
"       figure 2A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/43/3767/abstract/40,41\">",
"       40,41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cerebral angiography is a more invasive test that is associated with a higher risk of complications. Furthermore, the benefits of finding smaller aneurysms with angiography are unlikely to be of benefit for screening purposes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/17/5394?source=see_link\">",
"       \"Patient information: Brain aneurysm (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening for asymptomatic intracranial aneurysms in the general population is not indicated. Aneurysms have a baseline prevalence of 0.2 to 6 percent in adults; these have a low risk of rupture; interventions to treat aneurysms have an associated risk of complications. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Rationale'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Family members of patients with intracranial aneurysms are at increased risk of having an aneurysm. The risk increases with the degree of association and the number of family members affected. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Relatives of patients with cerebral aneurysm'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic syndromes associated with a higher risk of cerebral aneurysm formation include autosomal dominant polycystic kidney disease, Ehlers Danlos syndrome, pseudoxanthoma elasticum, glucocorticoid-remediable aldosteronism, and bicuspid aortic valve. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Hereditary syndromes associated with aneurysm formation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In populations with two or more first-degree relatives with intracranial aneurysm, screening programs have demonstrated an increased incidence of intracranial aneurysms, but the cost-effectiveness of screening in these populations has not been evaluated. Screening in these individuals should be considered on an individual basis. Our usual practice is to screen relatives with magnetic resonance yearly for three years and then expand the screening interval to every five years for those who had no aneurysms detected on the initial three scans. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Two or more affected first-degree relatives'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Theoretical modeling suggests that screening is not efficacious in populations with genetic syndromes associated with cerebral aneurysm formation or in family members with a single first-degree relative with aneurysmal subarachnoid hemorrhage or an intracranial aneurysm. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'One affected first-degree relative'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Hereditary syndromes associated with aneurysm formation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/1\">",
"      Tidswell P, Dias PS, Sagar HJ, et al. Cognitive outcome after aneurysm rupture: relationship to aneurysm site and perioperative complications. Neurology 1995; 45:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/2\">",
"      Rinkel GJ, Djibuti M, Algra A, van Gijn J. Prevalence and risk of rupture of intracranial aneurysms: a systematic review. Stroke 1998; 29:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/3\">",
"      Vernooij MW, Ikram MA, Tanghe HL, et al. Incidental findings on brain MRI in the general population. N Engl J Med 2007; 357:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/4\">",
"      STEHBENS WE. ANEURYSMS AND ANATOMICAL VARIATION OF CEREBRAL ARTERIES. Arch Pathol 1963; 75:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/5\">",
"      Unruptured intracranial aneurysms--risk of rupture and risks of surgical intervention. International Study of Unruptured Intracranial Aneurysms Investigators. N Engl J Med 1998; 339:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/6\">",
"      Roos EJ, Rinkel GJ, Velthuis BK, Algra A. The relation between aneurysm size and outcome in patients with subarachnoid hemorrhage. Neurology 2000; 54:2334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/7\">",
"      Bederson JB, Awad IA, Wiebers DO, et al. Recommendations for the management of patients with unruptured intracranial aneurysms: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 2000; 102:2300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/8\">",
"      Bederson JB, Connolly ES Jr, Batjer HH, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 2009; 40:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/9\">",
"      Neil-Dwyer G, Bartlett JR, Nicholls AC, et al. Collagen deficiency and ruptured cerebral aneurysms. A clinical and biochemical study. J Neurosurg 1983; 59:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/10\">",
"      Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med 2000; 342:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/11\">",
"      Ronkainen A, Hernesniemi J, Puranen M, et al. Familial intracranial aneurysms. Lancet 1997; 349:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/12\">",
"      Raaymakers TW. Aneurysms in relatives of patients with subarachnoid hemorrhage: frequency and risk factors. MARS Study Group. Magnetic Resonance Angiography in Relatives of patients with Subarachnoid hemorrhage. Neurology 1999; 53:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/13\">",
"      Bromberg JE, Rinkel GJ, Algra A, et al. Familial subarachnoid hemorrhage: distinctive features and patterns of inheritance. Ann Neurol 1995; 38:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/14\">",
"      Teasdale GM, Wardlaw JM, White PM, et al. The familial risk of subarachnoid haemorrhage. Brain 2005; 128:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/15\">",
"      Linn FH, Rinkel GJ, Algra A, van Gijn J. Incidence of subarachnoid hemorrhage: role of region, year, and rate of computed tomography: a meta-analysis. Stroke 1996; 27:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/16\">",
"      Rasing I, Nieuwkamp DJ, Algra A, Rinkel GJ. Additional risk of hypertension and smoking for aneurysms in people with a family history of subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2012; 83:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/17\">",
"      St Jean P, Hart B, Webster M, et al. Alpha-1-antitrypsin deficiency in aneurysmal disease. Hum Hered 1996; 46:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/18\">",
"      Woo D, Hornung R, Sauerbeck L, et al. Age at intracranial aneurysm rupture among generations: Familial Intracranial Aneurysm Study. Neurology 2009; 72:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/19\">",
"      Raaymakers TW, Rinkel GJ, Ramos LM. Initial and follow-up screening for aneurysms in families with familial subarachnoid hemorrhage. Neurology 1998; 51:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/20\">",
"      Schievink WI. Intracranial aneurysms. N Engl J Med 1997; 336:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/21\">",
"      Ronkainen A, Puranen MI, Hernesniemi JA, et al. Intracranial aneurysms: MR angiographic screening in 400 asymptomatic individuals with increased familial risk. Radiology 1995; 195:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/22\">",
"      Crawley F, Clifton A, Brown MM. Should we screen for familial intracranial aneurysm? Stroke 1999; 30:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/23\">",
"      Bor AS, Koffijberg H, Wermer MJ, Rinkel GJ. Optimal screening strategy for familial intracranial aneurysms: a cost-effectiveness analysis. Neurology 2010; 74:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/24\">",
"      Wermer MJ, Rinkel GJ, van Gijn J. Repeated screening for intracranial aneurysms in familial subarachnoid hemorrhage. Stroke 2003; 34:2788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/25\">",
"      Magnetic Resonance Angiography in Relatives of Patients with Subarachnoid Hemorrhage Study Group. Risks and benefits of screening for intracranial aneurysms in first-degree relatives of patients with sporadic subarachnoid hemorrhage. N Engl J Med 1999; 341:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/26\">",
"      Raaymakers TW. Functional outcome and quality of life after angiography and operation for unruptured intracranial aneurysms. On behalf of the MARS Study Group. J Neurol Neurosurg Psychiatry 2000; 68:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/27\">",
"      Fick GM, Gabow PA. Hereditary and acquired cystic disease of the kidney. Kidney Int 1994; 46:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/28\">",
"      Watson ML. Complications of polycystic kidney disease. Kidney Int 1997; 51:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/29\">",
"      Chapman AB, Rubinstein D, Hughes R, et al. Intracranial aneurysms in autosomal dominant polycystic kidney disease. N Engl J Med 1992; 327:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/30\">",
"      Schievink WI, Torres VE, Piepgras DG, Wiebers DO. Saccular intracranial aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1992; 3:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/31\">",
"      Huston J 3rd, Torres VE, Sulivan PP, et al. Value of magnetic resonance angiography for the detection of intracranial aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1993; 3:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/32\">",
"      Chauveau D, Pirson Y, Verellen-Dumoulin C, et al. Intracranial aneurysms in autosomal dominant polycystic kidney disease. Kidney Int 1994; 45:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/33\">",
"      Chauveau D, Sirieix ME, Schillinger F, et al. Recurrent rupture of intracranial aneurysms in autosomal dominant polycystic kidney disease. BMJ 1990; 301:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/34\">",
"      Litchfield WR, Anderson BF, Weiss RJ, et al. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 1998; 31:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/35\">",
"      Schievink WI, Raissi SS, Maya MM, Velebir A. Screening for intracranial aneurysms in patients with bicuspid aortic valve. Neurology 2010; 74:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/36\">",
"      Raaymakers TW, Buys PC, Verbeeten B Jr, et al. MR angiography as a screening tool for intracranial aneurysms: feasibility, test characteristics, and interobserver agreement. AJR Am J Roentgenol 1999; 173:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/37\">",
"      Wiebers DO, Torres VE. Screening for unruptured intracranial aneurysms in autosomal dominant polycystic kidney disease. N Engl J Med 1992; 327:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/38\">",
"      Huston J 3rd, Nichols DA, Luetmer PH, et al. Blinded prospective evaluation of sensitivity of MR angiography to known intracranial aneurysms: importance of aneurysm size. AJNR Am J Neuroradiol 1994; 15:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/39\">",
"      Li MH, Cheng YS, Li YD, et al. Large-cohort comparison between three-dimensional time-of-flight magnetic resonance and rotational digital subtraction angiographies in intracranial aneurysm detection. Stroke 2009; 40:3127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/40\">",
"      Schwartz RB, Tice HM, Hooten SM, et al. Evaluation of cerebral aneurysms with helical CT: correlation with conventional angiography and MR angiography. Radiology 1994; 192:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3767/abstract/41\">",
"      van Gelder JM. Computed tomographic angiography for detecting cerebral aneurysms: implications of aneurysm size distribution for the sensitivity, specificity, and likelihood ratios. Neurosurgery 2003; 53:597.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1135 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-189.2.19.178-DF24B1B659-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_43_3767=[""].join("\n");
var outline_f3_43_3767=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RELATIVES OF PATIENTS WITH CEREBRAL ANEURYSM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Two or more affected first-degree relatives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      One affected first-degree relative",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HEREDITARY SYNDROMES ASSOCIATED WITH ANEURYSM FORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other hereditary disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CHOICE OF SCREENING TEST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1135\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1135|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/27/43454\" title=\"figure 1\">",
"      Frequency of intracranial aneurysm rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/0/14349\" title=\"figure 2A\">",
"      Sensitivity of CTA for intracranial aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/56/5005\" title=\"figure 2B\">",
"      CTA false pos intracran aneurys",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=related_link\">",
"      Extrarenal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22615?source=related_link\">",
"      Familial hyperaldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/17/5394?source=related_link\">",
"      Patient information: Brain aneurysm (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=related_link\">",
"      Treatment of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25225?source=related_link\">",
"      Unruptured intracranial aneurysms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_43_3768="Hyperimmunoglobulin-D syndrome: Clinical manifestations and diagnosis";
var content_f3_43_3768=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hyperimmunoglobulin-D syndrome: Clinical manifestations and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/43/3768/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/43/3768/contributors\">",
"     Yoram C Padeh, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/43/3768/contributors\">",
"     Arye Rubinstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/43/3768/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/43/3768/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/43/3768/contributors\">",
"     Robert Sundel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/43/3768/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/43/3768/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/43/3768/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hyperimmunoglobulin-D syndrome (HIDS) is a rare genetic disorder characterized by recurrent febrile episodes typically associated with lymphadenopathy, abdominal pain, and an elevated serum polyclonal IgD level (MIM #260920). The syndrome can be further categorized into classical and variant forms. The classical form includes 76 percent of known cases and is inherited as an autosomal recessive trait. The variant form has similar clinical manifestations, though its genetic basis has not yet been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrent fever, not due to infection, is a clinical feature of several disorders that are referred to as autoinflammatory diseases. An overview of periodic and recurrent fevers and other autoinflammatory diseases is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=see_link\">",
"     \"Periodic fever syndromes and other autoinflammatory diseases: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hyper-IgD syndrome was initially described in 1984 by Jos van der Meer [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/2\">",
"     2",
"    </a>",
"    ]. The seminal paper on the clinical manifestations of HIDS was published by Joost Drenth in 1994 based on data and observations of 50 patients with the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/3\">",
"     3",
"    </a>",
"    ]. More than 60 percent of patients are of Dutch or French ancestry, although HIDS cases have been reported around the world, including in the United Kingdom, Germany, Italy, Turkey, the Czech Republic, the United States, Japan, and the Arabian peninsula [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. An Internet-based registry has been created to catalog and follow known patients with HIDS (",
"    <a class=\"external\" href=\"file://www.hids.net/\">",
"     www.hids.net",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The clinical and laboratory manifestations of HIDS are reviewed here. Pathophysiology and management of HIDS are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9720?source=see_link\">",
"     \"Hyperimmunoglobulin-D syndrome: Pathophysiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23670?source=see_link\">",
"     \"Hyperimmunoglobulin-D syndrome: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unremitting fever lasting several days and the presence of lymphadenopathy, splenomegaly,",
"    <span class=\"nowrap\">",
"     arthralgia/arthritis,",
"    </span>",
"    abdominal pain, and rash are characteristic of the recurrent episodes that occur in patients with HIDS. Headache may occur and vomiting",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diarrhea may accompany abdominal pain. With the exception of the skin and joint manifestations which tend to linger, other symptoms vanish as the fever declines and patients remain virtually symptom-free between attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The interval between attacks is commonly four to eight weeks, but can vary significantly even in the same patient. Children and adolescents often have shorter intervals, but no strict periodicity has been identified. Provocative factors include vaccinations, minor trauma, surgery, and stress, although a trigger is not always apparent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HIDS usually begin to experience febrile attacks during the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/3\">",
"     3",
"    </a>",
"    ]. Episodes are characterized by the rapid onset of fever, often heralded by chills, and an increase in temperature to over 101.3&ordm;F (38.5&ordm;C). The febrile episodes typically last four to seven days and the fever does not remit until the episode concludes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients or caregivers can predict the impending onset of fever by recognizing prodromal symptoms that include nasal congestion, sore throat, backache, fatigue, vertigo, headache, and even behavioral changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Lymphadenopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 90 percent of patients have palpable lymphadenopathy during a febrile episode. The cervical region is the most commonly involved site, but almost all lymph nodes groups may be affected. Nodes are tender",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rubbery on palpation. Lymph node biopsies show various nonspecific changes including hyperplasia and the presence of plasma cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Abdominal pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aside from fever, abdominal pain may be the cardinal feature of an attack. The level of pain may mimic an acute abdomen and has prompted appendectomies and exploratory laparotomies. Inevitably, the appendix was found to be normal. In a few cases abdominal adhesions have been found, sometimes extensive enough to cause a mechanical ileus [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Splenomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpable splenomegaly is noted in approximately 50 percent of patients, most of whom are children [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/3\">",
"     3",
"    </a>",
"    ]. The prevalence of splenomegaly in adults is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Arthralgia/arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eighty percent of HIDS patient may experience polyarthralgia with a febrile episode. Most of those with arthralgia develop objective signs of arthritis. Larger joints are more commonly affected than smaller ones, and often in a symmetrical fashion. Joint involvement has not been seen in the absence of an ongoing or preceding febrile episode. Joint symptoms tend to linger beyond the end of the febrile period. No evidence of long-term joint destruction has been noted [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/3,7\">",
"     3,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cutaneous manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous manifestations occur in over 80 percent of HIDS patients. An erythematous macular rash is the most commonly noted, followed in frequency by papules, urticaria, erythematous nodules, and petechiae. Eruptions typically consist of multiple lesions which may remain separate but may become confluent. Acral lesions occur more frequently than truncal lesions. Skin biopsies typically demonstrate endothelial swelling and perivascular inflammatory infiltrates [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/3,8\">",
"     3,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 12 percent of patients may develop serositis during an attack [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. Orbital tendonitis with tendomyositis may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/10\">",
"     10",
"    </a>",
"    ]. Secondary (AA) amyloidosis is a rare but serious long-term complication of HIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link&amp;anchor=H10#H10\">",
"     \"An overview of amyloidosis\", section on 'Clinical manifestations'",
"    </a>",
"    .) One case of nummular keratopathy successfully controlled with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    was also reported [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Variant HIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variant HIDS cases differ from classic HIDS in the lack of a known genetic mutation. Such patients can present later in life, even into adulthood, and sometimes manifest less common symptoms. In addition, the intervals between attacks tend to be more variable. These patients also have elevated serum IgD and IgA as diagnostic laboratory findings, though levels may be lower than in patients with classic HIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1894597\">",
"    <span class=\"h2\">",
"     Overlap syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although rare, some patients may develop features that overlap with other periodic fever syndromes. As an example, one case report highlights a 10-year-old boy with manifestations of both tumor necrosis factor receptor associated periodic syndrome (TRAPS) and HIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated serum levels of IgD and IgA are frequently noted. Reference ranges for these immunoglobulins vary by age (",
"    <a class=\"graphic graphic_table graphicRef62882 graphicRef53169 \" href=\"UTD.htm?5/9/5277\">",
"     table 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. When elevated, both IgD and IgA levels usually remain so even between attacks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     IgD level",
"    </span>",
"    &nbsp;&mdash;&nbsp;As its name suggests, HIDS is usually characterized by an elevated serum polyclonal IgD, greater than 14",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (100",
"    <span class=\"nowrap\">",
"     U/mL),",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/3\">",
"     3",
"    </a>",
"    ] though normal levels do not exclude the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Initially thought to be etiologically linked to the pathophysiology, some now consider elevated IgD levels to be an epiphenomenon secondary to the systemic inflammatory process [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     IgA level",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum IgA level is elevated (&gt;260",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    in more than 80 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/3,23\">",
"     3,23",
"    </a>",
"    ]. The elevation is typically due to an increase in polymeric-IgA1 rather than IgA1 monomer or IgA2 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Acute phase reactants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other laboratory findings during attacks are those associated with an acute systemic inflammatory process, including elevated levels of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/3,24\">",
"     3,24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Leukocytes in peripheral blood (predominantly neutrophils)",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate (ESR)",
"     </li>",
"     <li>",
"      C-reactive protein (CRP)",
"     </li>",
"     <li>",
"      Ferritin",
"     </li>",
"     <li>",
"      Serum amyloid A (SAA)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Forty five percent of patients may continue to have elevated SAA levels between attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Urinary mevalonic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excretion of mevalonic acid in the urine may be minimally elevated during febrile episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Urinary LTE4",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary leukotriene-E4 (LTE4) excretion may be elevated during febrile episodes, as illustrated in a study of seven children with HIDS. During flares, affected children had urinary leukotriene-E4 (LTE4) to creatine ratios of 46 to 199",
"    <span class=\"nowrap\">",
"     nmol/mol",
"    </span>",
"    creatinine with a mean of 92 (&gt;40",
"    <span class=\"nowrap\">",
"     nmol/mol",
"    </span>",
"    creatinine), compared with levels of 30 to 40",
"    <span class=\"nowrap\">",
"     nmol/mol",
"    </span>",
"    creatinine with a mean of 36 (&lt;40",
"    <span class=\"nowrap\">",
"     nmol/mol",
"    </span>",
"    creatinine) during asymptomatic intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/27\">",
"     27",
"    </a>",
"    ]. In 20 other children without HIDS but with bacterial or viral illnesses, the same investigators found urinary LTE4 levels to be undetectable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     HIDS and pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of data on HIDS and pregnancy. Two women with HIDS experienced a decrease in frequency of attacks during their pregnancies, no complications of pregnancy, and had healthy newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/28\">",
"     28",
"    </a>",
"    ]. Another woman has had no attacks or complications during three pregnancies (unpublished data).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until genetic testing became available to diagnose cases of HIDS with normal serum IgD levels, an elevated IgD was considered necessary for making the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/3,26\">",
"     3,26",
"    </a>",
"    ]. If the diagnosis is suspected on clinical grounds, serum IgD and IgA should be measured. If elevated, the diagnosis is made [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/29\">",
"     29",
"    </a>",
"    ]. Normal values for IgD and IgA differ by age in children and should be taken into consideration (",
"    <a class=\"graphic graphic_table graphicRef62882 graphicRef53169 \" href=\"UTD.htm?5/9/5277\">",
"     table 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The median period from disease onset to diagnosis is approximately 10 years in patients who lack a family history of HIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/30\">",
"     30",
"    </a>",
"    ]. This delay in diagnosis is due to the fact that symptoms manifested by patients with HIDS are typical of more common illnesses that are usually excluded before rarer diagnoses are considered. The periodic pattern of symptom recurrence is often the clue that finally leads to the correct diagnosis. Given the rarity of serious long-term complications, the rationale for confirming the diagnosis of HIDS is to minimize the morbidity associated with extensive work-ups and unnecessary surgeries [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/31\">",
"     31",
"    </a>",
"    ]. Common findings during and between attacks are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef79149 \" href=\"UTD.htm?32/38/33387\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If the diagnosis is suspected on clinical grounds, we suggest measuring serum IgD and IgA levels. If serum levels of these immunoglobulins are elevated, the diagnosis of HIDS is established [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/29\">",
"     29",
"    </a>",
"    ]. As noted earlier, normal values for IgD and IgA vary by age and should be taken into consideration (",
"    <a class=\"graphic graphic_table graphicRef62882 graphicRef53169 \" href=\"UTD.htm?5/9/5277\">",
"     table 1A-B",
"    </a>",
"    ). Cases of HIDS with normal serum IgD and IgA levels may be diagnosed using clinical and genetic data (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Genetic testing'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least 63 mutations in the mevalonate kinase (MVK) gene have been noted in association with HIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/26,32-34\">",
"     26,32-34",
"    </a>",
"    ]. The finding of a previously reported MVK gene mutation in a patient with clinical suspicion of HIDS establishes the diagnosis. Identification of the V377I mutation (most common) is confirmatory [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/29\">",
"     29",
"    </a>",
"    ], but in the absence of this mutation, genetic sequencing of the MVK gene may be requested if the clinical suspicion of HIDS is high. Nearly one-quarter of patients with compatible clinical symptoms, physical findings, and immunoglobulin levels do not have MVK mutations and are categorized as having variant HIDS.",
"   </p>",
"   <p>",
"    Genetic testing for HIDS is unlikely to be positive in patients whose febrile attacks began at &ge;5 years of age, last more than 14 days, and do not have associated joint pain [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic testing for other periodic fever syndromes (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Differential diagnosis'",
"    </a>",
"    below) may be necessary as some features may overlap [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/9\">",
"     9",
"    </a>",
"    ]. Identification of known mutations may be considered diagnostic only in the face of typical clinical manifestations as the genetic penetrance is less than 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Urine mevalonic acid/creatinine ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mevalonic acid excretion during acute febrile episodes may be assessed by determining the ratio of mevalonic acid to creatinine in an untimed sample of urine; an elevated ratio (&gt;20",
"    <span class=\"nowrap\">",
"     mmol/mol",
"    </span>",
"    creatinine); is suggestive of HIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/32\">",
"     32",
"    </a>",
"    ]. Techniques and sensitivities for measuring urinary mevalonic acid levels vary widely; in the opinion of some investigators it is an unreliable test for the diagnosis of HIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/31\">",
"     31",
"    </a>",
"    ]. An elevated ratio is suggestive evidence for HIDS in the appropriate clinical setting. We do not recommend the use of the urinary mevalonic acid to urine creatinine ratio as a confirmatory test for HIDS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Investigational",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased urinary excretion of LTE4 may be present during febrile episodes (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Urinary LTE4'",
"    </a>",
"    above). Further studies and standardization of testing techniques are required before urinary LTE4 levels can be considered a diagnostic tool for HIDS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of HIDS includes other causes of recurrent or periodic fever, of recurrent severe abdominal pain, and of elevated serum levels of IgD:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Causes of recurrent or periodic fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even when there is a family history of HIDS, other diseases, particularly infectious diseases and surgical emergencies, must be considered and excluded, when a child or adult presents with fever and abdominal pain. Among them are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical emergencies &mdash; appendicitis, intussusception, perforated peptic ulcer, etc",
"     </li>",
"     <li>",
"      Relapsing pancreatitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For the patient with recurrent or periodic fever in whom an infectious etiology has been excluded, other syndromes of unknown etiology or rare heritable diseases may be considered. An overview of the causes of periodic and recurrent fevers is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=see_link\">",
"     \"Periodic fever syndromes and other autoinflammatory diseases: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The periodic fever syndromes include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       F",
"      </strong>",
"      amilial",
"      <strong>",
"       M",
"      </strong>",
"      editerranean",
"      <strong>",
"       f",
"      </strong>",
"      ever (FMF) &mdash; The typical manifestations of FMF are recurrent attacks of severe pain (due to serositis at one or more sites) and fever, lasting one to three days, and then resolving spontaneously. In between attacks, patients feel entirely well.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       Colchicine",
"      </a>",
"      prevents attacks in most patients, an effect that is not seen in HIDS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25078?source=see_link\">",
"       \"Clinical manifestations and diagnosis of familial Mediterranean fever\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       T",
"      </strong>",
"      umor necrosis factor",
"      <strong>",
"       r",
"      </strong>",
"      eceptor-1-",
"      <strong>",
"       a",
"      </strong>",
"      ssociated",
"      <strong>",
"       p",
"      </strong>",
"      eriodic",
"      <strong>",
"       s",
"      </strong>",
"      yndrome (TRAPS) &mdash; The febrile episodes of TRAPS generally last longer than those of HIDS; they may continue for up to two weeks. Other clinical features of TRAPS that are not typically seen in HIDS include: conjunctivitis, periorbital edema, and myalgias. Abdominal pain may be prominent in both diseases, but arthritis in TRAPS is uncommon, and when present, is typically monoarticular. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28551?source=see_link\">",
"       \"Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       P",
"      </strong>",
"      eriodic",
"      <strong>",
"       f",
"      </strong>",
"      evers with",
"      <strong>",
"       a",
"      </strong>",
"      phthous stomatitis,",
"      <strong>",
"       p",
"      </strong>",
"      haryngitis and",
"      <strong>",
"       a",
"      </strong>",
"      denitis (PFAPA) syndrome &mdash; The PFAPA syndrome is a disease of unknown etiology and uncertain pathogenesis. It presents in childhood and is characterized by periodic fevers at regular intervals of four to six weeks and stereotypical symptoms of pharyngitis, aphthous ulcers, and cervical adenitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8377?source=see_link\">",
"       \"Periodic fever with aphthous stomatitis, pharyngitis and adenitis (PFAPA syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Muckle-Wells syndrome &mdash; The Muckle-Wells syndrome is a rare, periodic syndrome characterized by an urticarial rash, fever,",
"      <span class=\"nowrap\">",
"       arthralgia/arthritis,",
"      </span>",
"      and sensorineural hearing loss beginning in childhood. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24487?source=see_link&amp;anchor=H6#H6\">",
"       \"Cryopyrin-associated periodic syndromes and related disorders\", section on 'Muckle-Wells syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       F",
"      </strong>",
"      amilial",
"      <strong>",
"       c",
"      </strong>",
"      old",
"      <strong>",
"       a",
"      </strong>",
"      utoinflammatory",
"      <strong>",
"       s",
"      </strong>",
"      yndrome (FACS) &mdash; Formerly called familial cold urticaria, FACS is an unusual condition in which exposure to generalized cold, results in fever, an urticarial rash, conjunctival injection, and arthralgia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24487?source=see_link&amp;anchor=H5#H5\">",
"       \"Cryopyrin-associated periodic syndromes and related disorders\", section on 'Familial cold autoinflammatory syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mevalonic aciduria &mdash; Unlike patients with HIDS, those with mevalonic aciduria (MIM +251170) have no, or negligible, residual MVK activity, and excrete large amounts of mevalonic acid. This rare genetic disorder has a variable phenotype that include dysmorphic features, developmental delay, hepatosplenomegaly, cytopenias, and progressive cerebellar atrophy in addition to HIDS-like features of recurrent fever, lymphadenopathy, and skin rash [",
"      <a class=\"abstract\" href=\"UTD.htm?3/43/3768/abstract/37\">",
"       37",
"      </a>",
"      ]. The most severely affected die in infancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Causes of recurrent severe abdominal pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of acute abdominal pain in children and adults is very broad and is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11593?source=see_link\">",
"     \"Causes of acute abdominal pain in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=see_link\">",
"     \"Differential diagnosis of abdominal pain in adults\"",
"    </a>",
"    .) Nonsurgical causes of recurrent severe abdominal pain include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hereditary or acquired angioedema &mdash; Patients with hereditary or acquired angioedema due to abnormalities in the level or function of the regulatory C1 inhibitor (C1-Inh) protein may develop bowel wall swelling that can result in severe abdominal pain, nausea, and vomiting. Such symptoms can mimic other acute abdominal syndromes, but are distinguished from the abdominal pain of HIDS by the absence of fever. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=see_link\">",
"       \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute intermittent porphyria &mdash; Acute intermittent porphyria (AIP) typically begins after puberty and is more common in men than women. Abdominal pain, often severe, may be generalized or localized, and may be accompanied by fever. There are no cutaneous manifestations of AIP. Peripheral neuropathy, anxiety, or other psychiatric disorders are relatively common features of AIP that are not typically seen in HIDS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10439?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute intermittent porphyria\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Causes of elevated IgD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of an elevated IgD (though not always polyclonal) include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hodgkin disease",
"     </li>",
"     <li>",
"      Sarcoidosis",
"     </li>",
"     <li>",
"      Tuberculosis",
"     </li>",
"     <li>",
"      Aspergillosis",
"     </li>",
"     <li>",
"      Ataxia-telangiectasia",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       HIV/AIDS",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unremitting fever lasting four to seven days and the presence of palpable tender lymphadenopathy, splenomegaly,",
"      <span class=\"nowrap\">",
"       arthralgia/arthritis,",
"      </span>",
"      abdominal pain, and rash are characteristic of the recurrent episodes that occur in patients with HIDS. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms and signs of an episode of HIDS typically resolve along with the fever. An exception is arthralgia and arthritis, which may linger, but do not cause joint damage. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Arthralgia/arthritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The rash is usually an erythematous macular eruption, but may be papular, urticarial, nodular, or petechial in nature. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cutaneous manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory findings suggestive of HIDS include: elevated age-specific serum IgD",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      IgA levels, elevation of acute phase reactants, and urinary excretion of mevalonic acid during, but not between attacks. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the diagnosis of HIDS is suspected on clinical features, we suggest measurement of serum IgD and IgA levels. If an elevated age-specific level of IgD",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      IgA is noted, the diagnosis is established.",
"     </li>",
"     <li>",
"      If the IgD and IgA serum levels are not elevated, but HIDS is still suspected, we suggest genetic testing for the presence of a mutation in the mevalonate kinase gene as an aid to diagnosis. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Genetic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of HIDS includes other causes of recurrent or periodic fevers, of recurrent severe abdominal pain, and of elevated serum levels of IgD. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the patient with recurrent or periodic fever in whom an infectious etiology has been excluded, other syndromes of unknown etiology or rare heritable diseases may be considered. Among these are the PFAPA syndrome, TRAPS, FMF, Muckle-Wells, syndrome, FACS, and mevalonic aciduria. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Causes of recurrent or periodic fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonsurgical causes of recurrent severe abdominal pain include: hereditary or acquired angioedema and acute intermittent porphyria. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Causes of recurrent severe abdominal pain'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11593?source=see_link\">",
"       \"Causes of acute abdominal pain in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=see_link\">",
"       \"Differential diagnosis of abdominal pain in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Elevated serum IgD is not specific for HIDS and has been noted in patients with some neoplastic, infectious, heritable, and idiopathic disorders. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Causes of elevated IgD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/1\">",
"      Simon A, Cuisset L, Vincent MF, et al. Molecular analysis of the mevalonate kinase gene in a cohort of patients with the hyper-igd and periodic fever syndrome: its application as a diagnostic tool. Ann Intern Med 2001; 135:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/2\">",
"      van der Meer JW, Vossen JM, Radl J, et al. Hyperimmunoglobulinaemia D and periodic fever: a new syndrome. Lancet 1984; 1:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/3\">",
"      Drenth JP, Haagsma CJ, van der Meer JW. Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimore) 1994; 73:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/4\">",
"      Simon A, Mariman EC, van der Meer JW, Drenth JP. A founder effect in the hyperimmunoglobulinemia D and periodic fever syndrome. Am J Med 2003; 114:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/5\">",
"      Hammoudeh M. Hyperimmunoglobulinemia D syndrome in an Arab child. Clin Rheumatol 2005; 24:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/6\">",
"      D'Osualdo A, Picco P, Caroli F, et al. MVK mutations and associated clinical features in Italian patients affected with autoinflammatory disorders and recurrent fever. Eur J Hum Genet 2005; 13:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/7\">",
"      Loeliger AE, Kruize AA, Bijilsma JW, et al. Arthritis in hyperimmunoglobulinaemia D. Ann Rheum Dis 1993; 52:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/8\">",
"      Drenth JP, Boom BW, Toonstra J, Van der Meer JW. Cutaneous manifestations and histologic findings in the hyperimmunoglobulinemia D syndrome. International Hyper IgD Study Group. Arch Dermatol 1994; 130:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/9\">",
"      Ostuni P, Vertolli U, Marson P. Atypical hypergammaglobulinaemia D syndrome with amyloidosis: an overlap with familial Mediterranean fever? Clin Rheumatol 1996; 15:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/10\">",
"      Armbrust S, Drenth JP, Schr&ouml;der C, et al. Tendonitis in variant hyperimmunoglobulinaemia D and periodic fever syndrome--a rare disease with a new symptom. Eur J Pediatr 2005; 164:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/11\">",
"      Obici L, Manno C, Muda AO, et al. First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum 2004; 50:2966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/12\">",
"      van der Hilst JC, Simon A, Drenth JP. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 2005; 5:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/13\">",
"      Lachmann HJ, Goodman HJ, Andrews PA, et al. AA amyloidosis complicating hyperimmunoglobulinemia D with periodic fever syndrome: a report of two cases. Arthritis Rheum 2006; 54:2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/14\">",
"      Siewert R, Ferber J, Horstmann RD, et al. Hereditary periodic fever with systemic amyloidosis: is hyper-IgD syndrome really a benign disease? Am J Kidney Dis 2006; 48:e41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/15\">",
"      Kraus CL, Culican SM. Nummular keratopathy in a patient with Hyper-IgD Syndrome. Pediatr Rheumatol Online J 2009; 7:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/16\">",
"      Saulsbury FT, Remmers EF, Aksentijevich I. A novel mutation in TNFRSF1A associated with overlapping features of tumor necrosis factor receptor-associated periodic syndrome and hyper-IgD syndrome. Clin Exp Rheumatol 2010; 28:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/17\">",
"      Haraldsson A, Weemaes CM, J&oacute;nasd&oacute;ttir S, et al. Serum immunoglobulinD in infants and children. Scand J Immunol 2000; 51:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/18\">",
"      Stiehm ER, Fudenberg HH. Serum levels of immune globulins in health and disease: a survey. Pediatrics 1966; 37:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/19\">",
"      Di Rocco M, Caruso U, Waterham HR, et al. Mevalonate kinase deficiency in a child with periodic fever and without hyperimmunoglobulinaemia D. J Inherit Metab Dis 2001; 24:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/20\">",
"      Saulsbury FT. Hyperimmunoglobulinemia D and periodic fever syndrome (HIDS) in a child with normal serum IgD, but increased serum IgA concentration. J Pediatr 2003; 143:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/21\">",
"      Haraldsson A, Weemaes CM, De Boer AW, et al. Immunological studies in the hyper-immunoglobulin D syndrome. J Clin Immunol 1992; 12:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/22\">",
"      de Dios Garc&iacute;a-D&iacute;az J, Alvarez-Blanco MJ. High IgD could be a nonpathogenetic diagnostic marker of the hyper-IgD and periodic fever syndrome. Ann Allergy Asthma Immunol 2001; 86:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/23\">",
"      Klasen IS, G&ouml;ertz JH, van de Wiel GA, et al. Hyper-immunoglobulin A in the hyperimmunoglobulinemia D syndrome. Clin Diagn Lab Immunol 2001; 8:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/24\">",
"      Simon A, Bijzet J, Voorbij HA, et al. Effect of inflammatory attacks in the classical type hyper-IgD syndrome on immunoglobulin D, cholesterol and parameters of the acute phase response. J Intern Med 2004; 256:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/25\">",
"      van der Hilst JC, Drenth JP, Bodar EJ, et al. Serum amyloid A serum concentrations and genotype do not explain low incidence of amyloidosis in Hyper-IgD syndrome. Amyloid 2005; 12:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/26\">",
"      Houten SM, Kuis W, Duran M, et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet 1999; 22:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/27\">",
"      Frenkel J, Willemsen MA, Weemaes CM, et al. Increased urinary leukotriene E(4) during febrile attacks in the hyperimmunoglobulinaemia D and periodic fever syndrome. Arch Dis Child 2001; 85:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/28\">",
"      de Hullu JA, Drenth JP, Struyk AP, van der Meer JW. Hyper-IgD syndrome and pregnancy. Eur J Obstet Gynecol Reprod Biol 1996; 68:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/29\">",
"      Drenth JP, van der Meer JW. Hereditary periodic fever. N Engl J Med 2001; 345:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/30\">",
"      van der Hilst JC, Bodar EJ, Barron KS, et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) 2008; 87:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/31\">",
"      Grose C. Periodic fever in children with hyperimmunoglobulinemia D and mevalonate kinase mutations. Pediatr Infect Dis J 2005; 24:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/32\">",
"      Drenth JP, Cuisset L, Grateau G, et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat Genet 1999; 22:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/33\">",
"      Sarrauste de Menthi&egrave;re C, Terri&egrave;re S, Pugn&egrave;re D, et al. INFEVERS: the Registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res 2003; 31:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/34\">",
"      Mandey SH, Schneiders MS, Koster J, Waterham HR. Mutational spectrum and genotype-phenotype correlations in mevalonate kinase deficiency. Hum Mutat 2006; 27:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/35\">",
"      Steichen O, van der Hilst J, Simon A, et al. A clinical criterion to exclude the hyperimmunoglobulin D syndrome (mild mevalonate kinase deficiency) in patients with recurrent fever. J Rheumatol 2009; 36:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/36\">",
"      Drenth JP, van Der Meer JW. Periodic fevers enter the era of molecular diagnosis. BMJ 2000; 320:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3768/abstract/37\">",
"      Simon A, Kremer HP, Wevers RA, et al. Mevalonate kinase deficiency: Evidence for a phenotypic continuum. Neurology 2004; 62:994.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5954 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-791DB7C3D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_43_3768=[""].join("\n");
var outline_f3_43_3768=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Splenomegaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Arthralgia/arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cutaneous manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Variant HIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1894597\">",
"      Overlap syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      IgD level",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      IgA level",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Urinary mevalonic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Urinary LTE4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      HIDS and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Urine mevalonic acid/creatinine ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Investigational",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Causes of recurrent or periodic fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Causes of recurrent severe abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Causes of elevated IgD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5954\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5954|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/0/29707\" title=\"table 1A\">",
"      IgD mean by age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/57/6044\" title=\"table 1B\">",
"      IgA normal values by age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/38/33387\" title=\"table 2\">",
"      Features of HIDS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=related_link\">",
"      An overview of amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11593?source=related_link\">",
"      Causes of acute abdominal pain in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10439?source=related_link\">",
"      Clinical manifestations and diagnosis of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25078?source=related_link\">",
"      Clinical manifestations and diagnosis of familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24487?source=related_link\">",
"      Cryopyrin-associated periodic syndromes and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=related_link\">",
"      Differential diagnosis of abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=related_link\">",
"      Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23670?source=related_link\">",
"      Hyperimmunoglobulin-D syndrome: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9720?source=related_link\">",
"      Hyperimmunoglobulin-D syndrome: Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=related_link\">",
"      Periodic fever syndromes and other autoinflammatory diseases: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8377?source=related_link\">",
"      Periodic fever with aphthous stomatitis, pharyngitis and adenitis (PFAPA syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28551?source=related_link\">",
"      Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_43_3769="Treatment of antisocial personality disorder";
var content_f3_43_3769=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of antisocial personality disorder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/43/3769/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/43/3769/contributors\">",
"     Donald W Black, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/43/3769/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/43/3769/contributors\">",
"     Andrew Skodol, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/43/3769/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/43/3769/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/43/3769/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H19520647\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antisocial personality disorder (ASPD) is defined as a pattern of socially irresponsible, exploitative, and guiltless behavior that begins in childhood or early adolescence and is manifested by disturbances in many areas of life [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/1\">",
"     1",
"    </a>",
"    ]. ASPD is usually a lifelong disorder that begins in childhood and is fully manifest by the late 20s or early 30s [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Typical behaviors include criminality and failure to conform to the law, failure to sustain consistent employment, manipulation of others for personal gain, and failure to develop stable interpersonal relationships. Other features of ASPD include lacking empathy for others, rarely experiencing remorse, and failing to learn from the negative results of one&rsquo;s experiences [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic describes treatment for antisocial personality disorder. The epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis of antisocial personality disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/26/42409?source=see_link&amp;anchor=H31582541#H31582541\">",
"     \"Antisocial personality disorder: Epidemiology, clinical manifestations, course and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19520093\">",
"    <span class=\"h1\">",
"     MEDICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that patients with antisocial personality disorder (ASPD)",
"    <strong>",
"     not",
"    </strong>",
"    be routinely treated with medication for the disorder. No medications have been found to be efficacious in the treatment of ASPD. Medications may be useful in the treatment of severe aggressive behavior in patients with ASPD. (See",
"    <a class=\"local\" href=\"#H2291953\">",
"     'Aggressive behavior in ASPD'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Medication may also be appropriate to treat a comorbid psychiatric disorder in persons with ASPD, although medications with abuse potential should be avoided when possible. (See",
"    <a class=\"local\" href=\"#H1429137\">",
"     'Treatment of co-occurring disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2291953\">",
"    <span class=\"h2\">",
"     Aggressive behavior in ASPD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive behavior, which can be prominent in some patients with ASPD, may be a target symptom of daily medication treatment. Pharmacotherapy for emergent management of the acutely agitated, aggressive patient is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=see_link\">",
"     \"Assessment and management of the acutely agitated or violent adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision to treat aggression with medication in patients with ASPD should be based upon:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The severity of symptoms in terms of impairing the individual&rsquo;s ability to function in their environment (eg, in the community or in an institutional setting)",
"     </li>",
"     <li>",
"      The patient&rsquo;s willingness to take the medication",
"     </li>",
"     <li>",
"      The availability of a clinician to monitor treatment and evaluate its effectiveness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with antisocial personality disorder and severe aggression who are willing to take medication, we suggest treatment with a second generation antipsychotic (SGAP) medication over other medications. Examples include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    (2 to 4",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    (100 to 300",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    If an SGAP is ineffective or not tolerated, a selective serotonergic antidepressant, eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    (100-200",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    would be our next choice. Other reasonable alternatives include mood stabilizers such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    carbonate or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , which should be used at doses and blood levels recommended for bipolar disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43065?source=see_link\">",
"     \"Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7758846\">",
"    <span class=\"h3\">",
"     Efficacy in aggressive behavior",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only one, negative trial has been conducted of pharmacotherapy to treat aggression specifically in patients with ASPD [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/5\">",
"     5",
"    </a>",
"    ]; the other clinical trials and case reports described below suggest that several medications may reduce aggressive behavior in samples associated with higher rates of ASPD, including prisoners and patients with a history of aggression, as well as in samples of children with conduct disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2291946\">",
"    <span class=\"h4\">",
"     Antipsychotic medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials of antipsychotic medications for aggressive behavior in patients with ASPD; however, case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/8,9\">",
"     8,9",
"    </a>",
"    ] suggest that these drugs may be useful:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case series of four patients with ASPD and aggressive behavior, referred to a maximum-security inpatient psychiatric facility for pretrial evaluation, found that voluntary treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      was associated with decreased irritability, impulsivity, and aggressiveness [",
"      <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/8\">",
"       8",
"      </a>",
"      ]. Typical dosage was 600 to 800",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      In a single case report, a 32 year old man with ASPD was successfully treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      for severe violent behavior [",
"      <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/9\">",
"       9",
"      </a>",
"      ]. He was initially treated with 6",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and developed extrapyramidal symptoms that required treatment with biperiden,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      . He continued treatment on a maintenance dose of risperidone 3",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adverse effects of second-generation antipsychotics include extrapyramidal symptoms, weight gain, and metabolic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7758895\">",
"    <span class=\"h4\">",
"     Selective serotonin reuptake inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective serotonergic reuptake inhibitors (SSRIs) have not been tested in randomized trials of patients with ASPD; however, three small trials of impulsive aggression or anger in patients with personality disorders have found mixed results.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial of 40 patients with a personality disorder, impulsive aggressive behavior, and irritability found sustained reductions in aggression and irritability in patients over three months of treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      compared to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 13-week trial randomly assigned 22 patients with mild to moderately severe borderline personality disorder to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/11\">",
"       11",
"      </a>",
"      ]. &nbsp;Patients treated with fluoxetine experienced a clinically and statistically significant reduction in anger compared to placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A trial randomly assigned 38 patients with borderline personality disorder to six weeks treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"       fluvoxamine",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/12\">",
"       12",
"      </a>",
"      ]. Patients taking fluvoxamine experienced a reduction in rapid mood shifts compared to placebo, but no difference was seen between groups on impulsivity or aggression. This latter finding may be due to gender-specific differences in impulsivity and aggression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2553932\">",
"    <span class=\"h4\">",
"     Lithium",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    carbonate has been found to reduce threatening behavior and assaults in prison inmates in one randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/13\">",
"     13",
"    </a>",
"    ]. In the trial, 66 male inmates with a history of chronic, impulsive aggressive behavior received either lithium or placebo for three months, dosed to achieve a blood level of 0.6 to 1.0 MEq per liter [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/14\">",
"     14",
"    </a>",
"    ]. Individuals receiving lithium committed fewer infractions of prison rules involving threatening behavior or assaults than individuals receiving placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2553986\">",
"    <span class=\"h4\">",
"     Anticonvulsants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticonvulsant medications have been found to reduce impulsive aggression in randomized trials of diverse study populations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. None of the studies were limited to individuals with ASPD; however, none of the trials excluded patients with personality disorders or substance use disorders.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of four randomized trials found",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      to reduce aggressive behavior in patients with a history of aggression [",
"      <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/16\">",
"       16",
"      </a>",
"      ]. Trials were conducted in a combination of prison and community settings.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"       Oxcarbazepine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      , respectively, were found to reduce aggressive behavior in two randomized trials, one in a sample of patients with impulsive aggression [",
"      <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/17\">",
"       17",
"      </a>",
"      ] and the other with intermittent explosive disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two trials of divalproex in adults with a history of aggressive behavior showed mixed results [",
"      <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1428735\">",
"    <span class=\"h4\">",
"     Other medications in adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other drugs have been used to treat aggression primarily in brain-injured or intellectually challenged patients, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"     buspirone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Response to medication has been variable; while some patients have shown improvement, others failed to improve at all. Improvement, when it has occurred, has been partial, meaning that the individual had fewer outbursts than before, or had longer periods between them.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1428743\">",
"    <span class=\"h4\">",
"     Children with conduct disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited evidence of efficacy for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    , and divalproex in reducing aggression and other symptoms in children with disruptive behavior or diagnosed with conduct disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/26/42409?source=see_link&amp;anchor=H335149180#H335149180\">",
"     \"Antisocial personality disorder: Epidemiology, clinical manifestations, course and diagnosis\", section on 'Conduct disorder'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a randomized trial, 50 severely aggressive children with conduct disorder were treated with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      or placebo for eight weeks. Lithium led to greater reductions in aggressive behaviors, including bullying, fighting, and temper outbursts, compared to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a randomized trial, 20 children and adolescents (ages 10 to 18) with conduct disorder or oppositional defiant disorder were treated with either divalproex or placebo for six weeks. Divalproex reduced temper outbursts and mood lability compared to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a six-week, randomized trial of 118 children with severe disruptive behaviors, participants treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      showed greater reduction in disruptive behaviors than those treated with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a trial of 335 children with disruptive behavior disorder who had responded to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      treatment over 12 weeks, participants were randomly assigned to six months of treatment with risperidone or placebo. At the end of six months, time to symptom recurrence was significantly longer in patients who continued risperidone than in those switched to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19520100\">",
"    <span class=\"h1\">",
"     PSYCHOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials of cognitive-behavioral therapy (CBT) for persons with ASPD have been negative. However, it is possible that CBT may benefit those with milder forms of the disorder (eg, not physically dangerous) and who possess some insight and reason to improve. Examples of the latter would be patients who risk losing a spouse or job if their behavior were not controlled. Psychoanalysis or psychodynamic therapy were historically preferred approaches to treating ASPD, but these gradually have given way to CBT, which has been adapted from models developed for depression and anxiety disorders. (See",
"    <a class=\"local\" href=\"#H1429165\">",
"     'Efficacy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Antisocial persons often possess traits that actively interfere with the process of psychotherapy and make working with them difficult (eg, impulsivity, blaming others) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/4\">",
"     4",
"    </a>",
"    ]. No matter how determined the therapist may be to help an antisocial patient, it is possible that the patient&rsquo;s criminal past, irresponsibility, and tendency toward violence may render him thoroughly unlikable. For that reason, many therapists will find it difficult, if not impossible to work with such a patient. Therapists must be aware of their own feelings and remain vigilant to prevent countertransference from disrupting therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/25\">",
"     25",
"    </a>",
"    ]. The best prospects for treatment come with mental health professionals experienced in treating ASPD who are able to anticipate their emotions and to present an attitude of acceptance tempered with the need to set limits and confront manipulative behaviors without moralizing [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Psychotherapy may be ineffective or even harmful when provided to persons with psychopathy or severe ASPD [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. One perspective is that the rigid personality structure of these individuals generally resists outside influence [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/27\">",
"     27",
"    </a>",
"    ], observing that in therapy, many often simply go through the motions, and may even learn skills that help them better manipulate others. This concern is particularly pronounced for group therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/26/42409?source=see_link&amp;anchor=H335149172#H335149172\">",
"     \"Antisocial personality disorder: Epidemiology, clinical manifestations, course and diagnosis\", section on 'Psychopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1429122\">",
"    <span class=\"h2\">",
"     Cognitive behavioral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;CBT for ASPD focuses on the patient&rsquo;s beliefs about him or herself and others, and behaviors that impair social functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/26\">",
"     26",
"    </a>",
"    ]. The therapist focuses on evaluating situations in which the patient&rsquo;s distorted beliefs and attitudes may have interfered with interpersonal functioning or in achieving goals. Once the patient has gained an understanding of how he has contributed to his own problems, the therapist can help him or her to gradually make sensible changes in thinking and behavior. Guidelines are set for the patient&rsquo;s involvement, including regular attendance, active participation, and completion of homework outside of office visits [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/29\">",
"     29",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1429165\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two clinical trials of CBT for ASPD have been negative [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/6,30-32\">",
"     6,30-32",
"    </a>",
"    ]. As an example, a trial randomly assigned 52 men with ASPD and recent aggression to receive CBT plus treatment as usual or treatment as usual alone [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/31\">",
"     31",
"    </a>",
"    ]. At 12 months, no significant differences were seen between groups. Both groups reported a decrease in aggressive acts. Trends in favor of CBT were seen for problematic drinking, social functioning and beliefs about others, suggesting that larger randomized trials are needed.",
"   </p>",
"   <p>",
"    CBT may be useful in the treatment of some disorders that co-occur with ASPD. (See",
"    <a class=\"local\" href=\"#H1429137\">",
"     'Treatment of co-occurring disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108925031\">",
"    <span class=\"h2\">",
"     Other psychotherapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clinical trials of psychoanalytic or psychodynamic psychotherapy for ASPD.",
"   </p>",
"   <p>",
"    A subgroup analysis of a trial of psychoeducation and problem-solving therapy for personality disorders found no evidence of efficacy for ASPD. Twenty four patients with ASPD were randomly assigned to receive either brief psychoeducation plus problem-solving group sessions or to a waiting list with treatment as usual. After an average of 24 weeks, no difference was seen between groups on measures of problem solving or social functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although not tested in clinical trials, marital or family therapy may be useful for couples or families that include a family member with ASPD. As an example, family members may wish to receive guidance about their interactions with their antisocial relative. Likewise, a couple in which one member of the dyad is antisocial may benefit from gaining a better understanding of how the disorder has impacted the relationship and how best to respond. Couples therapy will not be beneficial if the antisocial person is disruptive or lacks empathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1321277\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several psychosocial interventions have been used to treat conduct disorder in children, seeking to reduce misbehavior and reduce the risk of ASPD in adulthood.",
"   </p>",
"   <p>",
"    Treatment programs for juvenile offenders that emphasize behavior modification or skills training may produce modest benefits and reduce recidivism [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/33\">",
"     33",
"    </a>",
"    ]. A meta-analysis found that the programs reduced recidivism among juvenile delinquents by 10 percent compared to a control condition. The most successful programs were more structured and specific, emphasizing behavior modification or skills training. &nbsp;",
"   </p>",
"   <p>",
"    Unsuccessful approaches have generally included traditional counseling and deterrent strategies such as &ldquo;shock&rdquo; incarceration. The latter gives young offenders stiff sentences that are later reduced to spur improvement. &ldquo;Scared straight&rdquo; type programs in which troubled youth visit prisons in an attempt to frighten them out of crime have also shown little success [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/34\">",
"     34",
"    </a>",
"    ]. &ldquo;Boot camps&rdquo; or &ldquo;wilderness&rdquo; programs have been developed in an effort to foster good behavior in misbehaving children. Taking place in isolated settings, the troubled children are separated from their peers and have little or no access to drugs and alcohol. Whether these programs offer more than transitory benefit is unclear.",
"   </p>",
"   <p>",
"    There is some evidence that early adjudication is helpful, and that youth who are apprehended, prosecuted, and punished for their first offenses are less likely to have adult convictions than those who escape penalties [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/35\">",
"     35",
"    </a>",
"    ]. In one follow-up study of 82 antisocial men, those who had done better had served brief jail sentences early in their life, a finding consistent with this observation in youth [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Family therapy for children with conduct disorder may offer the best help for dealing with misbehavior in children [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/37\">",
"     37",
"    </a>",
"    ]; this has not been tested in clinical trials.",
"    <sup>",
"    </sup>",
"    Treatment should focus on enhancing parental management skills to improve communication and to provide more effective and consistent discipline. Parents can learn to more effectively supervise the child, and learn how to steer impressionable children away from troubled peers. In these programs, parents also learn skills to help stop misbehavior before it escalates into violence, which may eventually help to reduce their child&rsquo;s risk for ASPD [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/38\">",
"     38",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1429137\">",
"    <span class=\"h1\">",
"     TREATMENT OF CO-OCCURRING DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend treating psychiatric disorders that co-occur with ASPD (eg, major depression, substance use disorders (SUDs), anxiety disorders) in antisocial patients. &nbsp;",
"   </p>",
"   <p>",
"    Research shows that many people with ASPD seek psychiatric care, particularly for co-occurring depression, substance misuse, or for problems relating to marital adjustment, anger dyscontrol, or suicidal behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    Others may present for court-mandated assessment (eg, an evaluation for competency to stand trial) or treatment.",
"   </p>",
"   <p>",
"    The antisocial person&rsquo;s mental health care needs can generally be addressed in outpatient settings where an array of services is available (eg, medication management, individual psychotherapy, family therapy). There is generally little reason to hospitalize antisocial patients, who can be disruptive to the hospital milieu [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/42\">",
"     42",
"    </a>",
"    ]. The exception is when the person needs supervision to provide a safe environment and protection from harm to self or others. Reasons to hospitalize antisocial persons include recent suicidal behavior, recent violent or assaultive acts, or needed",
"    <span class=\"nowrap\">",
"     alcohol/drug",
"    </span>",
"    detoxification or withdrawal monitoring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16487247\">",
"    <span class=\"h2\">",
"     Medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clinical trials on the efficacy of pharmacotherapy for psychiatric disorders co-occurring with ASPD. Medications may be effective in the treatment of disorders comorbid with ASPD; however, research suggests that patients with personality disorders (including ASPD) treated for comorbid depression do not respond as well to medication as do persons without a personality disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2665?source=see_link\">",
"     \"Pharmacotherapy for generalized anxiety disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=see_link\">",
"     \"Pharmacotherapy for posttraumatic stress disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/62/7145?source=see_link\">",
"     \"Bulimia nervosa in adults: Pharmacotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23561?source=see_link\">",
"     \"Pharmacotherapy for obsessive-compulsive disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26760?source=see_link\">",
"     \"Intermittent explosive disorder in adults: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/3/44088?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24197?source=see_link\">",
"     \"Treatment of acute stress disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1321101\">",
"    <span class=\"h3\">",
"     Addictive medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prescription of medications that are addictive or have potential for abuse should be avoided when possible in patients with ASPD.",
"   </p>",
"   <p>",
"    Benzodiazepines should not be used in patients with ASPD, who are at increased risk of addiction. It is possible that benzodiazepines will increase aggressive outbursts and other externalizing behaviors in these patients, an adverse response that has been documented in persons with borderline personality disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with adult attention deficit hyperactivity disorder (ADHD) co-occurring with ASPD should initially be treated with non-addicting medications such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/999?source=see_link\">",
"     atomoxetine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/45\">",
"     45",
"    </a>",
"    ]. As a second-line option, stimulant medication such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32454?source=see_link\">",
"     dextroamphetamine",
"    </a>",
"    can be prescribed in selected patients (eg, those without a history of substance abuse). Clinicians should monitor use of these medications closely due to their potential for abuse. Stimulants should not be used in patients with a current SUD, though their use can be considered for patients with a past SUD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32761?source=see_link\">",
"     \"Adult attention deficit hyperactivity disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of opiates to treat pain should be avoided in patients with ASPD when alternative treatments are available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=see_link\">",
"     \"Management of postoperative pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1320946\">",
"    <span class=\"h2\">",
"     Psychotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In psychiatric disorders for which it is effective, psychotherapy can be used to treat disorders that co-occur with ASPD. The therapist should understand that caveats that apply to psychotherapy for ASPD apply in these situations as well. &nbsp;(See",
"    <a class=\"local\" href=\"#H19520100\">",
"     'Psychotherapy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20505?source=see_link\">",
"     \"Psychotherapy for generalized anxiety disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25527?source=see_link\">",
"     \"Psychotherapy for specific phobia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28328?source=see_link\">",
"     \"Depression in adults: Psychodynamic psychotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32327?source=see_link\">",
"     \"Psychotherapy for social anxiety disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40297?source=see_link\">",
"     \"Psychotherapy for panic disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17674?source=see_link\">",
"     \"Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5032?source=see_link\">",
"     \"Psychotherapy for posttraumatic stress disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34391?source=see_link\">",
"     \"Psychotherapy for obsessive-compulsive disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8904?source=see_link\">",
"     \"Psychosocial interventions for schizophrenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/28/8646?source=see_link\">",
"     \"Binge-eating disorder: Cognitive-behavioral therapy (CBT)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24197?source=see_link\">",
"     \"Treatment of acute stress disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26760?source=see_link\">",
"     \"Intermittent explosive disorder in adults: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H808615\">",
"    <span class=\"h2\">",
"     SUD treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that substance use disorders (SUDs) co-occurring with ASPD be treated with medical management of withdrawal (if needed) followed by an inpatient or outpatient psychosocial addictions program, with a goal of abstinence. A study of antisocial persons with an SUD treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    maintenance found that patients who abstained from use were less likely to engage in antisocial or criminal behaviors, and had fewer family conflicts and emotional problems [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/26/42409?source=see_link&amp;anchor=H31582471#H31582471\">",
"     \"Antisocial personality disorder: Epidemiology, clinical manifestations, course and diagnosis\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=see_link\">",
"     \"Benzodiazepine poisoning and withdrawal\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1191?source=see_link\">",
"     \"Opioid detoxification during treatment for addiction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=see_link\">",
"     \"Treatment of opioid abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There have been two trials of contingency management for a substance use disorder co-occurring with ASPD, with largely negative results. Contingency management seeks to reduce substance abuse and dependence by linking use to systematically applied environmental consequences, ie, reinforcement and punishment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a clinical trial, 40 patients with ASPD and drug abuse were randomly assigned to receive either a structured contingency management intervention in addition to standard substance abuse treatment, or to standard substance abuse treatment alone [",
"      <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/47\">",
"       47",
"      </a>",
"      ]. Improvement was seen in both groups over 17 weeks of treatment, but no significant differences were seen between groups.",
"     </li>",
"     <li>",
"      In a clinical trial, 100 patients with opioid dependence and ASPD were randomly assigned to a structured contingency management intervention plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      maintenance or to methadone maintenance alone. No differences were seen between intervention groups in drug abstinence. The group receiving the experimental intervention had better attendance than subjects receiving methadone maintenance alone. [",
"      <a class=\"abstract\" href=\"UTD.htm?3/43/3769/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with a co-occurring SUD should be encouraged to attend meetings of Alcoholics Anonymous or sister organizations (eg, Narcotics Anonymous, Cocaine Addicts Anonymous). There are few formal treatment programs for pathological gambling; antisocial persons with the disorder should be encouraged to attend Gamblers Anonymous. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/26/42409?source=see_link&amp;anchor=H31582478#H31582478\">",
"     \"Antisocial personality disorder: Epidemiology, clinical manifestations, course and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1429506\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest cognitive-behavioral therapy (CBT) for persons with mild ASPD who possess some insight and reason to improve (eg, those who risk losing a spouse or job if their behavior is not controlled) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1429122\">",
"       'Cognitive behavioral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapists treating patients with antisocial personality disorder (ASPD) should be vigilant to prevent their potentially negative feelings and mindful of the potential for the antisocial person&rsquo;s manipulation of the therapeutic relationship. (See",
"      <a class=\"local\" href=\"#H19520100\">",
"       'Psychotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with antisocial personality disorder (ASPD)",
"      <strong>",
"       not",
"      </strong>",
"      be routinely treated with medication (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19520093\">",
"       'Medication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with antisocial personality disorder and severe aggression who are willing to take medication, we suggest treatment with a second-generation antipsychotic (SGAP) medication over other medications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Examples include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      (2 to 4",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      (100 to 300",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      <br/>",
"      <br/>",
"      If an SGAP is ineffective or not tolerated, a selective serotonergic antidepressant, eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      (100-200",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      would be our next choice. Other reasonable alternatives include mood stabilizers such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      carbonate or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      , which should be used at doses and blood levels recommended for bipolar disorder. (See",
"      <a class=\"local\" href=\"#H2291953\">",
"       'Aggressive behavior in ASPD'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"       \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43065?source=see_link\">",
"       \"Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When psychiatric disorders co-occur with ASPD (eg, depression, substance use disorders, anxiety disorders), treatment should typically be with the first-line medication or psychotherapy recommended for the comorbid disorder, although medications with potential for abuse should be avoided when possible. (See",
"      <a class=\"local\" href=\"#H1429137\">",
"       'Treatment of co-occurring disorders'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/26/42409?source=see_link&amp;anchor=H31582471#H31582471\">",
"       \"Antisocial personality disorder: Epidemiology, clinical manifestations, course and diagnosis\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     North C, Yutzy S. Goodwin &amp; Guze&rsquo;s Psychiatric Diagnosis, 6th ed, Oxford University Press, New Yrok 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/2\">",
"      Robins LN, Price RK. Adult disorders predicted by childhood conduct problems: results from the NIMH Epidemiologic Catchment Area project. Psychiatry 1991; 54:116.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     Black DW. Bad Boys, Bad Men &ndash; Confronting Antisocial Personality Disorder, Oxford University Press, New York 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/5\">",
"      Barratt ES, Stanford MS, Felthous AR, Kent TA. The effects of phenytoin on impulsive and premeditated aggression: a controlled study. J Clin Psychopharmacol 1997; 17:341.",
"     </a>",
"    </li>",
"    <li>",
"     National Collaborating Centre for Mental Health, National Institute for Health and Clinical Excellence (NICE), NICE Clinical Guideline 77, Antisocial Personality Disorder: Treatment, Management, and Prevention, January 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/7\">",
"      Khalifa N, Duggan C, Stoffers J, et al. Pharmacological interventions for antisocial personality disorder. Cochrane Database Syst Rev 2010; :CD007667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/8\">",
"      Walker C, Thomas J, Allen TS. Treating impulsivity, irritability, and aggression of antisocial personality disorder with quetiapine. Int J Offender Ther Comp Criminol 2003; 47:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/9\">",
"      Hirose S. Effective treatment of aggression and impulsivity in antisocial personality disorder with risperidone. Psychiatry Clin Neurosci 2001; 55:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/10\">",
"      Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 1997; 54:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/11\">",
"      Salzman C, Wolfson AN, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995; 15:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/12\">",
"      Rinne T, van den Brink W, Wouters L, van Dyck R. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 2002; 159:2048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/13\">",
"      M&uuml;ller-Oerlinghausen B, Lewitzka U. Lithium reduces pathological aggression and suicidality: a mini-review. Neuropsychobiology 2010; 62:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/14\">",
"      Sheard MH, Marini JL, Bridges CI, Wagner E. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry 1976; 133:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/15\">",
"      Huband N, Ferriter M, Nathan R, Jones H. Antiepileptics for aggression and associated impulsivity. Cochrane Database Syst Rev 2010; :CD003499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/16\">",
"      Jones RM, Arlidge J, Gillham R, et al. Efficacy of mood stabilisers in the treatment of impulsive or repetitive aggression: systematic review and meta-analysis. Br J Psychiatry 2011; 198:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/17\">",
"      Mattes JA. Oxcarbazepine in patients with impulsive aggression: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2005; 25:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/18\">",
"      Stanford MS, Helfritz LE, Conklin SM, et al. A comparison of anticonvulsants in the treatment of impulsive aggression. Exp Clin Psychopharmacol 2005; 13:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/19\">",
"      Davis JM, Janicak PG, Ayd FJ. Psychopharmacotherapy of the personality disordered patients. Psychiatr Ann 1995; 25:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/20\">",
"      Corrigan PW, Yudofsky SC, Silver JM. Pharmacological and behavioral treatments for aggressive psychiatric inpatients. Hosp Community Psychiatry 1993; 44:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/21\">",
"      Campbell M, Adams PB, Small AM, et al. Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1995; 34:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/22\">",
"      Donovan SJ, Stewart JW, Nunes EV, et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am J Psychiatry 2000; 157:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/23\">",
"      Aman MG, De Smedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002; 159:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/24\">",
"      Reyes M, Buitelaar J, Toren P, et al. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 2006; 163:402.",
"     </a>",
"    </li>",
"    <li>",
"     Strasburger LH. The treatment of antisocial syndromes: The therapist's feelings. In: Unmasking the Psychopath: Antisocial Personality and Related Syndromes, Reid WH, Dorr D, Walker JI, Bonner JW.  (Eds), WW Norton, New York 1986.",
"    </li>",
"    <li>",
"     Beck A, Freeman A, Davis DD, et al. Antisocial personality disorder. In: Cognitive Therapy of Personality Disorders, 2nd ed, Guilford Press, New York 2004.",
"    </li>",
"    <li>",
"     Hare RD. Without conscience: The disturbing world of psychopaths among us, Pocket Books, New York 1993.",
"    </li>",
"    <li>",
"     McCord W, McCord J. Psychopathy and delinquency, Grune and Stratton, New York 1956. p.84.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/29\">",
"      Davidson KM, Halford J, Kirkwood L, et al. CBT for violent men with antisocial personality disorder: reflections on the experience of carrying out therapy in MASCOT, a pilot randomized controlled trial. Personal Ment Health 2010; 4:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/30\">",
"      Gibbon S, Duggan C, Stoffers J, et al. Psychological interventions for antisocial personality disorder. Cochrane Database Syst Rev 2010; :CD007668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/31\">",
"      Davidson KM, Tyrer P, Tata P, et al. Cognitive behaviour therapy for violent men with antisocial personality disorder in the community: an exploratory randomized controlled trial. Psychol Med 2009; 39:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/32\">",
"      Huband N, McMurran M, Evans C, Duggan C. Social problem-solving plus psychoeducation for adults with personality disorder: pragmatic randomised controlled trial. Br J Psychiatry 2007; 190:307.",
"     </a>",
"    </li>",
"    <li>",
"     Lipsey MW. The effect of treatment on juvenile delinquents: Results from Meta-analysis presented at a meeting sponsored by the National Institute of Mental Health. Bethesda, MD. October 31 to November 3, 1992.",
"    </li>",
"    <li>",
"     Gibbons DC. Delinquent behavior, 3rd ed, Prentice Hall, Englewood Cliffs, NJ 1981.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/35\">",
"      Brown WK, Miller TP, Jenkins RL. The favorable effect of juvenile court adjudication and delinquent youth on the first contact with the juvenile justice system. Juv Fam Court J 1987; 38:21.",
"     </a>",
"    </li>",
"    <li>",
"     Robins L. Deviant Children Grown Up, Williams and Wilkins, Baltimore, MD 1966.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/37\">",
"      Sholevar GP. Family therapy for conduct disorders. Child Adolesc Psychiatr Clin N Am 2001; 10:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/38\">",
"      Kazdin AE. Treatment of antisocial behavior in children: current status and future directions. Psychol Bull 1987; 102:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/39\">",
"      Ullrich S, Coid J. Antisocial personality disorder: co-morbid Axis I mental disorders and health served use among a national household population. Personal Ment Health 2009; 3:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/40\">",
"      Shapiro S, Skinner EA, Kessler LG, et al. Utilization of health and mental health services. Three Epidemiologic Catchment Area sites. Arch Gen Psychiatry 1984; 41:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/41\">",
"      Black DW, Braun D. Antisocial patients: a comparison of those with and those without childhood conduct disorder. Ann Clin Psychiatry 1998; 10:53.",
"     </a>",
"    </li>",
"    <li>",
"     Carney FL. Inpatient treatment programs. In: The Psychopath: A comprehensive study of Antisocial Disorders and Behaviors, Reid WH.  (Ed), Brunner/Mazel, New York 1979.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/43\">",
"      Reich JH, Green AI. Effect of personality disorders on outcome of treatment. J Nerv Ment Dis 1991; 179:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/44\">",
"      Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 1988; 45:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/45\">",
"      Westmoreland P, Gunter T, Loveless P, et al. Attention deficit hyperactivity disorder in men and women newly committed to prison: clinical characteristics, psychiatric comorbidity, and quality of life. Int J Offender Ther Comp Criminol 2010; 54:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/46\">",
"      Cacciola JS, Alterman AI, Rutherford MJ, Snider EC. Treatment response of antisocial substance abusers. J Nerv Ment Dis 1995; 183:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/47\">",
"      Brooner RK, Kidorf M, King VL, Stoller K. Preliminary evidence of good treatment response in antisocial drug abusers. Drug Alcohol Depend 1998; 49:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3769/abstract/48\">",
"      Neufeld KJ, Kidorf MS, Kolodner K, et al. A behavioral treatment for opioid-dependent patients with antisocial personality. J Subst Abuse Treat 2008; 34:101.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14643 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-EFB8DDA1F5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_43_3769=[""].join("\n");
var outline_f3_43_3769=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1429506\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19520647\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19520093\">",
"      MEDICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2291953\">",
"      Aggressive behavior in ASPD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7758846\">",
"      - Efficacy in aggressive behavior",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2291946\">",
"      Antipsychotic medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7758895\">",
"      Selective serotonin reuptake inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2553932\">",
"      Lithium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2553986\">",
"      Anticonvulsants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1428735\">",
"      Other medications in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1428743\">",
"      Children with conduct disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19520100\">",
"      PSYCHOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1429122\">",
"      Cognitive behavioral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1429165\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H108925031\">",
"      Other psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1321277\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1429137\">",
"      TREATMENT OF CO-OCCURRING DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16487247\">",
"      Medication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1321101\">",
"      - Addictive medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1320946\">",
"      Psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H808615\">",
"      SUD treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1429506\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32761?source=related_link\">",
"      Adult attention deficit hyperactivity disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/26/42409?source=related_link\">",
"      Antisocial personality disorder: Epidemiology, clinical manifestations, course and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=related_link\">",
"      Assessment and management of the acutely agitated or violent adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=related_link\">",
"      Benzodiazepine poisoning and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/28/8646?source=related_link\">",
"      Binge-eating disorder: Cognitive-behavioral therapy (CBT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43065?source=related_link\">",
"      Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/3/44088?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/62/7145?source=related_link\">",
"      Bulimia nervosa in adults: Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28328?source=related_link\">",
"      Depression in adults: Psychodynamic psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26760?source=related_link\">",
"      Intermittent explosive disorder in adults: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17674?source=related_link\">",
"      Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=related_link\">",
"      Management of moderate and severe alcohol withdrawal syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1191?source=related_link\">",
"      Opioid detoxification during treatment for addiction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2665?source=related_link\">",
"      Pharmacotherapy for generalized anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23561?source=related_link\">",
"      Pharmacotherapy for obsessive-compulsive disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=related_link\">",
"      Pharmacotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=related_link\">",
"      Pharmacotherapy for posttraumatic stress disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Side effect management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8904?source=related_link\">",
"      Psychosocial interventions for schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=related_link\">",
"      Psychosocial treatment of alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20505?source=related_link\">",
"      Psychotherapy for generalized anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34391?source=related_link\">",
"      Psychotherapy for obsessive-compulsive disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40297?source=related_link\">",
"      Psychotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5032?source=related_link\">",
"      Psychotherapy for posttraumatic stress disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32327?source=related_link\">",
"      Psychotherapy for social anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25527?source=related_link\">",
"      Psychotherapy for specific phobia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24197?source=related_link\">",
"      Treatment of acute stress disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=related_link\">",
"      Treatment of opioid abuse and dependence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_43_3770="Management and prognosis of bullous pemphigoid";
var content_f3_43_3770=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management and prognosis of bullous pemphigoid",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/43/3770/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/43/3770/contributors\">",
"     Dedee F Murrell, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/43/3770/contributors\">",
"     Mae Ramirez, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/43/3770/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/43/3770/contributors\">",
"     John J Zone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/43/3770/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/43/3770/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/43/3770/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H24368172\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bullous pemphigoid is an autoimmune blistering disease characterized by autoantibody deposition at the epithelial basement membrane zone. The disorder most frequently affects elderly adults and classically presents with generalized pruritic urticarial plaques and tense subepithelial blisters (",
"    <a class=\"graphic graphic_picture graphicRef72866 graphicRef79112 graphicRef78910 \" href=\"UTD.htm?34/14/35050\">",
"     picture 1A-C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    First-line therapy for bullous pemphigoid consists of topical or systemic corticosteroids; both interventions are rapidly effective for this disease. Additional immunomodulatory therapies are often added to treatment to minimize the adverse effects of chronic corticosteroid therapy or to augment improvement in the disease.",
"   </p>",
"   <p>",
"    The management of bullous pemphigoid will be reviewed here. The epidemiology, pathogenesis, clinical features, and diagnosis of bullous pemphigoid are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15273?source=see_link\">",
"     \"Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link\">",
"     \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24368179\">",
"    <span class=\"h1\">",
"     APPROACH TO THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1140896505\">",
"    <span class=\"h2\">",
"     Goals of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major goals for the treatment of bullous pemphigoid are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decrease blister formation and pruritus",
"     </li>",
"     <li>",
"      Promote healing of blisters and erosions",
"     </li>",
"     <li>",
"      Improve quality of life",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These goals are fulfilled through an approach to treatment that includes a therapeutic regimen that attenuates autoantibody production and antibody-mediated inflammation while minimizing the risk for serious drug-induced adverse effects. In addition, the implementation of skin care measures and referrals to appropriate specialists for mucosal involvement may help to manage and minimize morbidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1140896512\">",
"    <span class=\"h2\">",
"     Approach to pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to treatment efficacy, cost, and availability, other factors influence the approach to therapy for bullous pemphigoid [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/1\">",
"     1",
"    </a>",
"    ]. Since patients are often elderly and dependent upon relatives or health care workers for personal care activities, their ability to comply with treatment must be considered. As an example, topical corticosteroid therapy is not a favorable option for patients who are unable to properly apply the medication and lack access to assistance.",
"   </p>",
"   <p>",
"    Because much of the morbidity and mortality related to bullous pemphigoid results from the combined effect of patient comorbidities and adverse effects of treatment, rather than from direct effects of the disease, treatment should be conservative. Elderly patients often have medical conditions that may increase risk for drug-related side effects. Thus, the minimal amount of medication required to achieve remission should be given.",
"   </p>",
"   <p>",
"    Our preferred first-line therapy for patients with bullous pemphigoid is a high potency topical corticosteroid due to evidence that supports the efficacy and relative safety of this treatment. A systemic glucocorticoid is another acceptable first-line treatment option that we typically use when factors such as drug cost, drug availability, or an inability to properly administer topical treatment preclude the use of topical therapy. In addition, patient preference for systemic therapy based upon quality of life concerns may prompt the selection of systemic treatment for patients who are more likely to tolerate oral glucocorticoids well (eg, nonelderly, otherwise healthy individuals). Particularly for patients with widespread involvement, systemic therapy is faster and easier to administer than topical therapy.",
"   </p>",
"   <p>",
"    Due to the chronic nature of bullous pemphigoid and the multiple adverse effects of systemic glucocorticoids, adjunctive agents are often added in an attempt to reduce long-term glucocorticoid-dependence. Immunosuppressants such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    are commonly prescribed. Antiinflammatory agents, including tetracyclines administered with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/27/38322?source=see_link\">",
"     nicotinamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    may also be of benefit.",
"   </p>",
"   <p>",
"    Biologic therapies may be effective for bullous pemphigoid which cannot be satisfactorily managed with the treatments above alone.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    and intravenous immunoglobulin are options for additional therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24368186\">",
"    <span class=\"h2\">",
"     General skin care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best approach to the care of blistered skin has not been definitively established. In our experience, daily rupturing of tense blisters is useful for reducing lateral extension of the blister edges. We instruct patients and caregivers to cleanse blisters with alcohol prior to rupturing them with a sterile needle. Since the overlying epithelial layer (blister roof) can act as a natural wound dressing, it should be left in place. Open erosions should be covered with non-stick dressings to reduce pain and the risk for infection.",
"   </p>",
"   <p>",
"    Superinfection is a significant concern in patients with bullous pemphigoid, particularly when numerous skin lesions are present and systemic immunosuppressants are being utilized for treatment. Patients and caregivers should be informed about the warning signs of infection to facilitate prompt diagnosis and treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1140896641\">",
"    <span class=\"h2\">",
"     Indications for referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of bullous pemphigoid is a multidisciplinary affair that ideally consists of management by a dermatologist in conjunction with the patient&rsquo;s primary care physician. Because mucosal surfaces can be involved, additional specialists may be added as needed. As an example, patients with signs of ocular involvement (eg, itching, burning sensations, visual changes) should be referred promptly to an ophthalmologist. Likewise, referral to a gastroenterologist or otolaryngologist should be performed for the rare patient who exhibits symptoms suggestive of esophageal, laryngeal, or pharyngeal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24368200\">",
"    <span class=\"h1\">",
"     FIRST-LINE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corticosteroids, administered topically or systemically, are the cornerstone of therapy. A topical corticosteroid is our preferred first-line treatment. When the clinical scenario indicates that topical corticosteroids are not an appropriate choice, we utilize a systemic glucocorticoid as the initial treatment. (See",
"    <a class=\"local\" href=\"#H1140896512\">",
"     'Approach to pharmacologic therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24368207\">",
"    <span class=\"h2\">",
"     Topical corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The topical corticosteroid selected should be a high potency agent (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ). We typically utilize",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    0.05% cream.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691465063\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of topical corticosteroids as monotherapy for bullous pemphigoid is supported by a multicenter randomized trial which found that patients with extensive bullous pemphigoid who were treated with topical corticosteroids had better clinical outcomes than patients with extensive bullous pemphigoid who were treated with systemic glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/2\">",
"     2",
"    </a>",
"    ]. The trial included 341 patients with newly diagnosed bullous pemphigoid (153 patients with moderate bullous pemphigoid [defined as &le;10 new bullae per day] and 188 patients with extensive bullous pemphigoid [defined as &gt;10 new bullae per day]). The patients were treated with either topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    propionate 0.05% cream (40 g applied twice daily to the entire cutaneous surface by the patient, a caregiver, or nurse) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for moderate disease and 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for severe disease). Treatment was continued in this manner until 15 days after disease control. Subsequently, clobetasol was gradually reduced over the course of 12 months. The dose of prednisone was reduced by 15 percent every three weeks until treatment was discontinued after 12 months.",
"   </p>",
"   <p>",
"    The results of the trial are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       One-year survival rates were significantly higher",
"      </strong>",
"      for patients with extensive bullous pemphigoid who were treated with topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"       clobetasol",
"      </a>",
"      than for patients with extensive bullous pemphigoid who were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (76 versus 58 percent).",
"     </li>",
"     <li>",
"      Patients with extensive bullous pemphigoid who were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"       clobetasol",
"      </a>",
"      <strong>",
"       responded significantly more quickly",
"      </strong>",
"      to treatment than patients with extensive disease who were treated systemically. By day 21, disease control was achieved in 99 versus 91 percent of patients.",
"     </li>",
"     <li>",
"      <strong>",
"       Severe complications were significantly less common",
"      </strong>",
"      in the extensive bullous",
"      <span class=\"nowrap\">",
"       pemphigoid/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"        clobetasol",
"       </a>",
"      </span>",
"      group than in the extensive bullous",
"      <span class=\"nowrap\">",
"       pemphigoid/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"        prednisone",
"       </a>",
"      </span>",
"      group (29 versus 54 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of this study suggest that for patients with extensive bullous pemphigoid, topical corticosteroid therapy is preferable to systemic glucocorticoid treatment. Among the patients with moderate bullous pemphigoid, the differences between the topical and systemic therapy groups for one year survival (both 69 percent), likelihood of disease control by day 21 (100 versus 95 percent, respectively), and severe complications (32 versus 38 percent, respectively) were not statistically significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691465005\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacies of two treatment regimens with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    propionate 0.05% cream were compared in a second randomized trial of 312 patients with newly-diagnosed bullous pemphigoid [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/3\">",
"     3",
"    </a>",
"    ]. A milder regimen (10 to 20 g per day for moderate disease and 20 to 30 g per day for extensive disease until 15 days after disease control, then tapered to discontinuation over four months) was as effective for attaining control of moderate and extensive bullous pemphigoid as the regimen used in the trial above (40 g per day tapered slowly over 12 months). In the trial, disease control was achieved by day 21 in 98 versus 100 percent of patients, respectively. As may have been expected, relapses were more likely to occur during the one-year trial in patients in the less aggressive treatment group (this group discontinued treatment after four months); one year disease-free survival rates were 30 versus 45 percent, respectively.",
"   </p>",
"   <p>",
"    In addition, after adjustments were made for patient age and general health status (Karnofsky score), a statistically significant reduction in the risk for mortality and life-threatening adverse effects was detected among patients with moderate bullous pemphigoid who were treated with the milder regimen compared to those treated with the higher dose regimen (HR 0.54, 95% CI 0.30-0.97). A significant difference in these factors was not seen among patients with extensive disease (HR 1.18, 95% CI 0.76-1.82).",
"   </p>",
"   <p>",
"    When treating patients with topical corticosteroid therapy, we typically prescribe twice daily applications of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    propionate 0.05% cream. For patients with limited involvement, we focus on application to affected areas. For patients with widespread lesions, we instruct patients and caregivers to apply the treatment to the trunk and extremities.",
"   </p>",
"   <p>",
"    After active inflammation, new blister formation, and pruritus have ceased for at least two weeks and 80 percent of existing blisters have healed, we begin to taper topical corticosteroid therapy by slowly reducing the amount of medication applied and the frequency of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/4\">",
"     4",
"    </a>",
"    ]. Tapering is continued as tolerated, and typically lasts four months or longer.",
"   </p>",
"   <p>",
"    The cost of topical corticosteroids (generally higher than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) and limited access to these agents may inhibit the use of topical corticosteroids in some clinical settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1140896757\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;High potency topical corticosteroids can result in cutaneous atrophy, striae, and folliculitis. Adrenal suppression is an additional concern with the extensive application of topical corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Among a subset of 28 patients evaluated for adrenal suppression in the dose-comparison trial above, only 5 of 18 patients in the mild regimen group (28 percent) and 1 of 8 patients in the higher dose regimen group (12 percent) had positive cosyntropin tests (an indicator of adrenal sufficiency) after seven days of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/3\">",
"     3",
"    </a>",
"    ]. The adverse effects of topical corticosteroids are reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24368214\">",
"    <span class=\"h2\">",
"     Systemic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;When topical corticosteroid therapy is not practical or feasible due to patient-specific characteristics or preferences, we utilize a systemic glucocorticoid (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) as initial therapy. (See",
"    <a class=\"local\" href=\"#H1140896512\">",
"     'Approach to pharmacologic therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691465156\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoids are well-accepted as effective treatments for BP and are widely used for this indication. As was evident in the randomized trial that compared topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , the response to prednisone is usually rapid [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/2\">",
"     2",
"    </a>",
"    ]. In the trial, 95 and 91 percent of patients with moderate or extensive bullous pemphigoid, respectively, who were treated with a systemic glucocorticoid achieved disease control by 21 days. (See",
"    <a class=\"local\" href=\"#H691465063\">",
"     'Efficacy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691465163\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoids are typically administered orally.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    are commonly utilized, though other formulations may also be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimum regimen for systemic glucocorticoid therapy remains to be determined. The efficacy of two different doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    was investigated in a French multicenter randomized trial of 50 patients that compared starting doses of 0.75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day and 1.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. The difference in the proportion of patients in the 0.75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    group and the 1.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    group who achieved clear skin by day 21 was not statistically significant (58 versus 64 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our practice, we typically treat patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    with starting doses ranging from 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    to 0.75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, with the initial starting dose dependent on the severity of disease and patient comorbidities. We continue the effective dose until active inflammation, new blister formation, and pruritus have ceased for at least two weeks and 80 percent of existing blisters have healed. This is followed by a slow taper of the glucocorticoid as tolerated over the course of several months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691465171\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoid therapy can lead to serious acute and long-term side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/11\">",
"     11",
"    </a>",
"    ]. The adverse effects of systemic glucocorticoid therapy are reviewed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    ). Measures to prevent osteopenia should be implemented in patients receiving chronic systemic glucocorticoid therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24368221\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOID-SPARING AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data to support the efficacy of glucocorticoid-sparing agents in BP are limited, in clinical practice, immunosuppressive and antiinflammatory drugs are commonly used with the intent of minimizing dependence on systemic glucocorticoid therapy. The clinical response to glucocorticoid-sparing agents tends to be slower than for systemic glucocorticoids; these drugs often take several weeks to take effect [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We usually begin treatment with a glucocorticoid-sparing agent just prior to the start of glucocorticoid tapering. The systemic glucocorticoid is then tapered slowly over the course of several months, with the goal of completely discontinuing the systemic glucocorticoid and sustaining improvement with only the glucocorticoid-sparing agent. The systemic drugs utilized as glucocorticoid-sparing agents have also been utilized in place of glucocorticoids as initial therapy for bullous pemphigoid. We consider this option when patient comorbidities or other factors limit the use of topical corticosteroid and systemic glucocorticoid therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24368228\">",
"    <span class=\"h2\">",
"     Immunosuppressive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressants are frequently used as glucocorticoid-sparing agents in bullous pemphigoid. However, the decision to add an immunosuppressive agent should not be taken lightly, since like systemic glucocorticoids, these agents may cause serious adverse effects. In some elderly patients, the risks of adding an immunosuppressant may exceed those of maintaining low dose (eg, 5 mg per day or less)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24368235\">",
"    <span class=\"h3\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are limited on the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    in bullous pemphigoid [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. Although a randomized trial that compared azathioprine plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    to treatment with the same regimen of prednisolone given alone did not find that the addition of azathioprine increased the likelihood of achieving disease control [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/13\">",
"     13",
"    </a>",
"    ], a separate randomized trial of 25 patients with bullous pemphigoid that allowed for adjustments in the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    based upon the clinical response found support for a glucocorticoid-sparing effect [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/14\">",
"     14",
"    </a>",
"    ]. After three years, less prednisone had been taken by patients in the combination therapy group than in the group solely treated with prednisone (mean total dose of 6732 mg versus 3688 mg). &nbsp;",
"   </p>",
"   <p>",
"    Despite the limited evidence to support its use,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    is commonly used as a glucocorticoid-sparing agent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/17\">",
"     17",
"    </a>",
"    ]. Doses between 0.5 and 2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day are typically used [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A major side effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    therapy is myelosuppression. A thiopurine methyltransferase (TPMT) level should be checked prior to the initiation azathioprine to determine the appropriate dose and minimize the risk for myelosuppression. The maximum doses of azathioprine for patients with high (&gt;19 U), medium (13.7 to 19 U), and low TPMT (5 to 13.7 U) activity are 2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, and 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other potential adverse effects include malignancy, gastrointestinal disorders, and infections. We typically monitor a complete blood count, renal function tests, and liver function tests every two weeks for the first three months of therapy and periodically (every two to three months) thereafter. The adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link&amp;anchor=H7#H7\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24368242\">",
"    <span class=\"h3\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil may be of value for the treatment of bullous pemphigoid [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]. The only randomized trial of mycophenolate mofetil in bullous pemphigoid was an unblinded randomized trial of 73 patients that compared treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) plus mycophenolate mofetil (2 g per day) to methylprednisolone (0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/16\">",
"     16",
"    </a>",
"    ]. The two regimens appeared similarly effective. All patients in both groups (with the exception of two patients who died and one patient who was lost to follow-up in the azathioprine group) achieved clinical remission. The differences between the mycophenolate mofetil and azathioprine groups in the mean number of days to remission (42&plusmn;55 versus 24&plusmn;19 days, respectively) and the mean cumulative doses of methylprednisolone (5754&plusmn;9693 versus 4967&plusmn;12,191 mg, respectively) were not statistically significant. However, mycophenolate mofetil was better tolerated.",
"   </p>",
"   <p>",
"    In adults, we typically utilize",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil at a dose of 1.5 to 2 g per day, with a maximum dose of 3 g per day. Treatment with mycophenolate mofetil is often well tolerated; gastrointestinal distress is the most common side effect. An enteric-coated formulation of mycophenolate sodium has improved gastrointestinal tolerability, and has appeared effective for bullous pemphigoid in several patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. If feasible, it is good to check MMF serum levels as these may vary widely on standard doses.",
"   </p>",
"   <p>",
"    Our laboratory monitoring schedule typically consists of a complete blood count, renal function tests, and liver function tests every two to four weeks for the first three months of therapy and then periodically thereafter. The adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil are reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2855?source=see_link\">",
"     \"Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum levels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    may vary widely among individuals given similar doses [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/26\">",
"     26",
"    </a>",
"    ]. Thus, when patients have a poor clinical response or develop drug toxicity at standard dosing, we check a mycophenolic acid trough level when such testing is feasible. The dose is adjusted to maintain a therapeutic blood level prior to concluding that a patient is unresponsive to mycophenolate mofetil. In one retrospective study, mycophenolic acid trough levels among three patients who responded to treatment with 1 to 3 g per day of mycophenolate mofetil were between 1.5 and 6.3",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1643378736\">",
"    <span class=\"h3\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized trials have evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    in bullous pemphigoid. However, case reports and uncontrolled studies suggest that methotrexate may be beneficial when used alone or in combination with topical corticosteroid or systemic glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/27-33\">",
"     27-33",
"    </a>",
"    ]. A 2009 retrospective review of published reports (English language) with at least five patients identified 62 patients with bullous pemphigoid who were treated with methotrexate (5 to 25 mg per week), including 45 who received methotrexate without another systemic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/31\">",
"     31",
"    </a>",
"    ]. Among the 45 patients who received only methotrexate and a topical corticosteroid, 93 percent responded well to treatment, and all 17 patients treated with methotrexate and systemic glucocorticoids achieved disease control. The results of a subsequent retrospective study suggest that monotherapy with methotrexate may also be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    is typically administered at a dose of between 5 and 20 mg per week. A low dose (eg, 5 mg per week) is used as initial therapy and the drug is slowly titrated upward (eg, by 2.5 mg per week) based upon patient tolerance and the response to therapy. Patients treated with methotrexate should also be given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    to reduce the risk for hematologic and common gastrointestinal side effects. Frequent hematologic monitoring for pancytopenia is essential. We typically obtain a complete blood count, renal function tests, and liver function tests five to six days after the initial dose and every one to two weeks for two to four weeks and one to two weeks after dose escalation. Subsequently, we obtain these tests every three months. Additional potential side effects include hepatotoxicity and pulmonary fibrosis. The side effects of methotrexate are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1559624994\">",
"    <span class=\"h2\">",
"     Antiinflammatory agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data to support the use of antimicrobial agents with antiinflammatory properties, such as tetracyclines and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    , in bullous pemphigoid are limited. However, the favorable tolerability of these agents makes them reasonable options for therapy. We typically consider these agents when a glucocorticoid-sparing regimen is required for patients with mild bullous pemphigoid (patients with localized BP or patients who develop only a few new bullae per day). In these patients, the risks of immunosuppressants often outweigh the benefits. We also consider a trial of these agents in patients with more severe bullous pemphigoid who are not good candidates for immunosuppressants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1559625001\">",
"    <span class=\"h3\">",
"     Antibiotics and nicotinamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     Tetracycline",
"    </a>",
"    antibiotics (eg, tetracycline,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    ), often in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/27/38322?source=see_link\">",
"     nicotinamide (niacinamide)",
"    </a>",
"    , have been utilized for the treatment of bullous pemphigoid [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/34-40\">",
"     34-40",
"    </a>",
"    ]. In addition to case reports and uncontrolled studies that document treatment efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/34-36\">",
"     34-36",
"    </a>",
"    ], a small unblinded randomized trial did not find significant differences in efficacy between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and tetracycline plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/27/38322?source=see_link\">",
"     nicotinamide",
"    </a>",
"    in patients with BP. In the randomized trial (n = 20), eight weeks of tetracycline (500 mg four times per day) plus nicotinamide (500 mg three times per day) was compared to prednisone (40 to 80 mg per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/37\">",
"     37",
"    </a>",
"    ]. Out of the 14 patients treated with tetracycline and nicotinamide, there were five complete responses, five partial responses, one failure to respond, and one case of worsening disease. Two patients were unavailable for follow-up. Among the six patients treated with prednisone, one had a complete response and the remainder responded partially to therapy. A larger, blinded randomized trial is necessary to confirm the comparative efficacy of these regimens.",
"   </p>",
"   <p>",
"    When treating with tetracyclines in adults, we typically administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    as 500 mg four times daily;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    are often given as 100 mg twice daily. We use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/27/38322?source=see_link\">",
"     nicotinamide",
"    </a>",
"    at a dose of 500 mg four times daily. A tetracycline shortage in North America has limited the use of this agent.",
"   </p>",
"   <p>",
"    Common side effects of tetracyclines include photosensitivity and gastrointestinal distress. Tetracyclines are contraindicated in children under the age of nine years due to adverse effects on tooth development.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/27/38322?source=see_link\">",
"     Nicotinamide",
"    </a>",
"    therapy is occasionally associated with headaches or gastrointestinal distress.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     Erythromycin",
"    </a>",
"    , another antibiotic with antiinflammatory properties, may also be beneficial for bullous pemphigoid. Erythromycin has been associated with improvement in children with bullous pemphigoid when given alone or in conjunction with other therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1559625008\">",
"    <span class=\"h3\">",
"     Dapsone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data supporting the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    are limited. No randomized trials have been performed. A 2009 review of published case reports and case series found that clinical improvement was documented in 139 of 170 patients who were treated with dapsone (50 to 300 mg per day) alone or in combination with topical corticosteroids, systemic glucocorticoids, or immunosuppressive agents [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In particular, the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    as monotherapy was reviewed in a retrospective series of 36 patients with bullous pemphigoid. Among 15 patients treated with dapsone alone (50 to 200 mg per day), 20 percent appeared to respond to therapy, with 7 percent achieving complete remission [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/44\">",
"     44",
"    </a>",
"    ]. Patients who were concomitantly treated with topical corticosteroids and dapsone (n = 19) seemed to have better outcomes; the rates of response and complete response were 63 and 47 percent, respectively.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    is usually initiated at a low dose (eg, 25 or 50 mg per day in adults) and titrated upward as tolerated. Adverse effects include hemolytic anemia, methemoglobinemia, agranulocytosis, hypersensitivity, and motor neuropathy. We typically obtain a complete blood count with differential at baseline and once weekly for four weeks, then every two weeks for two months, and every three to four months thereafter. We obtain renal and liver function tests at least at baseline and every three months. &nbsp;",
"   </p>",
"   <p>",
"    Severe hemolytic anemia may occur in patients with glucose-6-phosphate deficiency during treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    . We evaluate patients for G6PD deficiency prior to initiating dapsone therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691465200\">",
"    <span class=\"h1\">",
"     REFRACTORY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biologic therapies are a treatment option for patients who fail to respond to topical corticosteroids, systemic glucocorticoids, and glucocorticoid-sparing agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24368264\">",
"    <span class=\"h2\">",
"     Intravenous immunoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immunoglobulin (IVIG) is occasionally utilized for the treatment of bullous pemphigoid. A 2012 review of published reports identified 45 patients (including 43 adults and 2 infants) with bullous pemphigoid who were treated with IVIG with or without concomitant immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/45\">",
"     45",
"    </a>",
"    ]. Most adults were treated with 2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per cycle, with cycles repeated every four weeks. Among the adult patients, 86 percent attained clinical improvement; improvement occurred within an average of three months.",
"   </p>",
"   <p>",
"    Although further studies are necessary to determine the optimal regimen and indications for IVIG, factors that have been proposed to contribute to favorable responses include multiple treatment cycles [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/45,46\">",
"     45,46",
"    </a>",
"    ], coadministration of an immunosuppressant [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/47\">",
"     47",
"    </a>",
"    ], and shorter durations of disease prior to the initiation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The beneficial effects of IVIG on bullous pemphigoid are supported by evidence that serum levels of BP180 and BP230 antibodies decline in response to treatment. In an uncontrolled study of 10 patients with BP, treatment with IVIG was associated with the induction of both serologic and clinical remissions in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1483971202\">",
"     'Assessing response to therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The adverse effects of IVIG are reviewed separately. The high cost of IVIG limits the use of this therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=see_link\">",
"     \"Intravenous immune globulin: Adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24368271\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is a humanized chimeric monoclonal antibody that targets and destroys CD20+ B and pre-B cells. Case reports and small case series indicate that rituximab may be effective for bullous pemphigoid that is refractory to conventional therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. In a retrospective series of patients with refractory pemphigoid who were given four weekly infusions of rituximab (375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    three of the five patients with bullous pemphigoid achieved complete remission. One patient achieved only partial remission, and the remaining patient died shortly after the first infusion. All patients were concomitantly treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other systemic immunosuppressive therapies.",
"   </p>",
"   <p>",
"    Major side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=see_link\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1483971087\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional medications that have appeared to be of benefit for bullous pemphigoid in a small numbers of patients include topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/52,53\">",
"     52,53",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/54,55\">",
"     54,55",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/56,57\">",
"     56,57",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/58,59\">",
"     58,59",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/60\">",
"     60",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. A few case reports document beneficial effects of immunoadsorption in patients with refractory bullous pemphigoid [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Data conflict on the efficacy of plasmapheresis (plasma exchange) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/13,66\">",
"     13,66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113672261\">",
"    <span class=\"h1\">",
"     MUCOUS MEMBRANE INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral mucosal involvement, which usually manifests as oral erosions, occurs in 10 to 30 percent of patients with bullous pemphigoid [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/67\">",
"     67",
"    </a>",
"    ]. Similar to mucous membrane pemphigoid, oral mucous membrane involvement in bullous pemphigoid can often be managed with topical corticosteroid therapy (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39544?source=see_link\">",
"     \"Management of mucous membrane pemphigoid\"",
"    </a>",
"    ). In addition, our experience suggests that mucous membrane involvement frequently improves during systemic therapy for cutaneous disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1483971202\">",
"    <span class=\"h1\">",
"     ASSESSING RESPONSE TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The level of BP180 antibodies in serum usually correlates with the clinical activity of bullous pemphigoid [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/68\">",
"     68",
"    </a>",
"    ]. Thus, many clinicians, including ourselves, use measurement of these antibodies in conjunction with the clinical evaluation to assess the response to therapy.",
"   </p>",
"   <p>",
"    Discontinuation of treatment may be attempted once patients have remained in complete remission on minimal therapy (eg, &le;0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or &le;20 g of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    propionate per week) for at least two months [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/4\">",
"     4",
"    </a>",
"    ]. If relapse occurs, treatment is reinitiated.",
"   </p>",
"   <p>",
"    High titers of BP180 antibodies at the time of cessation of therapy may portend an increased likelihood for disease relapse. In a prospective study of 114 patients with bullous pemphigoid, a high ELISA anti-BP180-NC16A titer at the time of cessation of oral glucocorticoid or topical corticosteroid therapy was an independent predictor of disease relapse within one year [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link&amp;anchor=H53290547#H53290547\">",
"     \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Antigen-specific serological testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24368306\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course of BP is variable. In general, BP follows a chronic, relapsing course [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/69-72\">",
"     69-72",
"    </a>",
"    ]. Long-term remission may occur after months to years. In an early report that preceded the use of systemic glucocorticoids, 8 of 30 patients entered remission after 3 to 38 months of active disease.",
"   </p>",
"   <p>",
"    BP is a potentially fatal disease. Estimates for one-year overall mortality of patients with BP have ranged from 11 to 48 percent, with most studies finding increased rates of mortality compared subjects without BP [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A French prospective cohort study of 312 patients with BP found an overall one-year mortality rate of 38 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/74\">",
"       74",
"      </a>",
"      ]. The risk for death was more than six times greater for patients with BP than for age and sex matched subjects in the general population.",
"     </li>",
"     <li>",
"      A Swiss study that evaluated the course of BP in 115 patients found probabilities of death one, two, and three years after diagnosis of 21, 28, and 39 percent, respectively. The mortality rate for patients with BP was approximately three times greater than for age and sex-matched subjects in the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/73\">",
"       73",
"      </a>",
"      ]. The increase in likelihood for death was most pronounced among patients less than 70 years in age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For unknown reasons, the mortality rates reported in Europe (19 to 48 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/72-80\">",
"     72-80",
"    </a>",
"    ] have generally been higher than those reported in the United States (11 to 23 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/73,81\">",
"     73,81",
"    </a>",
"    ]. One retrospective cohort study in the United States failed to find an increase in mortality compared to the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reasons for an increase in death among patients with BP may be multifactorial. Complications secondary to therapeutic agents a likely contributing factor. In the Swiss study, the most common causes for death were heart disease, infection, and neurologic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/43/3770/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1643371701\">",
"    <span class=\"h1\">",
"     PATIENT SUPPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Pemphigus and Pemphigoid Foundation (",
"    <a class=\"external\" href=\"file://www.pemphigus.org/\">",
"     www.pemphigus.org",
"    </a>",
"    ) is a resource that provides patients and clinicians with information about BP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/11/3250?source=see_link\">",
"       \"Patient information: Bullous pemphigoid (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1643371716\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bullous pemphigoid is an uncommon autoimmune blistering disease that most commonly affects elderly adults. Multiple immunomodulatory therapies are utilized for the management of this disease. (See",
"      <a class=\"local\" href=\"#H24368172\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24368179\">",
"       'Approach to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with bullous pemphigoid we suggest treatment with a high potency topical corticosteroid such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"       clobetasol",
"      </a>",
"      0.05% cream (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). If topical corticosteroid therapy is not practical or feasible due to patient-specific characteristics or preferences, we suggest treatment with a systemic glucocorticoid (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24368200\">",
"       'First-line therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because bullous pemphigoid often persists for years, an immunosuppressive glucocorticoid-sparing agent, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , is often added to reduce the risk for glucocorticoid side effects.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       Tetracycline",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/27/38322?source=see_link\">",
"       nicotinamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      are additional options. Data to confirm the value of glucocorticoid-sparing agents in BP are lacking. (See",
"      <a class=\"local\" href=\"#H24368221\">",
"       'Glucocorticoid-sparing agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who require systemic treatment, but in whom systemic glucocorticoid therapy cannot be utilized (due to comorbidities or other factors), a glucocorticoid sparing agent may be utilized as the primary therapy. We typically use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      in this setting. (See",
"      <a class=\"local\" href=\"#H24368221\">",
"       'Glucocorticoid-sparing agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biologic therapy may be useful for the management of patients who fail to respond to topical corticosteroids, systemic glucocorticoids, and glucocorticoid-sparing agents. For these patients, we suggest treatment with intravenous immunoglobulin or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H691465200\">",
"       'Refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical course of bullous pemphigoid is variable. In addition to the clinical assessment, the measurement of serum levels of BP180 antibodies is useful for following the response to treatment. (See",
"      <a class=\"local\" href=\"#H1483971202\">",
"       'Assessing response to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Remission may occur after months or years. Bullous pemphigoid is a potentially fatal disease. (See",
"      <a class=\"local\" href=\"#H24368306\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/1\">",
"      Daniel BS, Borradori L, Hall RP 3rd, Murrell DF. Evidence-based management of bullous pemphigoid. Dermatol Clin 2011; 29:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/2\">",
"      Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/3\">",
"      Joly P, Roujeau JC, Benichou J, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol 2009; 129:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/4\">",
"      Murrell DF, Daniel BS, Joly P, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol 2012; 66:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/5\">",
"      Campbell LS, Chevalier M, Levy RA, Rhodes A. Hypothalamic-pituitary-adrenal axis suppression related to topical glucocorticoid therapy in a child with psoriatic exfoliative erythroderma. Pediatr Dermatol 2012; 29:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/6\">",
"      Walsh P, Aeling JL, Huff L, Weston WL. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol 1993; 29:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/7\">",
"      Keipert JA, Kelly R. Temporary Cushing's syndrome from percutaneous absorption of betamethasone 17-valerate. Med J Aust 1971; 1:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/8\">",
"      Dreno B, Sassolas B, Lacour P, et al. [Methylprednisolone versus prednisolone methylsulfobenzoate in pemphigoid: a comparative multicenter study]. Ann Dermatol Venereol 1993; 120:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/9\">",
"      Kirtschig G, Middleton P, Bennett C, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2010; :CD002292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/10\">",
"      Morel P, Guillaume JC. [Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study]. Ann Dermatol Venereol 1984; 111:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/11\">",
"      Frew JW, Murrell DF. Corticosteroid use in autoimmune blistering diseases. Immunol Allergy Clin North Am 2012; 32:283.",
"     </a>",
"    </li>",
"    <li>",
"     Stanley JR. Bullous Pemphigoid. In: Fitzpatrick's Dermatology in General Medicine, 7th ed, Wolff K (Ed), McGraw-Hill, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/13\">",
"      Guillaume JC, Vaillant L, Bernard P, et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1993; 129:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/14\">",
"      Burton JL, Harman RR, Peachey RD, Warin RP. Azathioprine plus prednisone in treatment of pemphigoid. Br Med J 1978; 2:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/15\">",
"      Ahmed AR, Maize JC, Provost TT. Bullous pemphigoid. Clinical and immunologic follow-up after successful therapy. Arch Dermatol 1977; 113:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/16\">",
"      Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol 2007; 143:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/17\">",
"      Wojnarowska F, Kirtschig G, Highet AS, et al. Guidelines for the management of bullous pemphigoid. Br J Dermatol 2002; 147:214.",
"     </a>",
"    </li>",
"    <li>",
"     Badalamenti SA, Kerdel FA. Azathioprine. In: Comprehensive Dermatologic Drug Therapy, 2nd ed, Wolverton SE.  (Ed), Elsevier, 2007. p.182.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/19\">",
"      Fox JC, Kenkare S, Petronic-Rosic V, et al. Bullous pemphigoid in late childhood successfully treated with mycophenolate mofetil as an adjuvant therapy. Pediatr Dermatol 2010; 27:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/20\">",
"      Eskin-Schwartz M, David M, Mimouni D. Mycophenolate mofetil for the management of autoimmune bullous diseases. Dermatol Clin 2011; 29:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/21\">",
"      Grundmann-Kollmann M, Korting HC, Behrens S, et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol 1999; 40:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/22\">",
"      B&ouml;hm M, Beissert S, Schwarz T, et al. Bullous pemphigoid treated with mycophenolate mofetil. Lancet 1997; 349:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/23\">",
"      Nousari HC, Griffin WA, Anhalt GJ. Successful therapy for bullous pemphigoid with mycophenolate mofetil. J Am Acad Dermatol 1998; 39:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/24\">",
"      Tursen U, Guney A, Kaya T, Ikizoglu G. Treatment of bullous pemphigoid with enteric-coated mycophenolate sodium. J Eur Acad Dermatol Venereol 2007; 21:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/25\">",
"      Marzano AV, Dassoni F, Caputo R. Treatment of refractory blistering autoimmune diseases with mycophenolic acid. J Dermatolog Treat 2006; 17:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/26\">",
"      Sokumbi O, el-Azhary RA, Langman LJ. Therapeutic dose monitoring of mycophenolate mofetil in dermatologic diseases. J Am Acad Dermatol 2013; 68:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/27\">",
"      Kwatra SG, Jorizzo JL. Bullous pemphigoid: a case series with emphasis on long-term remission off therapy. J Dermatolog Treat 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/28\">",
"      Du-Thanh A, Merlet S, Maillard H, et al. Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study. Br J Dermatol 2011; 165:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/29\">",
"      Kjellman P, Eriksson H, Berg P. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. Arch Dermatol 2008; 144:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/30\">",
"      Gunay U, Gunduz K, Ermertcan AT, Kandilolu AR. Coexistence of psoriasis and bullous pemphigoid: remission with low-dose methotrexate. Cutan Ocul Toxicol 2013; 32:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/31\">",
"      G&uuml;rcan HM, Ahmed AR. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol 2009; 161:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/32\">",
"      Heilborn JD, St&aring;hle-B&auml;ckdahl M, Albertioni F, et al. Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. J Am Acad Dermatol 1999; 40:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/33\">",
"      Bara C, Maillard H, Briand N, Celerier P. Methotrexate for bullous pemphigoid: preliminary study. Arch Dermatol 2003; 139:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/34\">",
"      Kolbach DN, Remme JJ, Bos WH, et al. Bullous pemphigoid successfully controlled by tetracycline and nicotinamide. Br J Dermatol 1995; 133:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/35\">",
"      Goon AT, Tan SH, Khoo LS, Tan T. Tetracycline and nicotinamide for the treatment of bullous pemphigoid: our experience in Singapore. Singapore Med J 2000; 41:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/36\">",
"      Berk MA, Lorincz AL. The treatment of bullous pemphigoid with tetracycline and niacinamide. A preliminary report. Arch Dermatol 1986; 122:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/37\">",
"      Fivenson DP, Breneman DL, Rosen GB, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994; 130:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/38\">",
"      Thomas I, Khorenian S, Arbesfeld DM. Treatment of generalized bullous pemphigoid with oral tetracycline. J Am Acad Dermatol 1993; 28:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/39\">",
"      Safa G, Darrieux L. Nonbullous pemphigoid treated with doxycycline monotherapy: report of 4 cases. J Am Acad Dermatol 2011; 64:e116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/40\">",
"      Kirtschig G, Khumalo NP. Management of bullous pemphigoid: recommendations for immunomodulatory treatments. Am J Clin Dermatol 2004; 5:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/41\">",
"      Majmudar V, Herath D, O'Toole EA, Harrison A. Bullous pemphigoid of childhood: a rare disease with diagnostic and management challenges. Clin Exp Dermatol 2010; 35:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/42\">",
"      Fox BJ, Odom RB, Findlay RF. Erythromycin therapy in bullous pemphigoid: possible anti-inflammatory effects. J Am Acad Dermatol 1982; 7:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/43\">",
"      G&uuml;rcan HM, Ahmed AR. Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data. Am J Clin Dermatol 2009; 10:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/44\">",
"      Bouscarat F, Chosidow O, Picard-Dahan C, et al. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. J Am Acad Dermatol 1996; 34:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/45\">",
"      Czernik A, Toosi S, Bystryn JC, Grando SA. Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update. Autoimmunity 2012; 45:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/46\">",
"      Chee SN, Murrell DF. The use of intravenous immunoglobulin in autoimmune bullous diseases. Immunol Allergy Clin North Am 2012; 32:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/47\">",
"      Czernik A, Bystryn JC. Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibodies. Arch Dermatol 2008; 144:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/48\">",
"      Gaitanis G, Alexis I, Pelidou SH, et al. High-dose intravenous immunoglobulin in the treatment of adult patients with bullous pemphigoid. Eur J Dermatol 2012; 22:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/49\">",
"      Sami N, Ali S, Bhol KC, Ahmed AR. Influence of intravenous immunoglobulin therapy on autoantibody titres to BP Ag1 and BP Ag2 in patients with bullous pemphigoid. J Eur Acad Dermatol Venereol 2003; 17:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/50\">",
"      Lourari S, Herve C, Doffoel-Hantz V, et al. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Eur Acad Dermatol Venereol 2011; 25:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/51\">",
"      Kasperkiewicz M, Shimanovich I, Ludwig RJ, et al. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol 2011; 65:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/52\">",
"      Calcaterra R, Carducci M, Franco G, et al. Topical tacrolimus treatment for localized pretibial bullous phemphigoid. J Eur Acad Dermatol Venereol 2009; 23:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/53\">",
"      Ko MJ, Chu CY. Topical tacrolimus therapy for localized bullous pemphigoid. Br J Dermatol 2003; 149:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/54\">",
"      Curley RK, Holden CA. Steroid-resistant bullous pemphigoid treated with cyclosporin A. Clin Exp Dermatol 1991; 16:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/55\">",
"      Thivolet J, Barthelemy H, Rigot-Muller G, Bendelac A. Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet 1985; 1:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/56\">",
"      Chave TA, Mortimer NJ, Shah DS, Hutchinson PE. Chlorambucil as a steroid-sparing agent in bullous pemphigoid. Br J Dermatol 2004; 151:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/57\">",
"      Milligan A, Hutchinson PE. The use of chlorambucil in the treatment of bullous pemphigoid. J Am Acad Dermatol 1990; 22:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/58\">",
"      Guilabert A, Lozano F, Iranzo P, et al. A case of aggressive bullous pemphigoid associated with the defective functional variant of Fc gamma receptor IIb: implications for pathogenesis? J Am Acad Dermatol 2011; 65:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/59\">",
"      Dawe RS, Naidoo DK, Ferguson J. Severe bullous pemphigoid responsive to pulsed intravenous dexamethasone and oral cyclophosphamide. Br J Dermatol 1997; 137:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/60\">",
"      Nousari HC, Anhalt GJ. Bullous pemphigoid treated with leflunomide: a novel immunomodulatory agent. Arch Dermatol 2000; 136:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/61\">",
"      Dufour C, Souillet AL, Chaneliere C, et al. Successful management of severe infant bullous pemphigoid with omalizumab. Br J Dermatol 2012; 166:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/62\">",
"      London VA, Kim GH, Fairley JA, Woodley DT. Successful treatment of bullous pemphigoid with omalizumab. Arch Dermatol 2012; 148:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/63\">",
"      Fairley JA, Baum CL, Brandt DS, Messingham KA. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol 2009; 123:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/64\">",
"      Ino N, Kamata N, Matsuura C, et al. Immunoadsorption for the treatment of bullous pemphigoid. Ther Apher 1997; 1:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/65\">",
"      M&uuml;ller PA, Br&ouml;cker EB, Klinker E, et al. Adjuvant treatment of recalcitrant bullous pemphigoid with immunoadsorption. Dermatology 2012; 224:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/66\">",
"      Roujeau JC, Guillaume JC, Morel P, et al. Plasma exchange in bullous pemphigoid. Lancet 1984; 2:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/67\">",
"      Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 1: Clinical manifestations. J Dtsch Dermatol Ges 2011; 9:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/68\">",
"      Schmidt E, Obe K, Br&ouml;cker EB, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 2000; 136:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/69\">",
"      Bernard P, Reguiai Z, Tancr&egrave;de-Bohin E, et al. Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study. Arch Dermatol 2009; 145:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/70\">",
"      Risser J, Lewis K, Weinstock MA. Mortality of bullous skin disorders from 1979 through 2002 in the United States. Arch Dermatol 2009; 145:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/71\">",
"      Parker SR, Dyson S, Brisman S, et al. Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States. J Am Acad Dermatol 2008; 59:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/72\">",
"      Roujeau JC, Lok C, Bastuji-Garin S, et al. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 1998; 134:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/73\">",
"      Cort&eacute;s B, Marazza G, Naldi L, et al. Mortality of bullous pemphigoid in Switzerland: a prospective study. Br J Dermatol 2011; 165:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/74\">",
"      Joly P, Baricault S, Sparsa A, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol 2012; 132:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/75\">",
"      Venning VA, Wojnarowska F. Lack of predictive factors for the clinical course of bullous pemphigoid. J Am Acad Dermatol 1992; 26:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/76\">",
"      Bernard P, Enginger V, Venot J, et al. [Survival prognosis in pemphigoid. A cohort analysis of 78 patients]. Ann Dermatol Venereol 1995; 122:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/77\">",
"      Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol 2002; 138:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/78\">",
"      Joly P, Benichou J, Lok C, et al. Prediction of survival for patients with bullous pemphigoid: a prospective study. Arch Dermatol 2005; 141:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/79\">",
"      Gudi VS, White MI, Cruickshank N, et al. Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland. Br J Dermatol 2005; 153:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/80\">",
"      Langan SM, Smeeth L, Hubbard R, et al. Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study. BMJ 2008; 337:a180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/43/3770/abstract/81\">",
"      Colbert RL, Allen DM, Eastwood D, Fairley JA. Mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol 2004; 122:1091.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15297 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-87E6A227E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_43_3770=[""].join("\n");
var outline_f3_43_3770=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1643371716\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24368172\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24368179\">",
"      APPROACH TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1140896505\">",
"      Goals of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1140896512\">",
"      Approach to pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24368186\">",
"      General skin care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1140896641\">",
"      Indications for referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24368200\">",
"      FIRST-LINE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24368207\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H691465063\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H691465005\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1140896757\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24368214\">",
"      Systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H691465156\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H691465163\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H691465171\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24368221\">",
"      GLUCOCORTICOID-SPARING AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24368228\">",
"      Immunosuppressive agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24368235\">",
"      - Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24368242\">",
"      - Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1643378736\">",
"      - Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1559624994\">",
"      Antiinflammatory agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1559625001\">",
"      - Antibiotics and nicotinamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1559625008\">",
"      - Dapsone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H691465200\">",
"      REFRACTORY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24368264\">",
"      Intravenous immunoglobulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24368271\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1483971087\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H113672261\">",
"      MUCOUS MEMBRANE INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1483971202\">",
"      ASSESSING RESPONSE TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24368306\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1643371701\">",
"      PATIENT SUPPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1643371716\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/15297\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15297|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/16/26885\" title=\"picture 1A\">",
"      Bullous pemphigoid multiple lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/33/31251\" title=\"picture 1B\">",
"      Bullous pemphigoid on urticarial plaque",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/53/24406\" title=\"picture 1C\">",
"      Bullous pemphigoid axillae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15297|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 1\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=related_link\">",
"      Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=related_link\">",
"      Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=related_link\">",
"      Diagnosis of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15273?source=related_link\">",
"      Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=related_link\">",
"      Intravenous immune globulin: Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39544?source=related_link\">",
"      Management of mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2855?source=related_link\">",
"      Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/11/3250?source=related_link\">",
"      Patient information: Bullous pemphigoid (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_43_3771="Causes eosinophilic pneumonia";
var content_f3_43_3771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of eosinophilic pneumonia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Idiopathic (acute or chronic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tropical filarial eosinophilia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parasitic infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allergic bronchopulmonary aspergillosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Churg-Strauss syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypereosinophilic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acquired immunodeficiency syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drugs (eg, aspirin, nonsteroidal antiinflammatory drugs, nitrofurantoin, sulfonamides, ampicillin, cocaine)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_43_3771=[""].join("\n");
var outline_f3_43_3771=null;
var title_f3_43_3772="Estimated global incidence";
var content_f3_43_3772=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated annual incidence (000) of fire-related burn injuries* in 2004, by World Health Organization region",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Africa",
"       </td>",
"       <td class=\"subtitle1\">",
"        The Americas",
"       </td>",
"       <td class=\"subtitle1\">",
"        EMR&bull;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Europe",
"       </td>",
"       <td class=\"subtitle1\">",
"        SEAR&Delta;",
"       </td>",
"       <td class=\"subtitle1\">",
"        WPR&loz;",
"       </td>",
"       <td class=\"subtitle1\">",
"        World",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Population (000)",
"       </td>",
"       <td>",
"        689,632",
"       </td>",
"       <td>",
"        874,380",
"       </td>",
"       <td>",
"        519,688",
"       </td>",
"       <td>",
"        883,311",
"       </td>",
"       <td>",
"        1,671,904",
"       </td>",
"       <td>",
"        1,738,457",
"       </td>",
"       <td>",
"        6,436,826",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Burns (000)",
"       </td>",
"       <td>",
"        982",
"       </td>",
"       <td>",
"        163",
"       </td>",
"       <td>",
"        970",
"       </td>",
"       <td>",
"        523",
"       </td>",
"       <td>",
"        4069",
"       </td>",
"       <td>",
"        388",
"       </td>",
"       <td>",
"        7105",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Incidence rate (000)",
"       </td>",
"       <td>",
"        1.33",
"       </td>",
"       <td>",
"        0.19",
"       </td>",
"       <td>",
"        1.87",
"       </td>",
"       <td>",
"        0.59",
"       </td>",
"       <td>",
"        0.243",
"       </td>",
"       <td>",
"        0.22",
"       </td>",
"       <td>",
"        1.10",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Includes only burns covering 20 percent or more of total body surface area.",
"     <br>",
"      &bull; Eastern Mediterranean region.",
"      <br>",
"       &Delta; South-East Asia region.",
"       <br>",
"        &loz; Western Pacific region.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: World Health Organization. Disease and injury estimates for 2004. Morbidity and Mortality. Incidence. Annual incidence (000s) for selected causes, in WHO regions, estimates for 2004. www.who.int/healthinfo/global_burden_disease/estimates_regional/en/index.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_43_3772=[""].join("\n");
var outline_f3_43_3772=null;
var title_f3_43_3773="Causes of delirium and confusion";
var content_f3_43_3773=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F59893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F59893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common causes of delirium and confusional states",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drugs and toxins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prescription medications (eg, opioids, sedative-hypnotics, antipsychotics, lithium, skeletal muscle relaxers, polypharmacy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Non-prescription medications (eg, antihistamines)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drugs of abuse (eg, ethanol, heroin, hallucinogens, nonmedicinal use of prescription medications)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Withdrawal states (eg, ethanol, benzodiazepines)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medication side effects (eg, hyperammonemia from valproic acid, confusion from quinolones, serotonin syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Poisons:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Atypical alcohols (ethylene glycol, methanol)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Inhaled toxins (carbon monoxide, cyanide, hydrogen sulfide)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Plant-derived (eg, Jimson weed, Salvia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic infections; fever-related delirium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Metabolic derangements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electrolyte disturbance (elevated or depressed): sodium, calcium, magnesium, phosphate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endocrine disturbance (depressed or increased): thyroid, parathyroid, pancreas, pituitary, adrenal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypercarbia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperglycemia and hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperosmolar and hypoosmolar states",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoxemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inborn errors of metabolism: porphyria, Wilson's disease, etc.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nutritional: Wernicke's encephalopathy, vitamin B12 deficiency, possibly folate and niacin deficiencies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Brain disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CNS infections: encephalitis, meningitis, brain or epidural abscess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epileptic seizures, especially nonconvulsive status epilepticus*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head injury*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertensive encephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychiatric disorders*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Systemic organ failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematologic: thrombocytosis, hypereosinophilia, leukemic blast cell crisis, polycythemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver failure: acute, chronic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary disease, including hypercarbia and hypoxemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal failure: acute, chronic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Physical disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Burns",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electrocution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperthermia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothermia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trauma: with systemic inflammatory response syndrome, *head injury, fat embolism",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Disorders that, while not truly systemic or \"medical\", may produce the clinical picture of delirium or confusional state in all other aspects.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_43_3773=[""].join("\n");
var outline_f3_43_3773=null;
var title_f3_43_3774="Contents: Oncology";
var content_f3_43_3774=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      Oncology",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Oncology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     You receive the entire UpToDate library of specialties with your ",
"							subscription. Click on a section below to view a detailed list of topics associated ",
"							with that particular section. If you'd like to see the table of contents for other ",
"							specialties,",
"     <a href=\"UTD.htm?3/3/3134\">",
"      click here",
"     </a>",
"     .",
"     <br/>",
"     <br/>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?40/35/41535\">",
"         Breast cancer",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?37/1/37917\">",
"         Cancer survivorship",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?11/13/11487\">",
"         Chemotherapeutic agents",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?6/28/6606\">",
"         End of life care",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?8/34/8751\">",
"         Endocrine tumors",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?19/49/20242\">",
"         Gastrointestinal cancer",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?32/17/33040\">",
"         General oncologic issues",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?21/52/22336\">",
"         Genitourinary cancer",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?14/12/14528\">",
"         Gynecologic oncology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?14/35/14911\">",
"         Head and neck cancer",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?1/6/1120\">",
"         Leukemia myeloproliferative disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?14/23/14719\">",
"         Lung cancer",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?3/29/3537\">",
"         Lymphoma",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?4/16/4366\">",
"         Miscellaneous tumors",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?15/52/16207\">",
"         Neurooncology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?27/24/28045\">",
"         Oncology calculators",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?28/45/29406\">",
"         Plasma cell disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?37/4/37966\">",
"         Prostate cancer",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?4/22/4462\">",
"         Radiation therapy",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?20/22/20846\">",
"         Skin cancer",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?35/34/36398\">",
"         Soft tissue and bone tumors",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?12/24/12686\">",
"         Tumors immunocompromised host",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?11/43/11962\">",
"         What's new in oncology",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        &nbsp;",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        <a class=\"tocItem\" href=\"UTD.htm?18/22/18798\">",
"         Patient Information",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-925B8E3883-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f3_43_3774=[""].join("\n");
var outline_f3_43_3774=null;
var title_f3_43_3775="TEE multiple atrial septal defects";
var content_f3_43_3775=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/59313/teec2asd_conv.mp4?title=TEE+multiple+atrial+septal+defects\" style=\"width:383px;height:276px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple atrial septal defects",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 281px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transesophageal echocardiogram with color flow Doppler shows two distinct jets of blood flow (arrows) from the left atrium (LA) to right atrium (RA), a result of two separate atrial septal defects.",
"    <div class=\"footnotes\">",
"     Ao: aorta.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_43_3775=[""].join("\n");
var outline_f3_43_3775=null;
